

Integrated Science Assessment for Particulate Matter

(External Review Draft)

August 2018

National Center for Environmental Assessment—RTP Division
Office of Research and Development
U.S. Environmental Protection Agency
Research Triangle Park, NC

DISCLAIMER

1 This document is an external review draft, for review purposes only. This information is distributed solely
2 for the purpose of predissemination peer review under applicable information quality guidelines. It has
3 not been formally disseminated by EPA. It does not represent and should not be construed to represent
4 any Agency determination or policy. Mention of trade names or commercial products does not constitute
5 endorsement or recommendation for use.

CONTENTS

Integrated Science Assessment Team for Particulate Matter	xxv
Authors, Contributors, and Reviewers	xxviii
PREFACE	P-1
P.1 Legislative Requirements for the Review of the National Ambient Air Quality Standards	P-1
P.1.1. Overview and History of the Reviews of the Primary and Secondary National Ambient Air Quality Standard for Particulate Matter	P-3
P.2 Purpose and Overview of the Integrated Science Assessment	P-9
P.3 Process for Developing Integrated Science Assessments	P-11
P.3.1. Scope of the ISA	P-12
P.3.2. Evaluation of the Evidence	P-15
P.4 References	P-17
Executive Summary	ES-1
Purpose and Scope of the Integrated Science Assessment	ES-1
Sources and Exposure to PM	ES-4
Dosimetry of Inhaled PM	ES-6
Health and Welfare Effects of PM Exposure	ES-7
Health Effects of PM _{2.5} Exposure	ES-9
Health Effects of UFP Exposure	ES-14
Policy-Relevant Considerations for Health Effects Associated with Particulate Matter Exposure	ES-15
PM Exposure and Welfare Effects	ES-18
References	ES-20
CHAPTER 1 INTEGRATED SYNTHESIS	1-1
1.1 Introduction	1-2
1.1.1 Purpose	1-2
1.1.2 Organization of the ISA	1-2
1.2 From Emissions Sources to Exposure to Particulate Matter	1-4
1.2.1 Emission Sources and Distribution of Ambient Concentrations	1-4
1.2.1.1 Sources and Emissions of PM	1-5
1.2.1.2 Atmospheric Processes and PM Formation	1-7
1.2.1.3 Monitoring and Modeling of PM	1-8
1.2.1.4 National PM Concentrations	1-10
1.2.1.5 Spatial and Temporal Variability in PM Concentrations	1-10
1.2.1.6 Summary	1-13
1.2.2 Assessment of Human Exposure	1-13
1.3 Dosimetry of PM	1-17
1.4 Evaluation of the Health Effects of PM	1-20
1.4.1 Health Effects of PM _{2.5}	1-21
1.4.1.1 Respiratory Effects	1-21
1.4.1.1.1 Respiratory Effects Associated with Short-Term PM _{2.5} Exposure	1-22
1.4.1.1.2 Respiratory Effects Associated with Long-Term PM _{2.5} Exposure	1-23
1.4.1.2 Cardiovascular Effects	1-24
1.4.1.2.1 Cardiovascular Effects Associated with Short-Term PM _{2.5} Exposure	1-24
1.4.1.2.2 Cardiovascular Effects Associated with Long-Term PM _{2.5} Exposure	1-26

1.4.1.3	Nervous System Effects	1-28
1.4.1.3.1	Nervous System Effects Associated with Long-Term PM _{2.5} Exposure	1-28
1.4.1.4	Cancer	1-29
1.4.1.4.1	Cancer Associated with Long-Term PM _{2.5} Exposure	1-29
1.4.1.5	Mortality	1-30
1.4.1.5.1	Mortality Associated with Short-Term PM _{2.5} Exposure	1-30
1.4.1.5.2	Mortality Associated with Long-Term PM _{2.5} Exposure	1-31
1.4.2	Health Effects of PM _{10-2.5}	1-40
1.4.3	Health Effects of UFPs	1-40
1.4.3.1	Nervous System Effects Associated with Long-Term UFP Exposure	1-41
1.5	Policy-Relevant Considerations	1-44
1.5.1	Potential Copollutant Confounding	1-44
1.5.1.1	Short-term PM _{2.5} Exposure	1-45
1.5.1.2	Long-term PM _{2.5} Exposure	1-46
1.5.2	Timing of Effects	1-47
1.5.2.1	Averaging Time	1-47
1.5.2.2	Lag Structure of Associations	1-48
1.5.3	Concentration-Response (C-R) Relationship	1-49
1.5.3.1	Short-Term Exposure	1-49
1.5.3.2	Long-Term Exposure	1-50
1.5.4	PM Components and Sources	1-51
1.5.4.1	Respiratory Effects	1-52
1.5.4.2	Cardiovascular Effects	1-53
1.5.4.3	Mortality	1-54
1.5.5	Populations and Lifestyles at Potentially Increased Risk of a PM-related Health Effect	1-54
1.6	Welfare Effects of PM	1-57
1.6.1	Visibility Impairment	1-57
1.6.2	Climate Effects	1-58
1.6.3	Materials Effects	1-59
1.7	Summary of Causality Determinations for All Health and Welfare Effects	1-61
1.8	References	1-65

CHAPTER 2 SOURCES, ATMOSPHERIC CHEMISTRY, AND AMBIENT CONCENTRATIONS 2-1

2.1	Summary Overview	2-1
2.2	Atmospheric Size Distributions	2-2
2.3	Primary Sources and Atmospheric Formation	2-5
2.3.1	Primary PM _{2.5} Emissions	2-7
2.3.1.1	National Scale Emissions	2-7
2.3.1.2	Urban Scale Emissions	2-9
2.3.2	Secondary PM _{2.5} Formation	2-12
2.3.2.1	Precursor Emissions	2-13
2.3.2.2	Secondary Inorganic Aerosols	2-15
2.3.2.3	Secondary Organic Aerosols	2-17
2.3.3	Primary PM _{10-2.5} Emissions	2-19
2.3.4	Ultrafine Particles	2-20
2.3.4.1	Primary Sources	2-24
2.3.4.2	New Particle Formation	2-25
2.4	Measurement, Monitoring and Modeling	2-26
2.4.1	PM _{2.5} and PM ₁₀	2-26
2.4.2	PM _{10-2.5}	2-27

2.4.3	Ultrafine Particles: Number, Surface Area, Mass	2-28
2.4.3.1	Particle Number and Number Distribution	2-29
2.4.3.2	Surface Area	2-32
2.4.3.3	Mass	2-33
2.4.4	Chemical Components	2-34
2.4.5	Satellite Remote Sensing	2-35
2.4.6	Monitoring Networks	2-38
2.4.7	Chemistry-Transport Models	2-41
2.5	Ambient Concentrations	2-44
2.5.1	Spatial Distribution	2-44
2.5.1.1	Variability Across the U.S.	2-44
2.5.1.1.1	PM _{2.5}	2-44
2.5.1.1.2	PM ₁₀	2-48
2.5.1.1.3	PM _{10-2.5}	2-51
2.5.1.1.4	PM _{2.5} /PM ₁₀	2-54
2.5.1.1.5	Ultrafine Particles	2-56
2.5.1.1.6	PM _{2.5} Components	2-60
2.5.1.1.7	PM _{10-2.5} Components	2-63
2.5.1.1.8	Ultrafine Particle Components	2-64
2.5.1.1.9	Reactive Oxygen Species	2-65
2.5.1.2	Urban and Neighborhood Scale Variability	2-66
2.5.1.2.1	PM _{2.5}	2-66
2.5.1.2.2	PM ₁₀	2-67
2.5.1.2.3	PM _{10-2.5}	2-67
2.5.1.2.4	Ultrafine Particles	2-68
2.5.1.2.5	Chemical Components	2-69
2.5.2	Temporal Variability	2-70
2.5.2.1	Regional Trends	2-70
2.5.2.1.1	PM _{2.5}	2-70
2.5.2.1.2	PM ₁₀	2-73
2.5.2.1.3	PM _{10-2.5}	2-75
2.5.2.1.4	Ultrafine Particles	2-76
2.5.2.1.5	Chemical Components	2-76
2.5.2.2	Seasonal Variations	2-80
2.5.2.2.1	PM _{2.5}	2-80
2.5.2.2.2	PM _{10-2.5}	2-81
2.5.2.2.3	Ultrafine Particles	2-84
2.5.2.2.4	PM Components	2-84
2.5.2.3	Hourly and Weekday-Weekend Variability	2-86
2.5.3	Common Patterns of Particulate Matter Characteristics in the U.S.	2-87
2.5.4	Background Particulate Matter	2-91
2.5.4.1	Natural Background	2-92
2.5.4.2	Intercontinental Transport	2-93
2.6	Summary	2-95
2.7	References	2-98

CHAPTER 3 EXPOSURE TO AMBIENT PARTICULATE MATTER 3-1

3.1	Introduction	3-1
3.2	Conceptual Overview of Human Exposure	3-2
3.2.1	Exposure Terminology	3-2
3.2.2	Conceptual Model of Total Personal Exposure	3-5
3.2.3	Exposure Considerations Specific to PM	3-7
3.3	Methodological Considerations for Use of Exposure Data and Models	3-8
3.3.1	Surface Measurement	3-10
3.3.1.1	Ambient Monitoring	3-10
3.3.1.2	Personal Monitoring	3-11
3.3.2	Modeling	3-15
3.3.2.1	Data Averaging	3-17
3.3.2.2	Spatial Interpolation Methods	3-18
3.3.2.3	Land Use Regression and Spatiotemporal Modeling	3-20
3.3.2.3.1	Land Use Regression	3-20
3.3.2.3.2	Spatiotemporal Modeling	3-24
3.3.2.4	Mechanistic Models	3-25
3.3.2.4.1	Chemical Transport Model Applications for Exposure Concentration Estimation	3-25
3.3.2.4.2	Dispersion Modeling Applications for Exposure Concentration Estimation	3-28
3.3.2.4.3	Hybrid Approaches	3-30
3.3.3	Satellite-based Methods for Exposure Concentration Estimation	3-35
3.3.4	Microenvironmental Exposure Modeling	3-39
3.3.5	Exposure Assignment Methods in Epidemiologic Studies	3-42
3.4	Exposure Assessment and Interpretation of Epidemiologic Study Results	3-53
3.4.1	Relationships Influencing Exposure	3-53
3.4.1.1	Air Exchange Rate and Infiltration	3-53
3.4.1.2	Indoor–Outdoor Concentration Relationships	3-57
3.4.1.3	Personal–Ambient Concentration Relationships	3-61
3.4.2	Factors Contributing to Error in Estimating Exposure to PM	3-64
3.4.2.1	Time–Activity Patterns	3-65
3.4.2.2	Spatial Variability in Concentrations	3-69
3.4.2.3	Instrument Accuracy and Precision	3-72
3.4.2.4	Model Accuracy and Precision	3-74
3.4.3	Costressor Relationships	3-76
3.4.3.1	Temporal Relationships among Ambient PM and Copollutant Exposures	3-77
3.4.3.2	Spatial Relationships among Ambient PM and Copollutant Exposures	3-86
3.4.3.3	Personal and Indoor Relationships between PM and Copollutant Exposures	3-87
3.4.3.4	Traffic-related Noise	3-91
3.4.4	PM Composition and Exposure Assessment	3-92
3.4.4.1	Composition	3-92
3.4.4.2	Reactive Oxygen Species	3-101
3.4.5	Influence of Exposure Errors on Results from Epidemiologic Studies of Different Designs	3-104
3.4.5.1	Short-Term Exposure Studies	3-105
3.4.5.1.1	Time-Series Studies	3-105
3.4.5.1.2	Panel Studies	3-109
3.4.5.2	Long-Term Exposure Cohort Studies	3-110
3.5	Summary	3-116
3.6	References	3-119

CHAPTER 4 DOSIMETRY OF PARTICULATE MATTER 4-1

4.1	Introduction	4-1
4.1.1	Size Characterization of Inhaled Particles	4-3
4.1.2	Structure and Function of the Respiratory Tract	4-4
4.1.2.1	Anatomy	4-4
4.1.2.2	Breathing Rates	4-6
4.1.2.3	Epithelial Lining Fluid	4-8
4.1.3	Route of Breathing	4-9
4.1.4	Ventilation Distribution	4-12
4.1.5	Particle Inhalability	4-13
4.1.6	Thoracic and Respirable Particles	4-14
4.1.7	Dose and Dose Metrics	4-19
4.2	Particle Deposition	4-21
4.2.1	Mechanisms of Deposition	4-22
4.2.2	Deposition Patterns	4-24
4.2.2.1	Total Respiratory Tract Deposition	4-25
4.2.2.2	Extrathoracic Region	4-27
4.2.2.3	Tracheobronchial and Alveolar Region	4-32
4.2.2.4	Sites of Localized Deposition	4-32
4.2.3	Interspecies Patterns of Deposition	4-33
4.2.4	Factors Modulating Deposition	4-35
4.2.4.1	Physical Activity	4-35
4.2.4.2	Age	4-38
4.2.4.3	Sex	4-40
4.2.4.4	Body Mass Index	4-41
4.2.4.5	Anatomical Variability	4-41
4.2.4.6	Ventilation Distribution	4-43
4.2.4.7	Respiratory Tract Disease	4-44
4.2.4.8	Particle Hygroscopicity	4-45
4.2.5	Summary	4-47
4.3	Particle Clearance	4-48
4.3.1	Clearance Mechanisms	4-49
4.3.1.1	Extrathoracic Region	4-49
4.3.1.2	Tracheobronchial Region	4-49
4.3.1.3	Alveolar Region	4-51
4.3.2	Interspecies Clearance and Retention	4-53
4.3.3	Particle Translocation	4-54
4.3.3.1	Olfactory Delivery	4-55
4.3.3.2	Pulmonary Delivery	4-59
4.3.3.2.1	Membrane Translocation	4-59
4.3.3.2.2	Extrapulmonary Distribution	4-60
4.3.3.3	Transplacental Barrier Transport	4-65
4.3.4	Factors Modulating Particle Clearance	4-66
4.3.4.1	Age	4-66
4.3.4.2	Sex	4-67
4.3.4.3	Respiratory Tract Disease	4-67
4.3.4.4	Particle Overload	4-68
4.3.5	Summary	4-69
4.4	References	4-71

CHAPTER 5 RESPIRATORY EFFECTS **5-1**

5.1	Short-Term PM _{2.5} Exposure and Respiratory Effects	5-1
-----	---	-----

5.1.1	Biological Plausibility	5-3
5.1.2	Asthma Exacerbation	5-7
5.1.2.1	Hospital Admissions and Emergency Department (ED) Visits	5-8
5.1.2.1.1	Hospital Admissions	5-20
5.1.2.1.2	Emergency Department (ED) Visits	5-21
5.1.2.1.3	Summary of Asthma Hospital Admissions and Emergency Department (ED) Visits	5-22
5.1.2.2	Respiratory Symptoms and Asthma Medication Use in Populations with Asthma	5-23
5.1.2.3	Lung Function Changes in Populations with Asthma	5-29
5.1.2.3.1	Controlled Human Exposure Studies	5-35
5.1.2.3.2	Animal Toxicological Studies	5-36
5.1.2.3.3	Summary of Lung Function in Populations with Asthma	5-36
5.1.2.4	Subclinical Effects Underlying Asthma Exacerbation	5-37
5.1.2.4.1	Controlled Human Exposure Studies	5-45
5.1.2.4.2	Animal Toxicological Studies	5-45
5.1.2.4.3	Summary of Subclinical Effects Underlying Asthma Exacerbation	5-48
5.1.2.5	Summary of Asthma Exacerbations	5-48
5.1.3	Allergy Exacerbation	5-49
5.1.4	Chronic Obstructive Pulmonary Disease (COPD) Exacerbation	5-50
5.1.4.1	Hospital Admissions and Emergency Department (ED) Visits	5-51
5.1.4.1.1	Hospital Admissions	5-57
5.1.4.1.2	Emergency Department (ED) Visits	5-58
5.1.4.1.3	Summary of Chronic Obstructive Pulmonary Disease (COPD) Hospital Admissions and Emergency Department (ED) Visits	5-58
5.1.4.2	Respiratory Symptoms and Medication Use	5-59
5.1.4.3	Lung Function Changes in Adults with Chronic Obstructive Pulmonary Disease (COPD)	5-59
5.1.4.3.1	Epidemiologic Studies	5-59
5.1.4.3.2	Controlled Human Exposure Studies	5-63
5.1.4.4	Subclinical Effects Underlying Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)	5-63
5.1.4.4.1	Epidemiologic Studies	5-63
5.1.4.4.2	Controlled Human Exposure Studies	5-64
5.1.4.4.3	Animal Toxicological Studies	5-64
5.1.4.5	Summary of Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)	5-64
5.1.5	Respiratory Infection	5-65
5.1.5.1	Hospital Admissions and Emergency Department (ED) Visits	5-65
5.1.5.1.1	Hospital Admissions	5-73
5.1.5.1.2	Emergency Department (ED) Visits	5-74
5.1.5.2	Outpatient and Physician Visit Studies	5-75
5.1.5.3	Subclinical Effects Underlying Respiratory Infection	5-75
5.1.5.4	Summary of Respiratory Infection	5-75
5.1.6	Combinations of Respiratory-Related Hospital Admissions and Emergency Department (ED) Visits	5-76
5.1.6.1	Hospital Admissions	5-85
5.1.6.2	Emergency Department (ED) Visits	5-86
5.1.6.3	Summary of Respiratory-Related Hospital Admissions and Emergency Department (ED) Visits	5-87

5.1.7	Respiratory Effects in Healthy Populations	5-88
5.1.7.1	Epidemiologic Studies	5-88
5.1.7.2	Controlled Human Exposure Studies	5-95
5.1.7.3	Animal Toxicological Studies	5-96
5.1.7.4	Summary of Respiratory Effects in Healthy Populations	5-105
5.1.8	Respiratory Effects in Populations with Cardiovascular Disease	5-106
5.1.9	Respiratory Mortality	5-107
5.1.10	Policy-Relevant Considerations	5-108
5.1.10.1	Examination of Potential Copollutant Confounding	5-109
5.1.10.1.1	PM _{2.5} within the Multipollutant Mixture	5-114
5.1.10.2	Model Specification	5-117
5.1.10.3	Lag Structure	5-119
5.1.10.4	The Role of Season and Temperature on PM _{2.5} Associations	5-123
5.1.10.4.1	Season	5-124
5.1.10.4.2	Temperature	5-128
5.1.10.5	Averaging Time of PM _{2.5} Concentrations	5-129
5.1.10.6	Concentration-Response Relationship and Threshold Analyses	5-131
5.1.11	PM _{2.5} Components and Sources and Respiratory Effects	5-138
5.1.11.1	Elemental and Black Carbon	5-140
5.1.11.2	Organic Carbon	5-143
5.1.11.3	Secondary PM _{2.5} —Sulfate, Nitrate, Ammonium	5-144
5.1.11.4	Metals	5-145
5.1.11.5	Other PM _{2.5} components	5-147
5.1.11.6	Sources of PM _{2.5}	5-147
5.1.11.7	Summary	5-149
5.1.12	Summary and Causality Determination	5-149
5.2	Long-Term Exposure PM _{2.5} Exposure and Respiratory Effects	5-155
5.2.1	Biological Plausibility	5-156
5.2.2	Lung Function and Development	5-159
5.2.2.1	Lung Development	5-159
5.2.2.1.1	Epidemiologic Studies	5-160
5.2.2.1.2	Animal Toxicological Studies	5-165
5.2.2.2	Lung Function	5-166
5.2.2.2.1	Children	5-166
5.2.2.2.2	Adults	5-173
5.2.2.3	Summary of Lung Function and Development	5-174
5.2.3	Development of Asthma	5-175
5.2.3.1	Asthma in Children	5-175
5.2.3.1.1	Copollutant Confounding	5-181
5.2.3.1.2	Concentration-Response Relationship	5-181
5.2.3.2	Asthma in Adults	5-182
5.2.3.3	Subclinical Effects Underlying Development of Asthma	5-186
5.2.3.3.1	Epidemiologic Studies	5-186
5.2.3.3.2	Animal Toxicological Study	5-187
5.2.4	Development of Allergic Disease	5-187
5.2.5	Development of Chronic Obstructive Pulmonary Disease (COPD)	5-189
5.2.6	Respiratory Infection	5-191
5.2.7	Severity of Respiratory Disease	5-193
5.2.7.1	Epidemiologic Studies	5-194

5.2.7.2	Animal Toxicological Study	5-194
5.2.8	Subclinical Effects in Healthy Populations	5-195
5.2.9	Subclinical Effects in Populations with Cardiovascular Disease	5-200
5.2.10	Respiratory Mortality	5-202
5.2.10.1	Potential Copollutant Confounding of the PM _{2.5} -Mortality Relationship	5-205
5.2.11	Respiratory Effects and Declining PM _{2.5} Concentrations	5-207
5.2.11.1	Bronchitis	5-207
5.2.11.2	Pulmonary Function	5-208
5.2.11.3	Summary	5-209
5.2.12	Associations Between PM _{2.5} Components and Sources and Respiratory Effects	5-210
5.2.12.1	Elemental Carbon, Black Carbon, and Organic Carbon	5-212
5.2.12.2	Metals	5-213
5.2.12.3	Oxidative Potential	5-213
5.2.12.4	Summary	5-214
5.2.13	Summary and Causality Determination	5-214
5.3	Short-Term PM _{10-2.5} Exposure and Respiratory Effects	5-219
5.3.1	Biological Plausibility	5-220
5.3.2	Asthma Exacerbation	5-223
5.3.2.1	Hospital Admissions and Emergency Department (ED) Visits	5-224
5.3.2.1.1	Concentration-Response Relationship	5-229
5.3.2.2	Respiratory Symptoms and Medication Use	5-230
5.3.2.3	Lung Function	5-231
5.3.2.4	Subclinical Effects Underlying Asthma Exacerbation	5-232
5.3.2.4.1	Epidemiologic Studies	5-232
5.3.2.4.2	Controlled Human Exposure Studies	5-233
5.3.2.4.3	Animal Toxicological Studies	5-234
5.3.2.5	Summary of Asthma Exacerbation	5-234
5.3.3	Chronic Obstructive Pulmonary Disease (COPD) Exacerbation	5-235
5.3.3.1	Hospital Admissions and Emergency Department (ED) Visits	5-239
5.3.3.1.1	Hospital Admissions	5-239
5.3.3.1.2	Emergency Department (ED) Visits	5-239
5.3.3.2	Other Epidemiologic Studies	5-240
5.3.3.3	Summary of Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)	5-240
5.3.4	Respiratory Infection	5-240
5.3.4.1	Hospital Admissions and Emergency Department (ED) Visits	5-241
5.3.4.2	Outpatient and Physician Visit Studies	5-245
5.3.4.3	Summary of Respiratory Infection	5-245
5.3.5	Combinations of Respiratory-Related Hospital Admissions and Emergency Department (ED) Visits	5-246
5.3.6	Respiratory Effects in Healthy Populations	5-254
5.3.6.1	Epidemiologic Studies	5-255
5.3.6.2	Controlled Human Exposure	5-255
5.3.6.3	Animal Toxicological Studies	5-256
5.3.6.4	Summary of Respiratory Effects in Healthy Populations	5-257
5.3.7	Respiratory Mortality	5-257
5.3.7.1	Characterizing the PM _{10-2.5} -Respiratory Mortality Relationship	5-258
5.3.7.1.1	Copollutant Confounding	5-258
5.3.7.1.2	Lag Structure of Associations	5-261
5.3.7.1.3	Effect Modification	5-262
5.3.8	Summary and Causality Determination	5-263

5.4	Long-Term PM _{10-2.5} Exposure and Respiratory Effects	5-266
5.4.1	Biological Plausibility	5-267
5.4.2	Lung Function and Lung Development	5-269
5.4.3	Development of Asthma	5-270
5.4.4	Development of Allergic Disease	5-271
5.4.5	Respiratory Infection	5-271
5.4.6	Severity of Asthma	5-271
5.4.7	Subclinical Effects in Healthy Populations	5-272
5.4.8	Respiratory Mortality	5-273
5.4.9	Summary and Causality Determination	5-273
5.5	Short-Term UFP Exposure and Respiratory Effects	5-276
5.5.1	Biological Plausibility	5-276
5.5.2	Asthma Exacerbation	5-280
5.5.2.1	Epidemiologic Studies	5-280
5.5.2.2	Controlled Human Exposure	5-284
5.5.2.3	Animal Toxicological Studies	5-284
5.5.3	Chronic Obstructive Pulmonary Disease (COPD) Exacerbation	5-285
5.5.4	Respiratory Infection	5-288
5.5.5	Combinations of Respiratory-Related Hospital Admissions and Emergency Department (ED) Visits	5-291
5.5.6	Respiratory Effects in Healthy Populations	5-294
5.5.6.1	Lung Function	5-294
5.5.6.1.1	Epidemiologic Studies	5-294
5.5.6.1.2	Controlled Human Exposure Studies	5-296
5.5.6.1.3	Animal Toxicological Studies	5-296
5.5.6.2	Summary of Respiratory Effects in Healthy Populations	5-298
5.5.7	Respiratory Effects in Populations with Cardiovascular Disease	5-299
5.5.8	Respiratory Mortality	5-299
5.5.9	Summary and Causality Determination	5-300
5.6	Long-Term UFP Exposure and Respiratory Effects	5-302
5.6.1	Biological Plausibility	5-303
5.6.2	Development of Asthma	5-305
5.6.3	Subclinical Effects in Healthy Populations and Populations with Cardiovascular Disease	5-306
5.6.4	Respiratory Mortality	5-308
5.6.5	Summary and Causality Determination	5-309
5.7	References	5-311

CHAPTER 6 CARDIOVASCULAR EFFECTS **6-1**

6.1	Short-Term PM _{2.5} Exposure and Cardiovascular Effects	6-1
6.1.1	Biological Plausibility	6-3
6.1.2	Ischemic Heart Disease and Myocardial Infarction	6-6
6.1.2.1	Emergency Department Visits and Hospital Admissions	6-7
6.1.2.1.1	Emergency Department (ED) Visits and Hospital Admissions for Acute Myocardial Infarction (MI) and Angina Pectoris	6-11
6.1.2.2	Panel Epidemiologic Studies of ST Segment Depression	6-14
6.1.3	Heart Failure and Impaired Heart Function	6-15
6.1.3.1	Emergency Department Visits and Hospital Admissions	6-16
6.1.3.2	Controlled Human Exposure Studies of Impaired Heart Function	6-21
6.1.3.3	Toxicology Studies of Impaired Heart Function	6-21
6.1.4	Cardiac Electrophysiology, Arrhythmia, and Cardiac Arrest	6-22

6.1.4.1	Emergency Department Visits and Hospital Admissions for Arrhythmia and Out-of-Hospital Cardiac Arrest	6-23
6.1.4.1.1	Arrhythmias	6-23
6.1.4.1.2	Out-of-Hospital Cardiac Arrest	6-26
6.1.4.2	Panel Epidemiologic Studies for Arrhythmia and Conduction Abnormalities	6-30
6.1.4.2.1	Conduction Abnormalities	6-36
6.1.4.3	Controlled Human Exposure Studies for Arrhythmia and Conduction Abnormalities	6-38
6.1.4.4	Toxicology Studies for Arrhythmia and Conduction Abnormalities	6-39
6.1.5	Cerebrovascular Disease and Stroke	6-41
6.1.5.1	Emergency Department Visits and Hospital Admissions	6-41
6.1.6	Blood Pressure and Hypertension	6-46
6.1.6.1	Emergency Department Visits and Hospital Admissions	6-47
6.1.6.2	Panel Epidemiologic Studies of Changes in Blood Pressure (BP)	6-50
6.1.6.3	Controlled Human Exposure Studies of Changes in Blood Pressure (BP)	6-56
6.1.6.4	Toxicological Studies of Changes in Blood Pressure (BP)	6-58
6.1.6.4.1	Renin-Angiotensin System	6-59
6.1.7	Peripheral Vascular Disease, Venous Thromboembolism, Pulmonary Embolism	6-60
6.1.7.1	Emergency Department (ED) Visits and Hospital Admission	6-61
6.1.8	Emergency Department Visits and Hospital Admission Studies of Combined Cardiovascular-Related Effects	6-64
6.1.9	Epidemiologic Studies of Cardiovascular Mortality	6-70
6.1.10	Heart Rate (HR) and Heart Rate Variability (HRV)	6-72
6.1.10.1	Epidemiologic Panel Studies of Heart Rate (HR) and Heart Rate Variability (HRV)	6-73
6.1.10.2	Controlled Human Exposure Studies of Heart Rate (HR) and Heart Rate Variability (HRV)	6-79
6.1.10.3	Toxicology Studies of Heart Rate (HR) and Heart Rate Variability (HRV)	6-81
6.1.10.3.1	Heart Rate Variability (HRV)	6-82
6.1.11	Systemic Inflammation and Oxidative Stress	6-83
6.1.11.1	Epidemiologic Panel Studies of Systemic Inflammation and Oxidative Stress	6-84
6.1.11.2	Controlled Human Exposure Studies of Short-Term PM _{2.5} Exposure and Systemic Inflammation and Oxidative Stress	6-87
6.1.11.3	Toxicology Studies of Systemic Inflammation and Oxidative Stress	6-89
6.1.11.3.1	Oxidative Stress	6-90
6.1.12	Coagulation	6-91
6.1.12.1	Panel Epidemiologic Studies of Coagulation	6-92
6.1.12.2	Controlled Human Exposure Studies of Coagulation	6-94
6.1.12.3	Toxicology Studies of Coagulation and Thrombosis	6-96
6.1.13	Endothelial Dysfunction and Arterial Stiffness	6-97
6.1.13.1	Panel Epidemiologic Studies of Impaired Vascular Function	6-98
6.1.13.1.1	Digital Vascular Function	6-98
6.1.13.1.2	Arterial Stiffness	6-99
6.1.13.1.3	Biomarkers of Endothelial Injury	6-99
6.1.13.2	Controlled Human Exposure Studies of Short-Term PM _{2.5} Exposure and Impaired Vascular Function	6-102
6.1.13.2.1	Arterial Stiffness	6-104
6.1.13.3	Toxicology Studies of Impaired Vascular Function	6-105
6.1.14	Policy-Relevant Considerations	6-106
6.1.14.1	Potential Copollutant Confounding of the PM _{2.5} -Cardio Vascular Disease (CVD) Relationship	6-107

6.1.14.1.1	PM _{2.5} within the Multipollutant Mixture	6-113
6.1.14.2	The Role of Season and Temperature on PM _{2.5} Associations	6-113
6.1.14.3	The Effect of Lag Structure on Associations of Short-Term PM _{2.5} Exposure and Cardiovascular Effects	6-115
6.1.15	Associations between PM _{2.5} Components and Sources and Cardiovascular Effects	6-118
6.1.15.1	Elemental and Black Carbon	6-121
6.1.15.2	Organic Carbon	6-123
6.1.15.3	Secondary PM _{2.5} —Sulfate, Nitrate, Ammonium	6-124
6.1.15.4	Metals	6-124
6.1.15.5	Other PM _{2.5} components	6-125
6.1.15.6	Sources of PM _{2.5}	6-125
6.1.15.7	Associations Between PM _{2.5} Components and Sources and Effects in People with Diabetes	6-127
6.1.15.8	Toxicology Studies of Individual Components and Sources as Part of the PM Mixture	6-128
6.1.16	Summary and Causality Determination	6-133
6.2	Long-Term PM _{2.5} Exposure and Cardiovascular Effects	6-137
6.2.1	Biological Plausibility	6-139
6.2.2	Ischemic Heart Disease and Myocardial Infarction	6-142
6.2.2.1	Epidemiologic Studies	6-142
6.2.3	Cerebrovascular Disease and Stroke	6-149
6.2.3.1	Epidemiologic Studies	6-149
6.2.3.1.1	Subclinical Cerebrovascular Disease	6-155
6.2.4	Atherosclerosis	6-156
6.2.4.1	Epidemiologic Studies	6-157
6.2.4.2	Toxicological Studies of Atherosclerosis	6-162
6.2.5	Heart Failure and Impaired Heart Function	6-163
6.2.5.1	Epidemiologic Studies	6-164
6.2.5.2	Toxicology Studies of Impaired Heart Function	6-167
6.2.6	Cardiac Electrophysiology and Arrhythmia	6-169
6.2.6.1	Epidemiologic Studies	6-170
6.2.7	Blood Pressure and Hypertension	6-172
6.2.7.1	Epidemiologic Studies	6-172
6.2.7.1.1	Blood Pressure	6-172
6.2.7.1.2	Hypertension	6-178
6.2.7.1.3	Gestational Hypertension and Preeclampsia	6-180
6.2.7.1.4	Renal Function	6-180
6.2.7.2	Toxicology Studies of Changes in Blood Pressure (BP)	6-180
6.2.7.2.1	Renin-Angiotensin System	6-181
6.2.8	Peripheral Vascular Disease (PVD), Venous Thromboembolism, Pulmonary Embolism	6-182
6.2.8.1	Epidemiologic Studies	6-182
6.2.9	Aggregated Clinical Cardiovascular Outcomes	6-185
6.2.10	Long-Term PM _{2.5} Exposure and Cardiovascular Mortality	6-187
6.2.11	Heart Rate (HR) and Heart Rate Variability (HRV)	6-190
6.2.11.1	Epidemiologic Studies of Heart Rate Variability (HRV)	6-190
6.2.11.2	Toxicological Studies of Heart Rate (HR) and Heart Rate Variability (HRV)	6-191
6.2.12	Systemic Inflammation and Oxidative Stress	6-192
6.2.12.1	Epidemiologic Studies	6-192
6.2.12.2	Toxicology Studies	6-193
6.2.13	Coagulation	6-195
6.2.13.1	Epidemiologic Studies	6-195

6.2.14 Impaired Vascular Function and Arterial Stiffness	6-196
6.2.14.1 Epidemiologic Studies	6-196
6.2.14.2 Toxicology Studies	6-197
6.2.15 Copollutant Confounding	6-198
6.2.16 Shape of the Concentration-Response Function	6-203
6.2.17 Associations between PM _{2.5} Components and Sources and Cardiovascular Effects	6-211
6.2.17.1 Toxicology Studies of Individual Components and Sources as Part of a PM Mixture	6-215
6.2.18 Summary and Causality Determination	6-217
6.3 Short-Term PM _{10-2.5} Exposure and Cardiovascular Effects	6-221
6.3.1 Biological Plausibility	6-222
6.3.2 Ischemic Heart Disease and Myocardial Infarction	6-225
6.3.2.1 Emergency Department Visits and Hospital Admissions	6-225
6.3.3 Heart Failure and Impaired Heart Function	6-226
6.3.3.1 Emergency Department Visits and Hospital Admissions	6-226
6.3.3.2 Toxicology Studies of Impaired Heart Function	6-227
6.3.4 Cardiac Electrophysiology, Arrhythmia, and Cardiac Arrest	6-227
6.3.4.1 Emergency Department Visits and Hospital Admissions for Arrhythmia and Out-of-Hospital Cardiac Arrest	6-228
6.3.4.1.1 Out-of-Hospital Cardiac Arrest	6-228
6.3.4.2 Panel Epidemiologic Studies for Arrhythmia and Conduction Abnormalities	6-229
6.3.5 Cerebrovascular Disease and Stroke	6-229
6.3.5.1 Emergency Department Visits and Hospital Admissions	6-229
6.3.6 Blood Pressure and Hypertension	6-230
6.3.6.1 Panel Epidemiologic Studies of Changes in Blood Pressure (BP)	6-231
6.3.6.2 Controlled Human Exposure Studies of Changes in Blood Pressure (BP)	6-231
6.3.6.3 Toxicology Studies of Changes in Blood Pressure (BP)	6-233
6.3.7 Emergency Department Visits and Hospital Admission Studies of Cardiovascular-Related Effects	6-233
6.3.8 Epidemiologic Studies of Cardiovascular Mortality	6-236
6.3.9 Heart Rate (HR) and Heart Rate Variability (HRV)	6-242
6.3.9.1 Epidemiologic Panel Studies of Heart Rate (HR) and Heart Rate Variability (HRV)	6-242
6.3.9.2 Controlled Human Exposure Studies of Heart Rate (HR) and Heart Rate Variability (HRV)	6-242
6.3.10 Systemic Inflammation and Oxidative Stress	6-243
6.3.10.1 Epidemiologic Panel Studies of Systemic Inflammation and Oxidative Stress	6-244
6.3.10.2 Controlled Human Exposure Studies of Systemic Inflammation and Oxidative Stress	6-244
6.3.11 Coagulation	6-246
6.3.11.1 Panel Epidemiologic Studies of Coagulation	6-246
6.3.11.2 Controlled Human Exposure Studies of Coagulation and Thrombosis	6-246
6.3.12 Endothelial Dysfunction and Arterial Stiffness	6-246
6.3.12.1 Controlled Human Exposure Studies of Impaired Vascular Function	6-247
6.3.13 Summary and Causality Determination	6-248
6.4 Long-Term PM _{10-2.5} Exposure and Cardiovascular Effects	6-251
6.4.1 Biological Plausibility	6-252
6.4.2 Ischemic Heart Disease and Myocardial Infarction	6-254
6.4.3 Heart Failure and Impaired Heart Function	6-258
6.4.3.1 Epidemiologic Studies	6-259
6.4.3.2 Toxicology Studies of Impaired Heart Function	6-261
6.4.4 Cerebrovascular Disease and Stroke	6-261
6.4.5 Atherosclerosis	6-265

6.4.6	Blood Pressure and Hypertension	6-268
6.4.6.1	Epidemiologic Studies	6-268
6.4.6.2	Toxicology Studies of Changes in Blood Pressure (BP)	6-268
6.4.7	Peripheral Vascular Disease (PVD), Venous Thromboembolism, Pulmonary Embolism	6-269
6.4.8	Cardiovascular Mortality	6-269
6.4.9	Systemic Inflammation and Oxidative Stress	6-272
6.4.9.1	Epidemiologic Studies	6-272
6.4.9.2	Toxicology Studies	6-272
6.4.10	Summary and Causality Determination	6-272
6.5	Short-Term UFP Exposure and Cardiovascular Effects	6-275
6.5.1	Biological Plausibility	6-276
6.5.2	Ischemic Heart Disease and Myocardial infarction	6-278
6.5.2.1	Emergency Department Visits and Hospital Admissions	6-279
6.5.2.2	Panel Epidemiologic Studies of ST Segment Depression	6-279
6.5.3	Heart Failure and Impaired Heart Function	6-279
6.5.3.1	Emergency Department Visits and Hospital Admissions	6-280
6.5.3.2	Toxicology Studies of Impaired Heart Function	6-280
6.5.4	Cardiac Electrophysiology, Arrhythmia, and Cardiac Arrest	6-281
6.5.4.1	Emergency Department Visits and Hospital Admissions for Arrhythmia and Out-of-Hospital Cardiac Arrest	6-281
6.5.4.2	Panel Epidemiologic Studies for Arrhythmia and Conduction Abnormalities	6-282
6.5.4.3	Controlled Human Exposure Studies for Arrhythmia and Conduction Abnormalities	6-282
6.5.4.4	Toxicological Studies for Arrhythmia and Conduction Abnormalities	6-283
6.5.5	Cerebrovascular Disease and Stroke	6-283
6.5.5.1	Emergency Department Visits and Hospital Admissions	6-284
6.5.6	Blood Pressure and Hypertension	6-284
6.5.6.1	Emergency Department Visits and Hospital Admissions	6-284
6.5.6.2	Panel Epidemiologic Studies of Changes in Blood Pressure (BP)	6-285
6.5.6.3	Controlled Human Exposure Toxicology Studies of Changes in Blood Pressure (BP)	6-286
6.5.6.4	Toxicological Studies of Changes in Blood Pressure (BP)	6-286
6.5.7	Emergency Department Visits and Hospital Admission Studies of Cardiovascular-Related Effects	6-287
6.5.8	Epidemiologic Studies of Cardiovascular Mortality	6-288
6.5.9	Heart Rate (HR) and Heart Rate Variability (HRV)	6-289
6.5.9.1	Epidemiologic Panel Studies of Heart Rate (HR) and Heart Rate Variability (HRV)	6-289
6.5.9.2	Controlled Human Exposure Studies of Heart Rate (HR) and Heart Rate Variability (HRV)	6-290
6.5.9.3	Toxicology Studies of Heart Rate (HR) and Heart Rate Variability (HRV)	6-291
6.5.10	Systemic Inflammation and Oxidative Stress	6-292
6.5.10.1	Epidemiologic Panel Studies of Systemic Inflammation and Oxidative Stress	6-292
6.5.10.2	Controlled Human Exposure Studies of Short-Term UFP Exposure and Systemic Inflammation and Oxidative Stress	6-293
6.5.10.3	Toxicological Studies of Short-Term Ultrafine Particle (UFP) Exposure and Systemic Inflammation and Oxidative Stress	6-294
6.5.11	Coagulation	6-295
6.5.11.1	Panel Epidemiologic Studies	6-295
6.5.11.2	Controlled Human Exposure Studies	6-296
6.5.12	Endothelial Dysfunction and Arterial Stiffness	6-297
6.5.12.1	Panel Epidemiologic Studies	6-297
6.5.12.2	Controlled Human Exposure Studies	6-298

6.5.13 Summary and Causality Determination	6-299
6.6 Long-Term UFP Exposure and Cardiovascular Effects	6-302
6.6.1 Biological Plausibility	6-302
6.6.2 Atherosclerosis	6-302
6.6.3 Heart Failure and Impaired Heart Function	6-303
6.6.4 Blood Pressure and Hypertension	6-304
6.6.5 Systemic Inflammation and Oxidative Stress	6-304
6.6.5.1 Epidemiologic Studies	6-304
6.6.5.2 Toxicology Studies	6-305
6.6.6 Summary and Causality Determination	6-305
6.7 References	6-307

CHAPTER 7 METABOLIC EFFECTS 7-1

7.1 Short-Term PM _{2.5} Exposure and Metabolic Effects	7-4
7.1.1 Biological Plausibility	7-5
7.1.2 Glucose and Insulin Homeostasis	7-7
7.1.2.1 Epidemiologic Studies	7-8
7.1.2.2 Toxicological Studies	7-10
7.1.2.3 Summary	7-12
7.1.3 Other Indicators of Metabolic Function	7-12
7.1.3.1 Inflammation	7-12
7.1.3.2 Liver Function	7-13
7.1.3.3 Blood Lipids	7-14
7.1.3.3.1 Epidemiologic Studies	7-14
7.1.3.3.2 Toxicological Studies	7-14
7.1.3.4 Blood Pressure	7-15
7.1.4 Summary and Causality Determination	7-15
7.2 Long-term PM _{2.5} Exposure and Metabolic Effects	7-16
7.2.1 Biological Plausibility	7-17
7.2.2 Metabolic Syndrome	7-19
7.2.3 Glucose and Insulin Homeostasis	7-22
7.2.3.1 Epidemiologic Studies	7-22
7.2.3.2 Toxicological Studies	7-25
7.2.3.3 Summary	7-30
7.2.4 Type 2 Diabetes Mellitus	7-30
7.2.4.1 Epidemiologic Studies of Type 2 Diabetes Mellitus	7-31
7.2.4.2 Summary	7-36
7.2.5 Other Indicators of Metabolic Function	7-37
7.2.5.1 Inflammation	7-37
7.2.5.2 Liver Function	7-42
7.2.5.2.1 Epidemiologic Studies	7-42
7.2.5.2.2 Toxicological Studies	7-44
7.2.5.3 Endocrine Hormones	7-44
7.2.5.4 Adiposity and Weight Gain	7-44
7.2.5.4.1 Epidemiologic Studies	7-45
7.2.5.4.2 Toxicological Studies	7-47
7.2.5.5 Blood Lipids	7-47
7.2.5.5.1 Epidemiologic Studies	7-47
7.2.5.5.2 Toxicological Studies	7-47
7.2.5.6 Blood Pressure and Hypertension	7-47

7.2.6	Gestational Diabetes	7-48
7.2.7	Type 1 Diabetes	7-48
7.2.7.1	Epidemiologic Studies	7-48
7.2.7.2	Toxicological Studies	7-50
7.2.8	Associations between PM _{2.5} Components and Sources and Metabolic Effects	7-50
7.2.9	Copollutant Confounding	7-50
7.2.10	Metabolic Disease Mortality	7-51
7.2.11	Summary and Causality Determination	7-54
7.3	Short-term PM _{10-2.5} Exposure and Metabolic Effects	7-57
7.4	Long-Term PM _{10-2.5} Exposure and Metabolic Effects	7-58
7.4.1	Biological Plausibility	7-58
7.4.2	Type 2 Diabetes	7-59
7.4.3	Summary and Causal Determination	7-61
7.5	Short-Term UFP Exposure and Metabolic Effects	7-62
7.6	Long-Term UFP Exposure and Metabolic Effects	7-63
7.7	Reference	7-65

CHAPTER 8 NERVOUS SYSTEM EFFECTS 8-1

8.1	Short-term PM _{2.5} Exposure and Nervous System Effects	8-1
8.1.1	Biological Plausibility	8-2
8.1.2	Activation of the Sympathetic Nervous System and the Hypothalamic-Pituitary-Adrenal (HPA)Stress Axis	8-6
8.1.2.1	Controlled Human Exposure Study	8-6
8.1.2.2	Animal Toxicological Studies	8-7
8.1.3	Brain Inflammation and Oxidative Stress	8-8
8.1.3.1	Controlled Human Exposure Study	8-9
8.1.3.2	Animal Toxicological Studies	8-9
8.1.4	Diseases of the Nervous System and Depression	8-11
8.1.5	Components and Sources of PM _{2.5}	8-15
8.1.6	Summary and Causality Determination	8-17
8.2	Long-term PM _{2.5} Exposure and Nervous System Effects	8-19
8.2.1	Biological Plausibility	8-20
8.2.2	Activation of the Sympathetic Nervous System and the Hypothalamic-Pituitary-Adrenal (HPA)Stress Axis	8-25
8.2.3	Brain Inflammation and Oxidative Stress	8-26
8.2.4	Morphologic Changes in the Brain	8-30
8.2.5	Cognitive and Behavioral Effects	8-34
8.2.5.1	Animal Toxicological Studies	8-34
8.2.5.2	Epidemiologic Studies	8-35
8.2.6	Neurodegenerative Diseases	8-45
8.2.7	Neurodevelopmental Effects	8-49
8.2.7.1	Cognitive and Behavioral Effects	8-49
8.2.7.2	Autism	8-53
8.2.8	Components and Sources of PM _{2.5}	8-56
8.2.9	Summary and Causality Determination	8-60
8.3	Short-term PM _{10-2.5} Exposure and Nervous System Effects	8-64
8.3.1	Biological Plausibility	8-65
8.3.2	Activation of the Sympathetic Nervous System and the Hypothalamic-Pituitary-Adrenal (HPA)Stress Axis	8-67
8.3.3	Brain Inflammation and Oxidative Stress	8-68
8.3.4	Summary and Causality Determination	8-69
8.4	Long-term PM _{10-2.5} Exposure and Nervous System Effects	8-70

8.4.1	Biological Plausibility	8-71
8.4.2	Brain Inflammation and Oxidative Stress	8-73
8.4.3	Cognitive and Behavioral Effects in Adults	8-73
8.4.4	Neurodevelopmental Effects	8-74
8.4.5	Summary and Causality Determination	8-77
8.5	Short-term UFP Exposure and Nervous System Effects	8-78
8.5.1	Biological Plausibility	8-79
8.5.2	Activation of the Sympathetic Nervous System and the Hypothalamic-Pituitary-Adrenal (HPA) Stress Axis	8-82
8.5.2.1	Controlled Human Exposure Study	8-82
8.5.2.2	Animal Toxicological Study	8-83
8.5.3	Brain Inflammation and Oxidative Stress	8-84
8.5.4	Cognitive and Behavioral Effects	8-86
8.5.4.1	Epidemiologic Studies	8-86
8.5.4.2	Animal Toxicological Studies	8-86
8.5.5	Summary and Causality Determination	8-87
8.6	Long-term UFP Exposure and Nervous System Effects	8-88
8.6.1	Biological Plausibility	8-89
8.6.2	Activation of the Sympathetic Nervous System and the Hypothalamic-Pituitary-Adrenal (HPA) Stress Axis	8-92
8.6.3	Brain Inflammation and Oxidative Stress	8-93
8.6.4	Morphologic Changes	8-95
8.6.5	Cognitive and Behavioral Effects	8-97
8.6.6	Neurodevelopmental Effects	8-98
8.6.6.1	Epidemiologic Studies	8-98
8.6.6.2	Animal Toxicological Studies	8-100
8.6.7	Summary and Causality Determination	8-103
8.7	References	8-106

CHAPTER 9 REPRODUCTIVE AND DEVELOPMENTAL EFFECTS 9-1

9.1	PM _{2.5} Exposure and Reproductive and Developmental Effects	9-2
9.1.1	Male and Female Reproduction and Fertility	9-3
9.1.1.1	Biological Plausibility	9-3
9.1.1.2	Male Reproduction	9-6
9.1.1.3	Female Reproduction	9-8
9.1.2	Pregnancy and Birth Outcomes	9-10
9.1.2.1	Biological Plausibility	9-10
9.1.2.2	Maternal Health during Pregnancy	9-13
9.1.2.3	Fetal Growth, Birth Weight, and Body Length at Birth	9-16
9.1.2.4	Preterm Birth	9-25
9.1.2.5	Birth Defects	9-32
9.1.2.6	Fetal and Infant Mortality	9-34
9.1.3	Developmental Effects	9-35
9.1.3.1	Respiratory Developmental Effects	9-36
9.1.3.2	Neurodevelopmental Effects	9-37
9.1.3.3	Cardiovascular Effects	9-38
9.1.3.4	Postnatal Growth and Development	9-39
9.1.4	Associations Between PM _{2.5} Components and Sources and Reproductive and Developmental Effects	9-39
9.1.5	Summary and Causality Determination	9-41
9.1.5.1	Male and Female Fertility and Reproduction	9-41
9.1.5.2	Pregnancy and Birth Outcomes	9-43

9.1.5.3	Developmental Outcomes	9-46
9.2	PM _{10-2.5} Exposure and Reproductive and Developmental Effects	9-46
9.2.1	Male and Female Reproduction and Fertility	9-46
9.2.1.1	Biological Plausibility	9-46
9.2.1.2	Male and Female Reproduction and Fertility	9-47
9.2.2	Pregnancy and Birth Outcomes	9-47
9.2.2.1	Biological Plausibility	9-47
9.2.2.2	Pregnancy and Birth Outcomes	9-48
9.2.3	Developmental Outcomes	9-51
9.2.4	Summary and Causality Determination	9-51
9.2.4.1	Male and Female Fertility and Pregnancy	9-51
9.2.4.2	Pregnancy and Birth Outcomes	9-53
9.3	UFP Exposure and Reproductive and Developmental Effects	9-54
9.3.1	Male and Female Reproduction and Fertility	9-55
9.3.1.1	Biological Plausibility	9-55
9.3.1.2	Male Reproductive Function	9-56
9.3.1.3	Female Reproduction and Fertility	9-57
9.3.2	Pregnancy and Birth Outcomes	9-58
9.3.2.1	Biological Plausibility	9-58
9.3.2.2	Pregnancy and Birth Outcomes	9-59
9.3.3	Developmental Effects	9-60
9.3.3.1	Neurodevelopmental Outcomes	9-60
9.3.3.1.1	Neurobehavioral Outcomes, Animal Toxicology	9-60
9.3.3.1.2	Changes in Brain Structure, Animal Toxicology	9-61
9.3.4	Summary and Causality Determination	9-62
9.3.4.1	Male and Female Reproduction and Fertility	9-62
9.3.4.2	Pregnancy and Birth Outcomes	9-63
9.4	References	9-65

CHAPTER 10 CANCER 10-1

10.1	Introduction	10-1
10.1.1	Evaluation of the Relationship Between Long-term PM Exposure and Cancer	10-1
10.1.2	Carcinogens and the Development of Cancer	10-2
10.2	PM _{2.5} Exposure and Cancer	10-3
10.2.1	Biological Plausibility	10-4
10.2.2	Genotoxicity	10-9
10.2.2.1	Mutagenicity	10-10
10.2.2.2	DNA Damage	10-14
10.2.2.2.1	Toxicological Evidence	10-14
10.2.2.2.2	Evidence from Controlled Human Exposure Studies	10-18
10.2.2.2.3	Epidemiologic Evidence	10-19
10.2.2.2.4	Summary	10-20
10.2.2.3	Cytogenetic Endpoints	10-21
10.2.2.3.1	Toxicological Evidence	10-21
10.2.2.3.2	Epidemiologic Evidence	10-21
10.2.2.3.3	Summary	10-24
10.2.2.4	Other Markers	10-24
10.2.2.4.1	Toxicological Evidence	10-24
10.2.2.4.2	Evidence from Controlled Human Exposure Studies	10-25

10.2.2.4.3	Epidemiologic Evidence _____	10-26
10.2.2.4.4	Summary _____	10-26
10.2.2.5	Summary of Genotoxicity _____	10-26
10.2.3	Epigenetic Effects _____	10-27
10.2.3.1	Methylation of Tumor Suppressor Genes _____	10-28
10.2.3.2	Methylation of Repetitive Line Elements _____	10-29
10.2.3.2.1	Toxicological Evidence _____	10-29
10.2.3.2.2	Epidemiologic Evidence _____	10-30
10.2.3.3	Noncoding mRNAs _____	10-33
10.2.3.4	Summary of Epigenetic Effects _____	10-34
10.2.4	Carcinogenic Potential _____	10-34
10.2.5	Cancer Incidence, Mortality, and Survival _____	10-36
10.2.5.1	Lung Cancer _____	10-36
10.2.5.1.1	Lung Cancer Mortality _____	10-43
10.2.5.1.2	Lung Cancer Incidence _____	10-49
10.2.5.1.3	Copollutant Models _____	10-53
10.2.5.1.4	Concentration-Response (C-R) Relationship _____	10-54
10.2.5.1.5	Summary _____	10-58
10.2.5.2	Other Cancers _____	10-59
10.2.5.2.1	Breast Cancer _____	10-62
10.2.5.2.2	Brain Cancer _____	10-63
10.2.5.2.3	Liver Cancer _____	10-63
10.2.5.2.4	Leukemia _____	10-64
10.2.5.2.5	Multiple Cancers _____	10-64
10.2.5.2.6	Summary _____	10-65
10.2.5.3	Cancer Survival _____	10-65
10.2.6	Associations between PM _{2.5} Sources and Components and Cancer _____	10-70
10.2.7	Summary and Causality Determination _____	10-71
10.3	PM _{10-2.5} Exposure and Cancer _____	10-75
10.3.1	Biological Plausibility _____	10-76
10.3.2	Genotoxicity _____	10-78
10.3.2.1	Toxicological Evidence _____	10-79
10.3.2.2	Evidence from Controlled Human Exposure Studies _____	10-81
10.3.2.3	Epidemiologic Evidence _____	10-81
10.3.2.4	Summary of Genotoxicity _____	10-81
10.3.3	Cancer Incidence and Mortality _____	10-82
10.3.3.1	Lung Cancer _____	10-82
10.3.3.1.1	Lung Cancer Incidence _____	10-82
10.3.3.2	Other Cancers _____	10-84
10.3.3.3	Summary _____	10-84
10.3.4	Summary and Causality Determination _____	10-84
10.4	UFP Exposure and Cancer _____	10-86
10.4.1	Biological Plausibility _____	10-86
10.4.2	Genotoxicity _____	10-89
10.4.2.1	Toxicological Evidence _____	10-89
10.4.2.2	Evidence from Controlled Human Exposure Studies _____	10-90
10.4.2.3	Summary of Genotoxicity _____	10-91
10.4.3	Cancer Incidence and Mortality _____	10-91

10.4.4 Summary and Causality Determination	10-91
10.5 References	10-93

CHAPTER 11 MORTALITY 11-1

11.1 Short-Term PM _{2.5} Exposure and Total Mortality	11-1
11.1.1 Biological Plausibility for Short-Term PM _{2.5} Exposure and Total (Nonaccidental) Mortality	11-8
11.1.2 Associations between Short-Term PM _{2.5} Exposure and Total (Nonaccidental) Mortality in All-Year Analyses	11-9
11.1.2.1 Examination of PM _{2.5} -Mortality Relationship through Causal Modeling Statistical Approaches	11-10
11.1.3 Associations between Short-Term PM _{2.5} and Cause-Specific Mortality in All-Year Analyses	11-13
11.1.4 Potential Copollutant Confounding of the PM _{2.5} -Mortality Relationship	11-15
11.1.5 Other Potential Confounders of the PM _{2.5} -Mortality Relationship	11-16
11.1.5.1 Long-Term Temporal Trends and Weather	11-16
11.1.5.2 Influence of Long-Term PM _{2.5} Concentrations on Short-Term PM _{2.5} Associations	11-19
11.1.6 Effect Modification of the PM _{2.5} -Mortality Relationship	11-19
11.1.6.1 Season	11-20
11.1.6.2 Temperature	11-21
11.1.6.3 City and Regional Characteristics	11-24
11.1.6.3.1 Composition/Mixtures	11-24
11.1.6.3.2 Exposure Factors	11-28
11.1.7 Evaluation of Exposure Assessment Techniques	11-32
11.1.7.1 Monitor Representativeness	11-32
11.1.7.2 Urban versus Rural Locations	11-33
11.1.8 Timing of Effects and Exposure Metrics	11-34
11.1.8.1 Lag Structure of Associations	11-34
11.1.8.2 24-Hour Average versus Subdaily (Peak) Exposures	11-37
11.1.9 Alternative PM Size Fractions and Exposure Metrics	11-37
11.1.10 Concentration-Response (C-R) Relationship and Threshold Analyses	11-38
11.1.11 Associations between PM _{2.5} Sources and Components and Mortality	11-41
11.1.11.1 PM _{2.5} Components	11-41
11.1.11.2 Sources	11-50
11.1.12 Summary and Causality Determination	11-52
11.2 Long-Term PM _{2.5} Exposure and Total Mortality	11-57
11.2.1 Biological Plausibility for Long-Term PM _{2.5} Exposure and Total Mortality	11-64
11.2.2 Associations between Long-Term PM _{2.5} Exposure and Mortality	11-64
11.2.2.1 Results of American Cancer Society (ACS) and Harvard Six Cities Cohort Studies	11-64
11.2.2.2 Results of other North American Cohort Studies	11-67
11.2.2.3 Cardiovascular Mortality	11-75
11.2.2.4 Respiratory Mortality	11-75
11.2.2.5 Causal Inference Studies	11-76
11.2.2.6 Studies of Temporal Trends and Life Expectancy	11-76
11.2.3 Potential Copollutant Confounding of the PM _{2.5} -Mortality Relationship	11-77
11.2.4 Evaluation of the PM _{2.5} -Mortality Concentration-Response Relationship	11-81
11.2.5 Evaluation of Factors That May Influence PM _{2.5} Associations	11-87
11.2.5.1 Comparison of Exposure Assessment Techniques	11-87
11.2.5.2 Comparison of Statistical Techniques	11-88
11.2.5.3 Effects of Different Long-Term Exposure Windows	11-89

11.2.6 Associations between PM _{2.5} Sources and Components and Mortality	11-90
11.2.7 Summary and Causality Determination	11-93
11.3 Short-Term PM _{10-2.5} Exposure and Total Mortality	11-99
11.3.1 Biological Plausibility for Short-Term PM _{10-2.5} Exposure and Total Mortality	11-102
11.3.2 Associations between Short-Term PM _{10-2.5} Exposure and Total (Nonaccidental) Mortality in All-Year Analyses	11-102
11.3.3 Associations between Short-Term PM _{10-2.5} Exposure and Cause-Specific Mortality in All-Year Analyses	11-103
11.3.4 Potential Confounding of the PM _{10-2.5} -Mortality Relationship	11-105
11.3.4.1 Copollutants	11-105
11.3.4.2 Long-Term Temporal Trends and Weather	11-108
11.3.5 Effect Modification of the PM _{10-2.5} -Mortality Relationship	11-109
11.3.5.1 Season and Temperature	11-110
11.3.5.2 Role of Exposure Assignment and Exposure Misclassification	11-110
11.3.6 PM _{10-2.5} -Mortality Concentration-Response (C-R) Relationship and Related Issues	11-111
11.3.6.1 Lag Structure of Associations	11-111
11.3.6.2 Concentration-Response Relationship and Threshold Analyses	11-112
11.3.7 Summary and Causality Determination	11-113
11.4 Long-Term PM _{10-2.5} Exposure and Total Mortality	11-116
11.4.1 Biological Plausibility for Long-Term PM _{10-2.5} Exposure and Total Mortality	11-117
11.4.2 Associations between Long-Term PM _{10-2.5} Exposure and Mortality	11-118
11.4.3 Summary and Causality Determination	11-121
11.5 Short-Term UFP Exposure and Total Mortality	11-122
11.5.1 Biological Plausibility for Short-Term UFP Exposure and Total Mortality	11-129
11.5.2 Associations Between Short-Term UFP Exposure and Total Mortality in Multicity Studies	11-129
11.5.3 Associations Between Short-Term UFP Exposure and Total Mortality in Single-City Studies	11-131
11.5.4 Summary and Causality Determination	11-134
11.6 Long-Term UFP Exposure and Total Mortality	11-137
11.6.1 Biological Plausibility for Long-Term UFP Exposure and Total Mortality	11-137
11.6.2 Associations between Long-Term UFP Exposure and Total Mortality	11-138
11.6.3 Summary and Causality Determination	11-138
11.7 References	11-140

CHAPTER 12 POPULATIONS AND LIFESTAGES POTENTIALLY AT INCREASED RISK OF A PARTICULATE MATTER-RELATED HEALTH EFFECT 12-1

12.1 Introduction	12-1
12.2 Approach to Evaluating and Characterizing the Evidence for Populations or Lifestages Potentially at Increased Risk	12-3
12.3 Pre-Existing Diseases/Conditions	12-5
12.3.1 Cardiovascular Disease	12-7
12.3.2 Pre-existing Diabetes and Metabolic Syndrome	12-10
12.3.3 Obesity	12-13
12.3.4 Elevated Cholesterol	12-16
12.3.5 Pre-existing Respiratory Disease	12-18
12.4 Genetic Factors	12-20
12.5 Sociodemographic Factors	12-23
12.5.1 Lifestage	12-23
12.5.1.1 Children	12-23
12.5.1.2 Older Adults	12-25
12.5.2 Sex	12-29
12.5.3 Socioeconomic Status	12-31

12.5.4 Race	12-35
12.5.5 Residential Location	12-39
12.5.5.1 Urban/Rural Residential Locations	12-39
12.5.5.2 Residential Proximity to Traffic	12-41
12.6 Behavioral and Other Factors	12-43
12.6.1 Smoking	12-43
12.6.2 Diet	12-44
12.7 Conclusions	12-47
12.8 References	12-52

CHAPTER 13 WELFARE EFFECTS 13-1

13.1 Introduction	13-1
13.2 Effects on Visibility	13-3
13.2.1 Introduction	13-3
13.2.2 Visibility Impairment	13-4
13.2.2.1 Visibility Metrics	13-4
13.2.2.2 Monitoring of Visibility Impairment	13-6
13.2.3 Relationship between Particulate Matter and Visibility Impairment	13-9
13.2.3.1 Estimated Mass Extinction	13-11
13.2.3.2 Hygroscopic Growth	13-14
13.2.3.3 Reconstructing b_{ext} from PM Speciation Data	13-15
13.2.4 Seasonal and Spatial Patterns of Visibility Impairment	13-16
13.2.4.1 Seasonal and Spatial Light Extinction $PM_{2.5}$ Species Contributions	13-18
13.2.4.2 Long-Term Trends	13-37
13.2.4.3 Characteristic Fine Particulate Mass Light Scattering Efficiencies	13-41
13.2.5 Human Perception of Haze and Landscape Features	13-42
13.2.6 Summary and Causality Determination	13-44
13.3 Effects on Climate	13-45
13.3.1 Introduction	13-45
13.3.2 Overview of the Physics of Climate Change and Radiative Forcing	13-46
13.3.2.1 Observed Recent Climate Change: Detection and Attribution	13-47
13.3.2.2 Metrics of Climate Change, Including Radiative Forcing	13-49
13.3.3 Effects of PM on Radiative Forcing: Mechanisms	13-52
13.3.3.1 Interactions of PM with Radiation	13-53
13.3.3.2 Interactions of PM with Clouds	13-55
13.3.3.3 Effects of Absorbing PM on Snow and Ice Albedo	13-55
13.3.3.4 Effect of Particle Size on the Interactions of PM with Climate	13-56
13.3.4 Estimates of Radiative Forcing from Total PM	13-56
13.3.4.1 Forcing Due to Interactions of PM with Radiation	13-58
13.3.4.2 Forcing Due to Interactions of PM with Clouds	13-61
13.3.4.3 Total Radiative Forcing Due to Interactions of PM with Clouds and Radiation	13-61
13.3.4.4 Forcing Due to the Effects of Absorbing PM on Albedo	13-62
13.3.4.5 Recent Trends in PM Forcing	13-62
13.3.5 Effects of PM on Climate by Species	13-64
13.3.5.1 Sulfate	13-66
13.3.5.2 Nitrate	13-67
13.3.5.3 Organic Carbon, Including Brown Carbon	13-67
13.3.5.4 Black Carbon	13-68
13.3.5.5 Dust	13-69
13.3.6 Climate Response to Changing PM, Including Feedbacks	13-69
13.3.7 Effect of PM on U.S. Regional Climate	13-71
13.3.8 Uncertainties in Estimates of PM Effects on Radiative Forcing and Climate: Summary	13-75

13.3.9 Summary and Causality Determination	13-77
13.4 Effects on Materials	13-78
13.4.1 Introduction	13-78
13.4.2 Soiling and Corrosion	13-79
13.4.3 Dose-Response Relationships	13-83
13.4.4 Damage Functions	13-86
13.4.5 Summary and Causality Determination	13-89
13.5 References	13-90

APPENDIX 1 EVALUATION OF STUDIES ON HEALTH EFFECTS OF PARTICULATE MATTER	1
1.1 References	9

INTEGRATED SCIENCE ASSESSMENT TEAM FOR PARTICULATE MATTER

Executive Direction

- Dr. John Vandenberg (Director)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Steven J. Dutton (Deputy Director)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Reeder Sams (Deputy Director—Acting)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Ms. Debra Walsh (Deputy Director—Retired)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Tara Greaver (Branch Chief—Acting)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Andrew Hotchkiss (Branch Chief—Acting)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Alan Vette (Branch Chief—Acting) —Air and Energy Research Program, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Jennifer Richmond-Bryant (Branch Chief—Acting)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Scientific Staff

- Mr. Jason Sacks (Assessment Lead, Integrated Science Assessment for Particulate Matter)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Barbara Buckley (Deputy Assessment Lead, Integrated Science Assessment for Particulate Matter)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Michelle Angrish—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Renee Beardslee (Separated)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. James Brown—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Evan Coffman—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Allen Davis—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Brooke Hemming—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Erin Hines—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Ellen Kirrane—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Dennis Kotchmar—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Meredith Lassiter—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Thomas Long—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Thomas Luben—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Stephen McDow—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Jennifer Nichols—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Molini M. Patel (Separated)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Joseph P. Pinto (Retired) —National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Jennifer Richmond-Bryant—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Michael Stewart—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Christopher Weaver—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Technical Support Staff

Ms. Marieka Boyd—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Kenneth J. Breito (Separated)—Senior Environmental Employment Program, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Annamarie Cory—Oak Ridge Associated Universities, Inc., National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Charlene Finley (Separated)—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Beth Gatling—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. William Griffin (Separated)—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Hillary Hollinger—Oak Ridge Associated Universities, Inc., National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Saturo Ito (Separated)—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Ryan Jones—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Emily Lau (Separated)—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Connie Meacham (Retired)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Danielle Moore—Senior Environmental Employment Program, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Francis Polakiewicz—Oak Ridge Associated Universities, Inc., National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Samuel Thacker—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Erin Vining—Oak Ridge Associated Universities, Inc., National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Richard N. Wilson—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

AUTHORS, CONTRIBUTORS, AND REVIEWERS

Authors

- Mr. Jason Sacks (Assessment Lead, Integrated Science Assessment for Particulate Matter)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Barbara Buckley (Deputy Assessment Lead, Integrated Science Assessment for Particulate Matter)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Neil Alexis†—Center for Environmental Medicine, Asthma and Lung Biology, UNC School of Medicine, University of North Carolina, Chapel Hill, NC
- Dr. Michelle Angrish—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Renee Beardslee (Separated)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Mr. Adam Benson (Separated)—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. James Brown—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Jennifer Richmond-Bryant—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Barbara Buckley—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Matt Campen†—Health Sciences: Clinical & Translational Science Center, University of New Mexico, Albuquerque, NM
- Dr. Elizabeth Chan¹—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Mr. Evan Coffman—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Mr. Allen Davis—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Steven J. Dutton—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Sorina Eftim†—ICF International, Fairfax, VA

¹ Current affiliation is Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. EPA, Research Triangle Park, NC.

Dr. Jay Gandy†—Fay W. Boozman College of Public Health, University of Arkansas, Little Rock, AR

Dr. Brooke Hemming—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Erin Hines—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Katelyn Holliday†—Postdoctoral Fellow in Epidemiology, University of North Carolina, Chapel Hill, NC

Dr. Veli-Matti Kerminen†—Institute for Atmospheric and Earth System Research, University of Helsinki, Finland

Dr. Marianthi-Anna Kioumourtzoglou†—Mailman School of Public Health, Columbia University, New York, NY

Dr. Ellen Kirrane—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Dennis Kotchmar—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Igor Koturbash†—Fay W. Boozman College of Public Health, University of Arkansas, Little Rock, AR

Dr. Markku Kulmala†—Institute for Atmospheric and Earth System Research, University of Helsinki, Finland

Dr. Meredith Lassiter—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Vijay Limaye (Separated)²—Region 5, U.S. Environmental Protection Agency, Chicago, IL

Dr. Petter Ljungman†—Institute of Environmental Medicine, Karolinska Institute, Solna, Sweden

Dr. Thomas Long—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Thomas Luben—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. William Malm†—Cooperative Institute for Research in the Atmosphere, Colorado State University, Fort Collins, CO

Dr. Joseph McDonald—National Risk Management Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Stephen McDow—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Loretta Mickley†—John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA

² Authored sections of the ISA through U.S. EPA's Skills Marketplace Program.

Mr. Ihab Mikati (Separated)—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. James Mulholland†—School of Civil and Environmental Engineering, College of Engineering, Georgia Tech University, Atlanta, GA

Dr. Jennifer Nichols—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Molini M. Patel (Separated)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Robert Pinder³—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Joseph P. Pinto (Retired)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Kristen Rappazzo—National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Maria Rosa†—Postdoctoral Fellow, Environmental Medicine & Public Health, Mount Sinai School of Medicine, New York, NY

Dr. Armistead Russell†—School of Civil and Environmental Engineering, College of Engineering, Georgia Tech University, Atlanta, GA

Dr. Brett Schichtel†—Cooperative Institute for Research in the Atmosphere, Colorado State University, Fort Collins, CO

Dr. Michael Stewart—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Lindsay Stanek—National Exposure Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Michelle Turner†—Barcelona Institute for Global Health, Barcelona, Spain

Dr. Laura Van Winkle†—Center for Health and the Environment, University of California, Davis, CA

Dr. James Wagner†—Institute for Integrative Toxicology, Michigan State University, East Lansing, MI

Dr. Christopher Weaver—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Greg Wellenius†—Institute at Brown for Environment & Society, Brown University, Providence, RI

Dr. Eric Whitsel†—Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC

³ Authored sections of the ISA through U.S. EPA's Skills Marketplace Program.

Dr. Catherine Yeckel†—Yale School of Public Health, Yale University, New Haven , CT

Dr. Antonella Zanobetti†—Harvard T.H. Chan School of Public Health, Harvard University, Cambridge, MA

Dr. Max Zhang†—Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY

†Under subcontract through ICF International

Contributors

Dr. Allison Elder†—University of Rochester Medical Center, University of Rochester, Rochester, NY

Dr. Brett Gantt—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. EPA, Research Triangle Park, NC

Mr. Tim Hanley—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. EPA, Research Triangle Park, NC

Dr. James Kelly—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. EPA, Research Triangle Park, NC

Ms. Rachel Long—University of North Carolina at Chapel Hill, Chapel Hill, NC

Ms. April Maxwell—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

†Under subcontract through ICF International

Reviewers

Dr. Sara Adar—School of Public Health, University of Michigan, Ann Arbor, Michigan

Dr. Ryan Allen—Faculty of Health Sciences. Simon Fraser University, Burnaby, BC, Canada

Ms. Breanna Alman, Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Janet Burke, National Exposure Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Dr. Wayne Cascio, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Mr. Chad Bailey, Office of Transportation and Air Quality, Office of Air and Radiation, U.S. Environmental Protection Agency, Ann Arbor, MI

Dr. Lisa Baxter, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Mr. Tim Benner, Office of Science and Policy, U.S. Environmental Protection Agency, Washington, DC

Dr. Elizabeth Chan, Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Jana Compton, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. EPA, Corvallis, OR

Dr. Leland Deck, Office of Air and Radiation, U.S. EPA, Washington, DC

Dr. David DeMarini, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Mr. Neal Fann, Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Aimen Farraj, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Dr. Arlene Fiore—Department of Earth and Environmental Sciences, Columbia University, Palisades, NY

Dr. Kristen Foley, National Exposure Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Dr. Ian Gilmour, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Dr. David Grantz—Department of Botany & Plant Sciences, University of California, Davis, CA

Dr. Nicole Hagan, Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Gayle Hagler, National Exposure Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Dr. Jaime Hart—Harvard T.H. Chan School of Public Health, Harvard University, Cambridge, MA

Dr. Michael Hays, National Risk Management Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Dr. Mehdi Hazari, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Ms. Marion Hoyer, Office of Transportation and Air Quality, Office of Air and Radiation, U.S. Environmental Protection Agency, Ann Arbor, MI

Ms. Sheila Igoe, Office of General Counsel, U.S. Environmental Protection Agency, Washington, DC

Dr. Kazuhiko Ito—New York City Department of Health & Mental Hygiene, New York, NY

Dr. Annie Jarabek, National Center for Environmental Assessment, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Dr. Ilona Jaspers—Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC

Dr. Scott Jenkins, Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Thomas Kirchstetter—Civil and Environmental Engineering, University of California, Berkley, CA

Dr. Mike Kleeman—Department of Civil and Environmental Engineering, University of California, Davis, CA

Dr. Urmila Kodavanti, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Dr. Morton Lippman—Department of Environmental Medicine, New York University, Tuxedo, NY

Dr. Danelle Lobdell, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Mr. Daniel Malashock, U.S. Public Health Service, Office of Children's Health Protection, U.S. Environmental Protection Agency, Washington, DC

Dr. Rohit Mathur, National Exposure Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Dr. Collette Miller, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Dr. Fred Miller—Frederick J. Miller & Associates, Raleigh-Durham, NC

Dr. Lucas Neas, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Dr. Zach Pekar, Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Kent Pinkerton—College of Biological Sciences, University of California, Davis, CA

Dr. Sanjay Rajagopalan—Department of Medicine, Case Western Reserve University, Cleveland, OH

Dr. Allen Robinson—Engineering and Public Policy, College of Engineering, Carnegie Mellon University, Pittsburgh, PA

Dr. Ivan Rusyn—Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX

Dr. Stefanie Sarnat—Rollins School of Public Health, Emory University, Atlanta, GA

Ms. Erika Sasser, Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Dina Schreinemachers, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. EPA, Research Triangle Park, NC

Mr. Matt Small, Region 9, U.S. Environmental Protection Agency, San Francisco, CA

Ms. Susan Stone, Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Adam Szpiro—Department of Biostatistics, University of Washington, Seattle, WA

Dr. Karren Wesson, Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Yifang Zhu—Jonathan and Karin Fielding School of Public Health, University of
California, Los Angeles, CA

PREFACE

1 The Preface to the Integrated Science Assessment for Particulate Matter (PM ISA) outlines the
2 legislative requirements of a National Ambient Air Quality Standard (NAAQS) review and the history of
3 the PM NAAQS. This information provides an understanding of the function of the ISA, and in terms of
4 providing a starting point for this PM ISA, presents the basis for the decisions that supported the previous
5 PM NAAQS review. In addition, the Preface details the purpose of the ISA as well as specific issues
6 pertinent to the evaluation of the scientific evidence that takes place within this ISA, including the scope
7 of the ISA and discipline specific decisions that governed parts of the review.

P.1 Legislative Requirements for the Review of the National Ambient Air Quality Standards

8 Two sections of the Clean Air Act (CAA) govern the establishment, review, and revision of the
9 National Ambient Air Quality Standards (NAAQS). Section 108 [42 U.S. Code (U.S.C.) 7408] directs the
10 Administrator to identify and list certain air pollutants and then to issue air quality criteria for those
11 pollutants. The Administrator is to list those air pollutants that in their “judgment, cause or contribute to
12 air pollution which may reasonably be anticipated to endanger public health or welfare,” “the presence of
13 which in the ambient air results from numerous or diverse mobile or stationary sources,” and “for which
14 ... [the Administrator] plans to issue air quality criteria ...” [42 U.S.C. 7408(a)(1); (CAA, 1990a)]. Air
15 quality criteria are intended to “accurately reflect the latest scientific knowledge useful in indicating the
16 kind and extent of all identifiable effects on public health or welfare, which may be expected from the
17 presence of [a] pollutant in the ambient air ...” [42 U.S.C. 7408(b)]. Section 109 [42 U.S.C. 7409; (CAA,
18 1990b)] directs the Administrator to propose and promulgate “primary” and “secondary” NAAQS for
19 pollutants for which air quality criteria are issued. Section 109(b)(1) defines a primary standard as one
20 “the attainment and maintenance of which in the judgment of the Administrator, based on such criteria
21 and allowing an adequate margin of safety, are requisite to protect the public health.”⁴ A secondary
22 standard, as defined in Section 109(b)(2), must “specify a level of air quality the attainment and
23 maintenance of which, in the judgment of the Administrator, based on such criteria, is requisite to protect

⁴ The legislative history of Section 109 indicates that a primary standard is to be set at “... the maximum permissible ambient air level... which will protect the health of any [sensitive] group of the population,” and that for this purpose “reference should be made to a representative sample of persons comprising the sensitive group rather than to a single person in such a group” S. Rep. No. 91:1196, 91st Cong., 2d Sess. 10 (1970).

1 the public welfare from any known or anticipated adverse effects associated with the presence of [the] air
2 pollutant in the ambient air.”⁵

3 The requirement that primary standards provide an adequate margin of safety was intended to
4 address uncertainties associated with inconclusive scientific and technical information available at the
5 time of standard setting. It was also intended to provide a reasonable degree of protection against hazards
6 that research has not yet identified.⁶ Both kinds of uncertainty are components of the risk associated with
7 pollution at levels below those at which human health effects can be said to occur with reasonable
8 scientific certainty. Thus, in selecting primary standards that provide an adequate margin of safety, the
9 Administrator is seeking not only to prevent pollution levels that have been demonstrated to be harmful
10 but also to prevent lower pollutant levels that may pose an unacceptable risk of harm, even if the risk is
11 not precisely identified as to nature or degree. The CAA does not require the Administrator to establish a
12 primary NAAQS at a zero-risk level or at background concentration levels, but rather at a level that
13 reduces risk sufficiently so as to protect public health with an adequate margin of safety.⁷ In so doing,
14 protection is provided for both the population as a whole and those groups and lifestages potentially at
15 increased risk for health effects from exposure to the air pollutant for which each NAAQS is set.

16 In addressing the requirement for an adequate margin of safety, the U.S. Environmental
17 Protection Agency (U.S. EPA) considers such factors as the nature and severity of the health effects
18 involved, the size of the sensitive group(s), and the kind and degree of the uncertainties. The selection of
19 any particular approach to providing an adequate margin of safety is a policy choice left specifically to
20 the Administrator’s judgment.⁸

21 In setting standards that are “requisite” to protect public health and welfare as provided in
22 Section 109(b), the U.S. EPA’s task is to establish standards that are neither more nor less stringent than
23 necessary for these purposes. In so doing, the U.S. EPA may not consider the costs of implementing the
24 standards.⁹ Likewise, “[a]ttainability and technological feasibility are not relevant considerations in the
25 promulgation of national ambient air quality standards.”¹⁰

⁵ Section 302(h) of the Act [42 U.S.C. 7602(h)] provides that all language referring to effects on welfare includes, but is not limited to, “effects on soils, water, crops, vegetation, man-made materials, animals, wildlife, weather, visibility and climate, damage to and deterioration of property, and hazards to transportation, as well as effects on economic values and on personal comfort and well-being...” (CAA, 2005).

⁶ See *Lead Industries Association v. EPA*, 647 F.2d 1130, 1154 [District of Columbia Circuit (D.C. Cir.) 1980]; *American Petroleum Institute v. Costle*, 665 F.2d 1176, 1186 (D.C. Cir. 1981); *American Farm Bureau Federation v. EPA*, 559 F. 3d 512, 533 (D.C. Cir. 2009); *Association of Battery Recyclers v. EPA*, 604 F. 3d 613, 617–18 (D.C. Cir. 2010).

⁷ See *Lead Industries v. EPA*, 647 F.2d at 1156 n.51; *Mississippi v. EPA*, 744 F. 3d 1334, 1339, 1351, 1353 (D.C. Cir. 2013).

⁸ See *Lead Industries Association v. EPA*, 647 F.2d at 1161–62; *Mississippi v. EPA*, 744 F. 3d at 1353.

⁹ See generally, *Whitman v. American Trucking Associations*, 531 U.S. 457, 465–472, 475–476 (2001).

¹⁰ See *American Petroleum Institute v. Costle*, 665 F. 2d at 1185.

1 Section 109(d)(1) requires that “not later than December 31, 1980, and at 5-year intervals
2 thereafter, the Administrator shall complete a thorough review of the criteria published under Section 108
3 and the national ambient air quality standards...and shall make such revisions in such criteria and
4 standards and promulgate such new standards as may be appropriate....” Section 109(d)(2) requires that
5 an independent scientific review committee “shall complete a review of the criteria...and the national
6 primary and secondary ambient air quality standards...and shall recommend to the Administrator any
7 new...standards and revisions of existing criteria and standards as may be appropriate....” Since the early
8 1980s, this independent review function has been performed by the Clean Air Scientific Advisory
9 Committee (CASAC).¹¹

P.1.1. Overview and History of the Reviews of the Primary and Secondary National Ambient Air Quality Standard for Particulate Matter

10 NAAQS are defined by four basic elements: indicator, averaging time, level, and form. The
11 indicator defines the pollutant to be measured in the ambient air for the purpose of determining
12 compliance with the standard. The averaging time defines the time period over which air quality
13 measurements are to be obtained and averaged or cumulated, considering evidence of effects associated
14 with various time periods of exposure. The level of a standard defines the air quality concentration used
15 (i.e., an ambient concentration of the indicator pollutant) in determining whether the standard is achieved.
16 The form of the standard defines the air quality statistic that is compared to the level of the standard in
17 determining whether an area attains the standard. For example, the form of the current primary annual
18 fine particulate matter (PM_{2.5}) standard is the annual mean averaged over 3 years. The Administrator
19 considers these four elements collectively in evaluating the protection to public health provided by the
20 primary NAAQS.

21 Particulate matter (PM) is the generic term for a broad class of chemically and physically diverse
22 substances that exist as discrete particles (liquid droplets or solids) over a wide range of sizes. Particles
23 originate from a variety of anthropogenic stationary and mobile sources, as well as from natural sources.
24 Particles may be emitted directly or formed in the atmosphere by transformations of gaseous emissions
25 such as sulfur oxides (SO_x), oxides of nitrogen (NO_x), ammonia (NH₃) and volatile organic compounds
26 (VOC). Examples of secondary particle formation include: (1) the conversion of SO₂ to sulfuric acid
27 (H₂SO₄) vapor that nucleates new particles or condenses on existing particles and further reacts with NH₃
28 to form various inorganic salts (e.g., ammonium sulfate, [NH₄]₂SO₄, or ammonium bisulfate, NH₄HSO₄);
29 (2) the conversion of nitrogen dioxide (NO₂) to nitric acid (HNO₃) vapor that condenses onto existing
30 particles and reacts further with ammonia to form ammonium nitrate (NH₄NO₃); and (3) reactions

¹¹ Lists of CASAC members and of members of the CASAC Augmented for the Particulate Matter Panel are available at:
[https://yosemite.epa.gov/sab/sabpeople.nsf/WebCommitteesSubcommittees/CASAC%20Particulate%20Matter%20Review%20Panel%20\(2015-2018\)](https://yosemite.epa.gov/sab/sabpeople.nsf/WebCommitteesSubcommittees/CASAC%20Particulate%20Matter%20Review%20Panel%20(2015-2018)).

involving gaseous VOC yielding organic compounds with low vapor pressures that nucleate or condense on existing particles to form secondary organic particulate matter (SOPM) (U.S. EPA, 2004). The chemical and physical properties of PM vary greatly with time, region, meteorology, and source category, thus complicating the assessment of health and welfare effects. These reviews are briefly described below, and further details are provided in the Integrated Review Plan (U.S. EPA, 2016).

The U.S. EPA first established NAAQS for PM in 1971 (36 FR 8186, April 30, 1971), based on the original criteria document (NAPCA, 1969).¹² The federal reference method (FRM) specified for determining attainment of the original standards was the high-volume sampler, which collects PM up to a nominal size of 25 to 45 micrometers (μm) (referred to as total suspended particulates or TSP). The primary standards were at $260 \mu\text{g}/\text{m}^3$, 24-hour average, not to be exceeded more than once per year, and $75 \mu\text{g}/\text{m}^3$, annual geometric mean. The secondary standards were $150 \mu\text{g}/\text{m}^3$, 24-hour average, not to be exceeded more than once per year, and $60 \mu\text{g}/\text{m}^3$, annual geometric mean. Since then, the Agency has completed multiple reviews of the air quality criteria and standards, as summarized in Table I.

Table I History of the National Ambient Air Quality Standards for particulate matter, 1971–2012.

Final Rule/Decision	Indicator	Averaging Time	Level	Form
1971 36 FR 8186 Apr 30, 1971	TSP	24 h	$260 \mu\text{g}/\text{m}^3$ (primary) $150 \mu\text{g}/\text{m}^3$ (secondary)	Not to be exceeded more than once per year
		Annual	$75 \mu\text{g}/\text{m}^3$ (primary) $60 \mu\text{g}/\text{m}^3$ (secondary)	Annual geometric mean
1987 52 FR 24634 Jul 1, 1987	PM_{10}	24 h	$150 \mu\text{g}/\text{m}^3$	Not to be exceeded more than once per year on average over a 3-yr period
		Annual	$50 \mu\text{g}/\text{m}^3$	Annual arithmetic mean, averaged over 3 yr
1997 62 FR 38652 Jul 18, 1997	$\text{PM}_{2.5}$	24 h	$65 \mu\text{g}/\text{m}^3$	98th percentile, averaged over 3 yr
		Annual	$15 \mu\text{g}/\text{m}^3$	Annual arithmetic mean, averaged over 3 yr ^a
	PM_{10}	24 h	$150 \mu\text{g}/\text{m}^3$	Initially promulgated 99th percentile, averaged over 3 yr; when 1997 standards were vacated in 1999, the form of 1987 standards remained in place (not to be exceeded more than once per yr on average over a 3-yr period)
		Annual	$50 \mu\text{g}/\text{m}^3$	Annual arithmetic mean, averaged over 3 yr

¹² Prior to the review initiated in 2007 (see below), the AQCD provided the scientific basis for the NAAQS.

Table I (Continued): History of the National Ambient Air Quality Standards for particulate matter, 1971–2012.

Final Rule/Decision	Indicator	Averaging Time	Level	Form
2006 71 FR 61144 Oct 17, 2006	PM _{2.5}	24 h	35 µg/m ³	98th percentile, averaged over 3 yr
		Annual	15 µg/m ³	Annual arithmetic mean, averaged over 3 yr ^a
	PM ₁₀	24 h	150 µg/m ³	Not to be exceeded more than once per yr on average over a 3-yr period
2012 78 FR 3085 Jan 15, 2013	PM _{2.5}	24 h	35 µg/m ³	98th percentile, averaged over 3-yr ^c
		Annual	12 µg/m ³ (primary) 15 µg/m ³ (secondary)	Annual arithmetic mean, averaged over 3-yr ^b
	PM ₁₀ ^d	24 h	150 µg/m ³	Not to be exceeded more than once per year on average over 3-yr

TSP = total suspended particulates.

^aThe level of the 1997 annual PM_{2.5} standard was to be compared to measurements made at the community-oriented monitoring site recording the highest level, or, if specific constraints were met, measurements from multiple community-oriented monitoring sites could be averaged ("spatial averaging"). This approach was judged to be consistent with the short-term exposure epidemiologic studies on which the annual PM_{2.5} standard was primarily based, in which air quality data were generally averaged across multiple monitors in an area or were taken from a single monitor that was selected to represent community-wide exposures, not localized "hot spots" (62 FR 38672). These criteria and constraints were intended to ensure that spatial averaging would not result in inequities in the level of protection afforded by the PM_{2.5} standards. Community-oriented monitoring sites were specified to be consistent with the intent that a spatially averaged annual standard provide protection for persons living in smaller communities, as well as those in larger population centers.

^bIn the revisions to the PM NAAQS finalized in 2006, U.S. EPA tightened the constraints on the spatial averaging criteria by further limiting the conditions under which some areas may average measurements from multiple community-oriented monitors to determine compliance (71 FR 61165-61167, October 17, 2006).

^cThe level of the 24-h standard is defined as an integer (zero decimal places) as determined by rounding. For example, a 3-yr average 98th percentile concentration of 35.49 µg/m³ would round to 35 µg/m³ and thus meet the 24-h standard and a 3-yr average of 35.50 µg/m³ would round to 36 and, hence, violate the 24-h standard (40 CFR Part 50 Appendix N).

^dThe U.S. EPA revoked the annual PM₁₀ NAAQS in 2006.

Note: When not specified, primary and secondary standards are identical.

1
2 In October 1979 (44 FR 56730, October 2, 1979), the U.S. EPA announced the first periodic
3 review of the air quality criteria and NAAQS for PM. Revised primary and secondary standards were
4 promulgated in 1987 (52 FR 24634, July 1, 1987). In the 1987 decision, the U.S. EPA changed the
5 indicator for particles from TSP to PM₁₀, in order to focus on the subset of inhalable particles small
6 enough to penetrate to the thoracic region of the respiratory tract (including the tracheobronchial and
7 alveolar regions), referred to as thoracic particles.¹³ The level of the 24-hour standards (primary and
8 secondary) was set at 150 µg/m³, and the form was one expected exceedance per year, on average over

¹³ PM₁₀ refers to particles with a nominal mean aerodynamic diameter less than or equal to 10 µm. More specifically, 10 µm is the aerodynamic diameter for which the efficiency of particle collection is 50%. Larger particles are not excluded altogether, but are collected with substantially decreasing efficiency while smaller particles are collected with increasing efficiency.

3 years. The level of the annual standards (primary and secondary) was set at 50 $\mu\text{g}/\text{m}^3$, and the form was annual arithmetic mean, averaged over 3 years.

In April 1994, the U.S. EPA announced its plans for the second periodic review of the air quality criteria and NAAQS for PM, and in 1997 the U.S. EPA promulgated revisions to the NAAQS (62 FR 38652, July 18, 1997). In the 1997 decision, the U.S. EPA determined that the fine and coarse fractions of PM_{10} should be considered separately. This determination was based on evidence that serious health effects were associated with short- and long-term exposures to fine particles in areas that met the existing PM_{10} standards. The U.S. EPA added new standards, using $\text{PM}_{2.5}$ as the indicator for fine particles (with $\text{PM}_{2.5}$ referring to particles with a nominal mean aerodynamic diameter less than or equal to 2.5 μm). These new standards were as follows: (1) an annual standard with a level of 15.0 $\mu\text{g}/\text{m}^3$, based on the 3-year average of annual arithmetic mean $\text{PM}_{2.5}$ concentrations from single or multiple community-oriented monitors;¹⁴ and (2) a 24-hour standard with a level of 65 $\mu\text{g}/\text{m}^3$, based on the 3-year average of the 98th percentile of 24-hour $\text{PM}_{2.5}$ concentrations at each monitor within an area. Also, the U.S. EPA established a new reference method for the measurement of $\text{PM}_{2.5}$ in the ambient air and adopted rules for determining attainment of the new standards. To continue to address the coarse fraction of PM_{10} (referred to as thoracic coarse particles or $\text{PM}_{10-2.5}$; generally including particles with a nominal mean aerodynamic diameter greater than 2.5 μm and less than or equal to 10 μm), the U.S. EPA retained the annual PM_{10} standard and revised the form of the 24-hour PM_{10} standard to be based on the 99th percentile of 24-hour PM_{10} concentrations at each monitor in an area. The U.S. EPA revised the secondary standards by setting them equal in all respects to the primary standards.

Following promulgation of the 1997 PM NAAQS, petitions for review were filed by a large number of parties, addressing a broad range of issues. In May 1999, the U.S. Court of Appeals for the District of Columbia Circuit (D.C. Circuit) upheld the U.S. EPA's decision to establish fine particle standards, holding that "the growing empirical evidence demonstrating a relationship between fine particle pollution and adverse health effects amply justifies establishment of new fine particle standards." *American Trucking Associations v. U.S. EPA*, 175 F. 3d 1027, 1055–56 (D.C. Cir. 1999). The D.C. Circuit also found "ample support" for the U.S. EPA's decision to regulate coarse particle pollution, but vacated the 1997 PM_{10} standards, concluding that the U.S. EPA had not provided a reasonable explanation justifying use of PM_{10} as an indicator for coarse particles. 175 F. 3d at 1054–55. Pursuant to the D.C. Circuit's decision, the U.S. EPA removed the vacated 1997 PM_{10} standards, and the pre-existing 1987 PM_{10} standards remained in place (65 FR 80776, December 22, 2000). The D.C. Circuit also upheld

¹⁴ The level of the 1997 annual $\text{PM}_{2.5}$ standard was to be compared to measurements made at the community-oriented monitoring site recording the highest concentration or, if specific constraints were met, measurements from multiple community-oriented monitoring sites could be averaged (i.e., "spatial averaging"). In the last review (completed in 2012) the U.S. EPA replaced the term "community-oriented" monitor with the term "area-wide" monitor. Area-wide monitors are those sited at the neighborhood scale or larger, as well as those monitors sited at micro-or middle scales that are representative of many such locations in the same CBSA (78 FR 3236, January 15, 2013).

1 the U.S. EPA's determination not to establish more stringent secondary standards for fine particles to
2 address effects on visibility. 175 F. 3d at 1027.

3 The D.C. Circuit also addressed more general issues related to the NAAQS, including issues
4 related to the consideration of costs in setting NAAQS and the U.S. EPA's approach to establishing the
5 levels of NAAQS. Regarding the cost issue, the court reaffirmed prior rulings holding that in setting
6 NAAQS the U.S. EPA is "not permitted to consider the cost of implementing those standards." Id. at
7 1040-41. Regarding the levels of NAAQS, the court held that the U.S. EPA's approach to establishing the
8 level of the standards in 1997 (i.e., both for PM and for the ozone NAAQS promulgated on the same day)
9 effected "an unconstitutional delegation of legislative authority." Id. at 1034-40. Although the court stated
10 that "the factors U.S. EPA uses in determining the degree of public health concern associated with
11 different levels of ozone and PM are reasonable," it remanded the rule to the U.S. EPA, stating that when
12 the U.S. EPA considers these factors for potential non-threshold pollutants "what U.S. EPA lacks is any
13 determinate criterion for drawing lines" to determine where the standards should be set.

14 The D.C. Circuit's holding on the cost and constitutional issues were appealed to the U.S.
15 Supreme Court. In February 2001, the Supreme Court issued a unanimous decision upholding the U.S.
16 EPA's position on both the cost and constitutional issues. *Whitman v. American Trucking Associations*,
17 531 U.S. 457, 464, 475-76. On the constitutional issue, the Court held that the statutory requirement that
18 NAAQS be "requisite" to protect public health with an adequate margin of safety sufficiently guided the
19 U.S. EPA's discretion, affirming the U.S. EPA's approach of setting standards that are neither more nor
20 less stringent than necessary.¹⁵

21 In October 1997, the U.S. EPA published its plans for the third periodic review of the air quality
22 criteria and NAAQS for PM (62 FR 55201, October 23, 1997). After the CASAC and public review of
23 several drafts, the U.S. EPA's NCEA finalized the Air Quality Criteria Document (AQCD) in October
24 2004 (U.S. EPA, 2004). The U.S. EPA's OAQPS finalized a Risk Assessment and Staff Paper in
25 December of 2005 (Abt, 2005; U.S. EPA, 2005).¹⁶ On December 20, 2005, the U.S. EPA announced its
26 proposed decision to revise the NAAQS for PM, and solicited comment on a broad range of options
27 (71 FR 2620, January 17, 2006). On September 21, 2006, the U.S. EPA announced its final decisions to
28 revise the primary and secondary NAAQS for PM to provide increased protection of public health and
29 welfare, respectively (71 FR 61144, October 17, 2006). With regard to the primary and secondary
30 standards for fine particles, the U.S. EPA revised the level of the 24-hour PM_{2.5} standards to 35 µg/m³,

¹⁵ The Supreme Court remanded the case to the Court of Appeals for resolution of any remaining issues that had not been addressed in that court's earlier rulings. Id. at 475-76. In a March 2002 decision, the Court of Appeals rejected all remaining challenges to the standards, holding that the EPA's PM_{2.5} standards were reasonably supported by the administrative record and were not "arbitrary and capricious" *American Trucking Associations v. EPA*, 283 F. 3d 355, 369-72 (D.C. Cir. 2002).

¹⁶ Prior to the review initiated in 2007, the Staff Paper, rather than the PA, presented the EPA staff's considerations and conclusions regarding the adequacy of existing NAAQS and, when appropriate, the potential alternative standards that could be supported by the evidence and information.

1 retained the level of the annual PM_{2.5} standards at 15.0 µg/m³, and revised the form of the annual PM_{2.5}
2 standards by narrowing the constraints on the optional use of spatial averaging. For the primary and
3 secondary standards for PM₁₀, the U.S. EPA retained the 24-hour standards, with levels at 150 µg/m³, and
4 revoked the annual standards.¹⁷ The Administrator judged that the available evidence generally did not
5 suggest a link between long-term exposure to existing ambient levels of coarse particles and health or
6 welfare effects. In addition, a new reference method was added for the measurement of PM_{10-2.5} in the
7 ambient air, in order to provide a basis for approving federal equivalent methods (FEMs) and to promote
8 the gathering of scientific data to support future reviews of the PM NAAQS.

9 Several parties filed petitions for review following promulgation of the revised PM NAAQS in
10 2006. These petitions addressed the following issues: (1) selecting the level of the primary annual PM_{2.5}
11 standard; (2) retaining PM₁₀ as the indicator of a standard for thoracic coarse particles, retaining the level
12 and form of the 24-hour PM₁₀ standard, and revoking the PM₁₀ annual standard; and (3) setting the
13 secondary PM_{2.5} standards identical to the primary standards. On February 24, 2009, the U.S. Court of
14 Appeals for the District of Columbia Circuit issued its opinion in the case *American Farm Bureau*
15 *Federation v. U.S. EPA*, 559 F. 3d 512 (D.C. Cir. 2009). The court remanded the primary annual PM_{2.5}
16 NAAQS to U.S. EPA because U.S. EPA failed to adequately explain why the standards provided the
17 requisite protection from both short- and long-term exposures to fine particles, including protection for
18 at-risk populations. *American Farm Bureau Federation v. U.S. EPA*, 559 F. 3d 512, 520–27 (D.C. Cir.
19 2009). With regard to the standards for PM₁₀, the court upheld U.S. EPA’s decisions to retain the 24-hour
20 PM₁₀ standard to provide protection from thoracic coarse particle exposures and to revoke the annual
21 PM₁₀ standard. *American Farm Bureau Federation*, 559 F. 2d at 533–38. For the secondary PM_{2.5}
22 standards, the court remanded the standards to U.S. EPA because the Agency failed to adequately explain
23 why setting the secondary PM standards identical to the primary standards provided the required
24 protection for public welfare, including protection from visibility impairment. *American Farm Bureau*
25 *Federation*, 559 F. 2d at 528–32. The U.S. EPA responded to the court’s remands as part of the next
26 review of the PM NAAQS, which was initiated in 2007 (discussed below).

27 In June 2007, the U.S. EPA initiated the fourth periodic review of the air quality criteria and the
28 PM NAAQS by issuing a call for information in the Federal Register (72 FR 35462, June 28, 2007).
29 Based on the NAAQS review process, as revised in 2008 and again in 2009,¹⁸ the U.S. EPA held

¹⁷ In the 2006 proposal, the EPA proposed to revise the 24-hour PM₁₀ standard in part by establishing a new PM_{10-2.5} indicator for thoracic coarse particles (i.e., particles generally between 2.5 and 10 µm in diameter). The EPA proposed to include any ambient mix of PM_{10-2.5} that was dominated by resuspended dust from high density traffic on paved roads and by PM from industrial sources and construction sources. The EPA proposed to exclude any ambient mix of PM_{10-2.5} that was dominated by rural windblown dust and soils and by PM generated from agricultural and mining sources. In the final decision, the existing PM₁₀ standard was retained, in part due to an “inability ...to effectively and precisely identify which ambient mixes are included in the [PM_{10-2.5}] indicator and which are not” (71 FR 61197, October 17, 2006).

¹⁸ The history of the NAAQS review process, including revisions to the process, is discussed at <http://www3.epa.gov/ttn/naaqs/review2.html>.

science/policy issue workshops on the primary and secondary PM NAAQS (72 FR 34003, June 20, 2007; 72 FR 34005, June 20, 2007), and prepared and released the planning and assessment documents that comprise the review process [i.e., IRP (U.S. EPA, 2008), ISA (U.S. EPA, 2009a)], REA planning documents for health and welfare (Office of Air and Radiation, 2009; U.S. EPA, 2009b), a quantitative health risk assessment (U.S. EPA, 2010b)¹⁹ and an urban-focused visibility assessment (U.S. EPA, 2010a),²⁰ and PA (U.S. EPA, 2011)]. In June 2012, the U.S. EPA announced its proposed decision to revise the NAAQS for PM (77 FR 38890, June 29, 2012).

In December 2012, the U.S. EPA announced its final decisions to revise the primary NAAQS for PM to provide increased protection of public health (78 FR 3086, January 15, 2013). With regard to primary standards for PM_{2.5}, the U.S. EPA revised the level of the annual PM_{2.5} standard²¹ to 12.0 µg/m³ and retained the 24-hour PM_{2.5} standard, with its level of 35 µg/m³. For the primary PM₁₀ standard, the U.S. EPA retained the 24-hour standard, with its level of 150 µg/m³, to continue to provide protection against effects associated with short-term exposure to thoracic coarse particles (i.e., PM_{10-2.5}). With regard to the secondary PM standards, the U.S. EPA generally retained the 24-hour and annual PM_{2.5} standards²² and the 24-hour PM₁₀ standard to address visibility and non-visibility welfare effects. On judicial review, the revised standards were upheld in all respects. *NAM v U.S. EPA*, 750 F.3d 921 (D.C. Cir. 2014).

P.2 Purpose and Overview of the Integrated Science Assessment

The Integrated Science Assessment (ISA) is a comprehensive evaluation and synthesis of the policy-relevant science “useful in indicating the kind and extent of identifiable effects on public health or welfare which may be expected from the presence of [a] pollutant in ambient air,” as described in Section 108 of the Clean Air Act (CAA, 1990a). This ISA communicates critical science judgments of the health and welfare criteria for particulate matter (PM). As such, this ISA serves as the scientific foundation for the review of the current primary (health-based) and secondary (welfare-based) National Ambient Air Quality Standards (NAAQS) for PM. In terms of the evaluation of the welfare-based

¹⁹ The quantitative assessment of health risks conducted in the last review was presented in the Quantitative Health Risk Assessment for Particulate Matter (U.S. EPA, 2010b). In the current review, quantitative assessments for health-related exposures and risks, if warranted, would be presented in the Health Risk and Exposure Assessment (HREA). For consistency with the documents developed under the current NAAQS process, the Quantitative Health Risk Assessment for Particulate Matter (U.S. EPA, 2010b) from the last review will be referenced in this document as the 2010 HREA.

²⁰ The quantitative assessment of welfare effects conducted in the last review was presented, in part, in the Urban-Focused Visibility Assessment (U.S. EPA, 2010a). In the current review, quantitative assessments for welfare effects, if warranted, would be presented in the Welfare Risk and Exposure Assessment (WREA). The Urban-Focused Visibility Assessment (U.S. EPA, 2010a) from the last review will be referenced in this document as the 2010 UFVA.

²¹ The U.S. EPA also eliminated the option for spatial averaging.

²² Consistent with the primary standard, the U.S. EPA eliminated the option for spatial averaging with the annual standard.

evidence, the PM ISA focuses specifically on the nonecological effects of PM (i.e., visibility, materials effects, and climate) because the ecological effects are assessed in the ISA for Oxides of Nitrogen, Oxides of Sulfur, and Particulate Matter—Ecological Criteria as a result of these criteria pollutants being interrelated through complex chemical and physical atmospheric processes and all contributing to nitrogen (N) and sulfur (S) deposition (U.S. EPA, 2016). While the focus of the evaluation of the visibility and climate evidence is on PM, for materials effects, as detailed in the Integrated Review Plan (IRP), the PM ISA summarizes soiling and deterioration of materials attributable to PM and related N and S components because of the difficulty associated with isolating the effects of gaseous and particulate N and S wet deposition and because the ISA for Oxides of Nitrogen, Oxides of Sulfur, and Particulate Matter—Ecological Criteria focuses only on ecological effects (U.S. EPA, 2016).

This ISA evaluates relevant scientific literature published since the 2009 PM ISA [(U.S. EPA, 2009a) or 2009 PM ISA], integrating key information and judgments contained in the 2009 PM ISA and previous assessments of PM, i.e., 2004 AQCD for PM (U.S. EPA, 2004), 1996 AQCD for PM (U.S. EPA, 1996), 1982 AQCD for PM and Sulfur Oxides (U.S. EPA, 1982) and its Addendum (U.S. EPA, 1986), and the 1969 AQCD for PM (NAPCA, 1969). Thus, this ISA updates the state of the science that was available for the 2009 PM ISA, which informed decisions on the primary and secondary PM NAAQS in the review completed in 2012. In 2012, the U.S. EPA lowered the annual $PM_{2.5}$ standard to a mean of $12 \mu\text{g}/\text{m}^3$, which is based on the annual mean averaged over 3 years, while retaining the 24-hour $PM_{2.5}$ standard of $35 \mu\text{g}/\text{m}^3$, which is based on the 98th percentile averaged over 3 years (78 FR 3086). As part of the primary annual $PM_{2.5}$ standard, the U.S. EPA eliminated the spatial averaging provision to avoid disproportionate impacts on susceptible populations (i.e., populations potentially at increased risk of a PM-related health effect). The $PM_{2.5}$ standards are meant to provide increased protection for children, older adults, and people with pre-existing heart and lung disease as well as other potential susceptible populations against an array of $PM_{2.5}$ -related health effects including premature mortality, increased hospital admissions and emergency department (ED) visits, and the development of chronic respiratory disease. Additionally, the U.S. EPA retained the current primary 24-hour PM_{10} standard at a level of $150 \mu\text{g}/\text{m}^3$, which is not to be exceeded more than once per year over 3 years, to protect against health effects due to short-term exposure to thoracic coarse particles ($PM_{10-2.5}$) including premature mortality and increased hospital admissions and ED visits (78 FR 3086).

In terms of the secondary PM standards, the U.S. EPA retained the annual $PM_{2.5}$ standard at $15 \mu\text{g}/\text{m}^3$ as well as the 24-hour $PM_{2.5}$ standard of $35 \mu\text{g}/\text{m}^3$ and the 24-hour PM_{10} standard of $150 \mu\text{g}/\text{m}^3$ (78 FR 3086). However, the form of the annual secondary $PM_{2.5}$ standard was changed to remove the option of spatial averaging. These secondary standards protect against non-visibility welfare effects including ecological effects, effects on materials, and climate impacts. To protect against PM-related visibility impairment, the U.S. EPA identified a target degree of protection defined as a $PM_{2.5}$ visibility index of 30 deciviews (dv), which is based on the 90th percentile of 24-hour average $PM_{2.5}$ concentrations over 3 years (78 FR 3086). However, an U.S. EPA analysis determined that the current secondary 24-hour $PM_{2.5}$ standard would provide sufficient protection, and in some cases greater protection, therefore a

1 distinct secondary standard was not needed to provide requisite protection for both visibility and non-
2 visibility related welfare effects.

3 This new review of the primary and secondary PM NAAQS is guided by several policy-relevant
4 questions that are identified in The Integrated Review Plan for the National Ambient Air Quality
5 Standards for Particulate Matter (U.S. EPA, 2016). To address these questions and update the scientific
6 judgments in the 2009 PM ISA (U.S. EPA, 2009a), this ISA aims to:

- 7 • Assess whether new information (since the last PM NAAQS review) further informs the
8 relationship between exposure to PM and specific health and nonecological welfare effects?
- 9 • Inform whether the current indicators (i.e., PM_{2.5} for fine particles and PM₁₀ for thoracic coarse
10 particles), averaging times (e.g., 24-hour average, annual average), and levels of the PM NAAQS
11 are appropriate?

12 In addressing policy-relevant questions, this ISA aims to characterize the independent health and
13 welfare effects of PM, specifically PM_{2.5} (fine PM; particulate matter with a nominal mean aerodynamic
14 diameter less than or equal to 2.5 μm) and PM_{10-2.5} (thoracic coarse or coarse PM; particulate matter with a
15 nominal mean aerodynamic diameter greater than 2.5 μm and less than or equal to 10 μm) and whether
16 there is evidence of an independent health effect for other size fractions [e.g., ultrafine particles (UFP),
17 generally considered as particulates with a diameter less than or equal to 0.1 μm (typically based on
18 physical size, thermal diffusivity or electrical mobility) (U.S. EPA, 2009a)] or specific PM components
19 (e.g., metals). In the characterization of whether there is evidence of an independent health and welfare
20 effect due to PM, the ISA considers possible influences of other atmospheric pollutants, including both
21 gaseous (i.e., O₃, NO₂, SO₂, and CO) and other PM size fractions. The information summarized in this
22 ISA will serve as the scientific foundation for the review of the current primary and secondary PM
23 NAAQS.

P.3 Process for Developing Integrated Science Assessments

24 The U.S. EPA uses a structured and transparent process for evaluating scientific information and
25 determining the causal nature of relationships between air pollution exposures and health effects [details
26 provided in the Preamble to the Integrated Science Assessments (U.S. EPA, 2015)]. The ISA
27 development process describes approaches for literature searches, criteria for selecting and evaluating
28 relevant studies, and a framework for evaluating the weight of evidence and forming causal
29 determinations. As part of this process, the ISA is reviewed by the Clean Air Scientific Advisory
30 Committee (CASAC), which is a formal independent panel of scientific experts, and by the public. As
31 this ISA informs the review of the primary and secondary PM NAAQS, it integrates and synthesizes
32 information characterizing exposure to PM and potential relationships with health and welfare effects.
33 Relevant studies include those examining atmospheric chemistry, spatial and temporal trends, and
34 exposure assessment, as well as U.S. EPA analyses of air quality and emissions data. Relevant health
35 research includes epidemiologic, controlled human exposure, and toxicological studies on health effects,

as well as studies on dosimetry and biological plausibility. Additionally, relevant welfare research includes studies examining visibility impairment, effects on materials, and climate impacts.

The U.S. EPA initiated the current review of the primary and secondary PM NAAQS in December 2014 with a call for information from the public (U.S. EPA, 2013). Subject-area experts and the public were also able to recommend studies and reports to consider for the ISA during a science/policy issue “kick-off” workshop held at the U.S. EPA in February 2015. Thereafter, the U.S. EPA routinely conducted literature searches to identify relevant peer-reviewed studies published since the previous ISA (i.e., since May 2009). Multiple search methods were used [Preamble to the ISAs (U.S. EPA, 2015), Section 2], including searches in the PubMed and Web of Science databases. These searches were meant to broadly capture all potentially relevant PM literature. To ensure the most policy-relevant evaluation of the current state of the science the scope of this PM ISA reflects not only the evolving PM literature base, but also the ability of the studies evaluated to directly inform the policy-relevant questions that form the basis of this review. Using both the scope of this ISA, detailed below, as well as the policy-relevant questions outlined in the PM IRP, studies that were uninformative based on title screening were excluded. Studies that were judged to be potentially relevant based on review of the abstract or full text and “considered” for inclusion in the ISA are documented in the Health and Environmental Research Online (HERO) website. The HERO project page for this ISA (<https://hero.epa.gov/hero/particulate-matter>) contains the references that are cited in the ISA, the references that were considered for inclusion but not cited, and electronic links to bibliographic information and abstracts.

P.3.1. Scope of the ISA

As initially detailed in the PM IRP (U.S. EPA, 2016) and further expanded upon here, when evaluating the broad body of literature across scientific disciplines, the U.S. EPA considers whether the studies fall within the scope of the PM ISA (i.e., provide information which can address key policy-relevant questions). As a result, the focus of the PM ISA with respect to the health effects evidence is on studies of short-term (i.e., hours up to 1 month) and long-term (i.e., 1 month to years) exposures conducted at concentrations of PM that are relevant to the range of human exposures across ambient microenvironments (up to 2 mg/m³, which is one to two orders of magnitude above ambient concentrations), and (1) include a composite measure of PM²³ or (2) characterize PM and apply some approach to assess the direct effect of PM when the exposure of interest is a source-based mixture (e.g., diesel exhaust, gasoline exhaust, wood smoke). For epidemiologic studies, the scope is further refined when evaluating the evidence for those health outcomes where the 2009 PM ISA concluded that a “causal relationship exists” (i.e., short- and long-term PM_{2.5} exposure and mortality and cardiovascular effects) to ensure the evaluation of the evidence focuses on the studies that are the most policy-relevant. As such, the focus is on those studies conducted in areas where mean PM_{2.5} concentrations are <20 µg/m³

²³ Composite measures of PM may include mass, volume, surface area, or number concentration.

1 or in the case of a multicity study where more than half of the cities have concentrations $<20 \mu\text{g}/\text{m}^3$.
2 However, studies where mean $\text{PM}_{2.5}$ concentrations exceed $20 \mu\text{g}/\text{m}^3$ are included if the studies address
3 specific areas where the evidence was limited, as identified in the 2009 PM ISA, such as copollutant
4 confounding. The scope is broader for experimental studies when examining biological plausibility for
5 PM health effects, and in some cases, includes in vitro studies, studies that use intratracheal (IT)
6 installation, studies examining relative toxicity, and studies conducted at concentrations $>2 \text{ mg}/\text{m}^3$.

7 In the first case, studies that focus on a single component, group of components, or source, must
8 also examine a composite measure of PM (e.g., mass of $\text{PM}_{2.5}$ and/or $\text{PM}_{10-2.5}$, or in the case of ultrafine
9 particles [UFP] mass, particle number, etc.). This requirement facilitates a comparison of effects or
10 associations observed for individual components or alternative metrics to the current mass-based PM
11 indicators. For experimental studies, to assess the relationship between $\text{PM}_{2.5}$ components and specific
12 health effects this ISA relies on the approach initially outlined in the 2009 PM ISA and further refined in
13 [Stanek et al. \(2011\)](#). This approach is consistent with the Health Effects Institute (HEI) Review Panel of
14 the National Particle Component Toxicity (NPACT) initiative that states both source categories and
15 component concentrations should be used directly in the health analyses with a focus on examining
16 consistencies and differences between the two approaches ([Lippmann et al., 2013](#)). As a result,
17 experimental studies included within this ISA fulfill the following four criteria (1) exposures examined
18 consist of $\text{PM}_{2.5}$ from U.S. airsheds or those representative of the U.S. (e.g., Europe, Canada);
19 (2) examined at least five PM components; (3) grouped PM components using statistical methods, for
20 which the groups were not predefined based on common physical or chemical properties (e.g., water
21 soluble vs. nonsoluble); and (4) applied a formal statistical analysis to investigate the relationship
22 between groups of PM components or PM sources and health effects. The criteria applied to both
23 experimental and epidemiologic studies in the evaluation of PM components ensures that a systematic
24 approach is used in both identifying and evaluating those studies that examine PM components.

25 The second case primarily applies to experimental studies that attempt to disentangle the effect of
26 PM on health from a complex air pollution mixture of particles, gases, and components distributed
27 between the gas and particle phases. Studies that conduct an assessment of the PM effect from a
28 source-based mixture (e.g., wood smoke, diesel exhaust, gasoline exhaust, etc.) are only included if they
29 use filtration (e.g., a particle trap) or another approach to differentiate between effects due to the mixture
30 and effects due to the particles alone.

31 Whereas the preceding paragraphs focused broadly on the scope of the entire PM ISA, there are
32 additional nuances that further frame the scope of the ISA, specifically with respect to UFPs. UFPs have
33 often been defined as particles $<0.1 \mu\text{m}$ ([U.S. EPA, 2009a](#)), but depending on the scientific discipline, the
34 methods employed and particle sizes examined to assess the UFP-health effects relationship varies. UFP
35 exposures in animal toxicological and controlled human exposure studies typically use a particle
36 concentrator, which can result in exposures to particles $<0.30 \mu\text{m}$ (Section [2.4.3.1](#)). While toxicological
37 studies typically rely on examining UFP mass, epidemiologic studies examine multiple UFP metrics

1 including particle number concentration (NC), mass concentration (MC), and surface area concentration
2 (SC). However, depending on the monitor used and the metric, the UFP size distribution that could be
3 included within each of these ranges can vary. Some studies that examine NC use no additional size
4 classification, instead measuring NC over the entire size range of the particle counter. In instances where
5 the entire size range is measured, limited available measurement data in the U.S. and Europe indicates
6 that approximately 67 to 90% of NC represents particles $<0.1\ \mu\text{m}$ (Section 2.4.3.1). Studies that examine
7 MC or SC often include a range of particle sizes up to $0.3\ \mu\text{m}$. Currently, a consensus has not been
8 reached within the scientific community on the metric that best represents exposure to UFPs (Baldauf et
9 al., 2016). As a result, in this ISA the focus of the evaluation of the UFP-health effects relationship is on
10 particles $<0.3\ \mu\text{m}$ for MC and SC metrics included in experimental studies, and any size range that
11 includes particles $<0.1\ \mu\text{m}$ for NC. Focusing on these criteria when evaluating UFP studies will provide
12 the most comprehensive assessment of UFPs and ensure that the metric examined represents primarily the
13 UFP size range.

14 Across disciplines, studies defined as examining UFPs, but focusing on the sources, transport,
15 and fate of fibers and unique nano-objects (namely, dots, hollow spheres, plates, rods, fibers, tubes) are
16 not reviewed because substantial exposures to fibers and unique nano-objects generally occur in the
17 occupational settings rather than the ambient environment. Furthermore, the in vivo disposition of unique
18 nano-objects is not likely relevant to the behavior of ultrafine (UF) aerosols found in ambient air, which
19 are created by combustion sources and photochemical formation of secondary organic aerosols. However,
20 some studies focusing on engineered nano- or ultrafine particles (e.g., carbon black, titanium dioxide) are
21 included where they contribute to an understanding of the dosimetry or biological plausibility of PM.

22 In addition to the specific parameters that broadly form the overall scope of the review of PM and
23 health effects, additional criteria were applied for the evaluation of the evidence for cancer. As detailed in
24 the PM IRP, the PM ISA focuses on whether PM can directly cause cancer through only inhalation
25 exposures at ambient and near-ambient concentrations (i.e., up to $2\ \text{mg}/\text{m}^3$). When evaluating the
26 epidemiologic evidence for cancer, consistent with the overall scope of the ISA, the focus is on those
27 studies with composite measures of PM. Whereas the ISA tends not to focus the evaluation of the health
28 effects evidence on in vitro studies, for the purposes of examining the mutagenicity of PM in vitro
29 systems are discussed because they inform the biological pathways underlying cancer. While some
30 components of PM are known carcinogens (e.g., benzene), as previously stated the focus of this ISA is on
31 composite measures of PM (e.g., $\text{PM}_{2.5}$) and, where applicable, comparison to effects or associations
32 observed for individual PM components to help inform the adequacy of current mass-based PM
33 indicators. As such, the relationship between PM exposure and cancer is evaluated similarly to that of
34 other health effects, resulting in the exclusion of studies that examine individual PM components without
35 a composite PM measure. The evaluation of cancer includes studies that use PM filter extracts with the
36 understanding that bioavailability of PM components in vivo is a complex issue not easily mimicked by
37 extraction of PM collected on filters. Overall, the evaluation of cancer in the ISA will primarily focus on
38 studies of inhaled PM since these studies are more relevant to ambient exposure conditions with the

1 recognition of the extensive historical evaluations on the mutagenicity, genotoxicity, and carcinogenicity
2 of whole PM exposures (i.e., not defined by size fraction).

3 For nonecological welfare effects (i.e., visibility, climate, and materials effects), this ISA will
4 build on information available during the last review describing the role of PM in visibility impairment,
5 radiative forcing resulting in global and regional climate change, and materials damage and soiling. For
6 visibility effects, studies are included which advance our understanding of visual impairment of airborne
7 PM, including studies of atmospheric chemistry, visibility preference, or other measures of adversity to
8 public welfare, in urban and rural settings. For climate effects, this ISA focuses on climate as the welfare
9 effect as listed in the Clean Air Act Amendments of 1970 with a focus on radiative forcing, surface
10 meteorological trends, and climate feedbacks, and not on downstream ecosystem effects, human health
11 effects, or future air quality projections resulting from changes in climate (CAAA, 1970). The primary
12 literature base for the evaluation of the effects of airborne and deposited PM on climate comes from
13 recent national and international climate assessments such as the National Climate Assessment (Melillo et
14 al., 2014) and International Panel on Climate Change (IPCC, 2014), as well as other recent and more
15 focused reports relevant to PM climate forcing [e.g., (U.S. EPA, 2012)]. The focus is on studies that
16 inform the independent role of PM in climate forcing as well as effects on U.S. national and regional
17 climate. For effects on materials, studies included in the PM ISA examine the role of PM and relevant
18 precursor gases on materials damage and soiling. Specifically, studies that examine both particulate and
19 gaseous contributions from oxides of nitrogen and oxides of sulfur along with other PM components are
20 included here due to the difficulty associated with isolating the effects of gaseous and particulate N and S
21 wet deposition.

P.3.2. Evaluation of the Evidence

22 The Preamble to the ISAs (U.S. EPA, 2015) describes the general framework for evaluating
23 scientific information, including criteria for assessing study quality and developing scientific conclusions.
24 Aspects specific to evaluating studies of PM are described in the Annex to the Preface, which were
25 applied to studies that fit the overall scope of the PM ISA. Categories of health and welfare effects were
26 considered for evaluation in this ISA if they were examined in previous U.S. EPA assessments for PM or
27 in multiple recent studies. Therefore, in this ISA the broad health effects categories evaluated include
28 those considered in the 2009 PM ISA (i.e., respiratory effects, cardiovascular effects, central nervous
29 system effects, cancer, and mortality) along with the addition of metabolic effects, while new research
30 indicates it is more appropriate to further refine the category of reproductive and developmental effects to
31 instead focus overall conclusions specifically on fertility and pregnancy effects, and birth outcomes
32 separately. While the welfare effects categories evaluated include visibility impairment, effects on
33 materials, and climate.

34 In forming the key science judgments for each of the health and welfare effects categories
35 evaluated, the PM ISA draws conclusions about relationships between PM exposure and health effects by

1 integrating information across scientific disciplines and related health outcomes and synthesizing
2 evidence from previous and recent studies. To impart consistency in the evaluation of health effects
3 evidence for epidemiologic studies, additional parameters to those outlined in the scope (Section P.3.1)
4 were developed. To facilitate a comparison of results across epidemiologic studies, risk estimates were
5 standardized to a defined increment for both short- and long-term exposure to PM_{2.5} and PM_{10-2.5}, unless
6 otherwise noted in the text. To determine the appropriate increment the distribution of PM_{2.5} and PM_{10-2.5}
7 concentrations were examined across the three most recent years of air quality data (2012–2014) within
8 the U.S. For both PM_{2.5} and PM_{10-2.5}, an increment of 10 µg/m³ was defined for short-term exposure
9 studies which approximates the 50th–95th percentile of concentrations and accounts for the variability
10 observed in daily PM_{2.5} concentrations. An increment of 5 µg/m³ was defined for long-term exposure
11 studies which approximates the 25th–75th percentile of concentrations and represents the variation
12 observed in long-term mean concentrations. Due to the lack of an extensive monitoring network for UFPs
13 within the U.S., results from studies examining UFP are not standardized and reflect the increment of
14 exposure defined in each study evaluated. Additionally, in the assessment of correlations, either with
15 other copollutants or variables, in epidemiologic studies high, moderate, or low correlations are explicitly
16 defined as the following: low correlation, $r < 0.40$; moderate correlation, $r \geq 0.40$ and $r < 0.70$; and high
17 correlation, $r \geq 0.70$. Consistency in the interpretation of the epidemiologic evidence through approaches
18 such as the standardization of risk estimates and the evaluation of correlations, in combination with the
19 integration of evidence across scientific disciplines supports a thorough evaluation of the current state of
20 the science for PM.

21 In the evaluation of the evidence determinations are made about causation, not just association,
22 and are based on judgments of aspects such as the consistency of evidence within a discipline, coherence
23 of effects across disciplines, and biological plausibility of observed effects as well as related uncertainties.
24 The ISA uses a formal causal framework [Table II of the Preamble to the ISAs (U.S. EPA, 2015)] to
25 classify the weight of evidence according to the five-level hierarchy summarized below.

- 26 • Causal relationship: the pollutant has been shown to result in health and welfare effects at
27 relevant exposures based on studies encompassing multiple lines of evidence and chance,
28 confounding, and other biases can be ruled out with reasonable confidence.
- 29 • Likely to be a causal relationship: there are studies in which results are not explained by chance,
30 confounding, or other biases, but uncertainties remain in the health and welfare effects evidence
31 overall. For example, the influence of co-occurring pollutants is difficult to address, or evidence
32 across scientific disciplines may be limited or inconsistent.
- 33 • Suggestive of, but not sufficient to infer, a causal relationship: health and welfare effects evidence
34 is generally supportive but not entirely consistent or is limited overall. Chance, confounding, and
35 other biases cannot be ruled out.
- 36 • Inadequate to infer the presence or absence of a causal relationship: there is insufficient quantity,
37 quality, consistency, or statistical power of results from studies of health and welfare effects.
- 38 • Not likely to be a causal relationship: several adequate health and welfare effects studies,
39 examining the full range of anticipated exposure concentrations and for health effects, potential
40 at-risk populations and lifestages consistently show no effect.

P.4 References

- Abt (Abt Associates Inc). (2005). Particulate matter health risk assessment for selected urban areas: Draft report (pp. 164). (EPA Contract No. 68-D-03-002). Research Triangle Park, NC: U.S. Environmental Protection Agency.
- Baldauf, RW; Devlin, RB; Gehr, P; Giannelli, R; Hassett-Sipple, B; Jung, H; Martini, G; McDonald, J; Sacks, JD; Walker, K. (2016). Ultrafine Particle Metrics and Research Considerations: Review of the 2015 UFP Workshop. *Int J Environ Res Public Health* 13. <http://dx.doi.org/10.3390/ijerph13111054>
- CAA. Clean Air Act, as amended by Pub. L. No. 101-549, section 108: Air quality criteria and control techniques, 42 USC 7408, 42 USC (1990a). <http://www.law.cornell.edu/uscode/text/42/7408>
- CAA (Clean Air Act). (1990b). Clean Air Act, as amended by Pub. L. No. 101-549, section 109: National primary and secondary ambient air quality standards, 42 USC 7409. <https://www.law.cornell.edu/uscode/text/42/7409>
- CAA (Clean Air Act). (2005). Clean Air Act, section 302: Definitions, 42 USC 7602. <http://www.gpo.gov/fdsys/pkg/USCODE-2005-title42/pdf/USCODE-2005-title42-chap85-subchapIII-sec7602.pdf>
- CAAA. Clean Air Act Amendments of 1970, Pub. L. No. 91-604, 84 Stat. 1676-1713 (1970).
- IPCC (Intergovernmental Panel on Climate Change). (2014). Climate change 2014: Synthesis report. In RK Pachauri; L Meyer (Eds.), Climate change 2014: Synthesis report Contribution of working groups I, II and III to the fifth assessment report of the Intergovernmental Panel on Climate Change. Geneva, Switzerland.
- Lippmann, M; Chen, LC; Gordon, T; Ito, K; Thurston, GD. (2013). National Particle Component Toxicity (NPACT) Initiative: Integrated epidemiologic and toxicologic studies of the health effects of particulate matter components: Investigators' Report [HEI] (pp. 5-13). (177). Boston, MA: Health Effects Institute.
- Melillo, JM; Richmond, T; Yohe, GW. (2014). Climate change impacts in the United States: The third National Climate Assessment. In JM Melillo; T Richmond; GW Yohe (Eds.), Climate change impacts in the United States: The third National Climate Assessment. Washington, D.C.: U.S. Government Printing Office. <http://nca2014.globalchange.gov/report>
- NAPCA (National Air Pollution Control Administration). (1969). Air quality criteria for particulate matter. Washington, DC.
- Office of Air and Radiation (EPA Office of Air and Radiation). (2009). Particulate matter national ambient air quality standards: Scope and methods plan for urban visibility impact assessment. (EPA-452/P-09-001). Research Triangle Park, NC: U.S. Environmental Protection Agency.
- Stanek, LW; Sacks, JD; Dutton, SJ; Dubois, JJB. (2011). Attributing health effects to apportioned components and sources of particulate matter: An evaluation of collective results [Review]. *Atmos Environ* 45: 5655-5663. <http://dx.doi.org/10.1016/j.atmosenv.2011.07.023>
- U.S. EPA (U.S. Environmental Protection Agency). (1982). Air quality criteria for particulate matter and sulfur oxides (final, 1982) [EPA Report]. (EPA 600/8-82/029a). Washington, DC: Environmental Criteria and Assessment Office. <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=46205>
- U.S. EPA (U.S. Environmental Protection Agency). (1986). Second addendum to air quality criteria for particulate matter and sulfur oxides (1982): Assessment of newly available health effects information [EPA Report]. (EPA/600/8-86/020F). Research Triangle Park, NC: Environmental Criteria and Assessment Office. <http://nepis.epa.gov/exe/ZyPURL.cgi?Dockey=30001FM5.txt>
- U.S. EPA (U.S. Environmental Protection Agency). (1996). Air quality criteria for particulate matter [EPA Report]. (EPA/600/P-95/001aF-cF. 3v). Research Triangle Park, National Center for Environmental Assessment-RTP Office NC.

- U.S. EPA (U.S. Environmental Protection Agency). (2004). Air quality criteria for particulate matter [EPA Report]. (EPA/600/P-99/002aF-bF). Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment- RTP Office. <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=87903>
- U.S. EPA (U.S. Environmental Protection Agency). (2005). Review of the national ambient air quality standards for particulate matter: policy assessment of scientific and technical information. oaqps staff paper [EPA Report]. (EPA/452/R-05/005). Research Triangle Park, NC.
- U.S. EPA (U.S. Environmental Protection Agency). (2008). Integrated review plan for the national ambient air quality standards for particulate matter [EPA Report]. Research Triangle Park, NC.
- U.S. EPA (U.S. Environmental Protection Agency). (2009a). Integrated science assessment for particulate matter [EPA Report]. (EPA/600/R-08/139F). Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment- RTP Division. <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=216546>
- U.S. EPA (U.S. Environmental Protection Agency). (2009b). Particulate matter national ambient air quality standards: Scope and methods plan for health risk and exposure assessment. (EPA-452/P-09-002). Research Triangle Park, NC: Office of Air Quality Planning and Standards.
- U.S. EPA (U.S. Environmental Protection Agency). (2010a). Particulate matter urban-focused visibility assessment. Final document. (EPA-452/R-10-004). Research Triangle Park, NC: Office of Air and Radiation.
- U.S. EPA (U.S. Environmental Protection Agency). (2010b). Quantitative Health Risk Assessment for Particulate Matter. Research Triangle Park, NC: US Environmental Protection Agency.
- U.S. EPA (U.S. Environmental Protection Agency). (2011). Policy assessment for the review of the particulate matter national ambient air quality standards [EPA Report]. (EPA 452/R-11-003). Research Triangle Park, NC.
- U.S. EPA (U.S. Environmental Protection Agency). (2012). Report to Congress on black carbon [EPA Report]. (EPA-450/R-12-001). <http://www.epa.gov/blackcarbon/2012report/fullreport.pdf>
- U.S. EPA (U.S. Environmental Protection Agency). (2013). Notice of workshop and call for information on integrated science assessment for oxides of nitrogen and oxides of sulfur. Fed Reg 78: 53452-53454.
- U.S. EPA (U.S. Environmental Protection Agency). (2015). Preamble to the integrated science assessments [EPA Report]. (EPA/600/R-15/067). Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment, RTP Division. <https://cfpub.epa.gov/ncea/isa/recordisplay.cfm?deid=310244>
- U.S. EPA (U.S. Environmental Protection Agency). (2016). Integrated review plan for the national ambient air quality standards for particulate matter [EPA Report]. (EPA-452/R-16-005). Research Triangle Park, NC. <https://yosemite.epa.gov/sab/sabproduct.nsf/0/eb862b233fbd0cde85257dda004fcb8c!OpenDocument&TabId=1&eRow=2.0>

EXECUTIVE SUMMARY


Purpose and Scope of the Integrated Science Assessment

1 This Integrated Science Assessment (ISA) is a comprehensive evaluation and synthesis of
2 policy-relevant science aimed at characterizing exposures to ambient particulate matter (PM), and health
3 and welfare effects associated with these exposures.²⁴ PM is a mixture of solid particles and liquid
4 droplets found in the ambient air²⁵, which encompasses multiple size fractions (e.g., fine PM [PM_{2.5},
5 particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm]; thoracic
6 coarse or coarse PM [PM_{10-2.5}, particulate matter with a nominal mean aerodynamic diameter greater than
7 2.5 µm and less than or equal to 10 µm]; and ultrafine particles [UFPs, generally considered as
8 particulates with a diameter less than or equal to 0.1 µm, typically based on physical size, thermal
9 diffusivity or electrical mobility]) and is comprised of various components (e.g., metals, black carbon,
10 etc.) (Figure ES-1). The evaluation of the science and the overarching conclusions of the ISA serves as
11 the scientific foundation for the review of the primary (health-based) and secondary (welfare-based)
12 National Ambient Air Quality Standard (NAAQS) for PM. This ISA focuses on nonecological welfare
13 effects²⁶ because ecological effects resulting from deposition of PM and PM components are being
14 considered in a separate assessment as part of the review of the secondary (welfare-based) NAAQS for
15 oxides of nitrogen and sulfur, and PM (U.S. EPA, 2018).

²⁴ The general process for developing an ISA, including the framework for evaluating weight of evidence and drawing scientific conclusions and causal judgments, is described in a companion document, *Preamble to the Integrated Science Assessments* (U.S. EPA, 2015), www.epa.gov/isa.

²⁵ As defined by U.S. EPA, <https://www.epa.gov/pm-pollution/particulate-matter-pm-basics>.

²⁶ From this point forward referred to as welfare effects.



Source: Permission pending, U.S. EPA²⁷

Figure ES-1 Comparison of PM size fractions.

In 2012, the U.S. Environmental Protection Agency (U.S. EPA) established a new annual PM_{2.5} primary standard of 12 μg/m³ (the annual mean averaged over 3 years) and retained the 24-hour PM_{2.5} standard of 35 μg/m³ (the 98th percentile averaged over 3 years) (75 FR 3086).²⁸ For the primary PM₁₀ standard, the U.S. EPA retained the 24-hour standard of 150 μg/m³ (not to be exceeded more than once per year on average over 3 years) to continue to provide protection against effects associated with short-term exposure to thoracic coarse particles (i.e., PM_{10-2.5}). Regarding the secondary PM standards, the U.S. EPA retained the 24-hour (i.e., 35 μg/m³) and annual (i.e., 15 μg/m³) PM_{2.5} standards²⁹ and the 24-hour PM₁₀ standard (i.e., 150 μg/m³) to address visibility and nonvisibility welfare effects. On judicial review, the revised and retained standards were upheld in all respects. *NAM v EPA*, 750 F.3d 921 (D.C. Cir. 2014).

This ISA updates the 2009 ISA for Particulate Matter [(U.S. EPA, 2009) hereafter referred to as the 2009 PM ISA] with studies and reports published from January 2009 through approximately January 2018. The U.S. EPA conducted in-depth searches to identify peer-reviewed literature on relevant topics such as health and welfare effects, atmospheric chemistry, ambient concentrations, and exposure. Information was also solicited from subject-matter experts and the public during a kick-off workshop held

²⁷ <https://www.epa.gov/pm-pollution/particulate-matter-pm-basics>.

²⁸ The legislative requirements and history of the PM NAAQS are described in detail in the Preface to this ISA.

²⁹ Consistent with the primary standard, the U.S. EPA eliminated the option for spatial averaging with the annual standard.

at the U.S. EPA in February 2015. To fully describe the state of available science, the U.S. EPA also included in this ISA the most relevant studies from previous assessments.

As in the 2009 PM ISA, this ISA determines the causal nature of relationships between health effects and exposure to PM_{2.5}, PM_{10-2.5}, and UFPs ([CHAPTER 5](#), [CHAPTER 6](#), [CHAPTER 7](#), [CHAPTER 8](#), [CHAPTER 9](#), [CHAPTER 10](#), and [CHAPTER 11](#)). To address this task a defined scope was developed to focus on those studies that inform whether PM exposure directly causes health effects (see Preface). Health effects are considered in relation to exposures at concentrations of PM that are relevant to the range of human exposures across ambient microenvironments, specifically within one to two orders of magnitude of current conditions (i.e., up to 2 mg/m³) (Preface, Section [P.3.1](#)). The ISA also evaluates the relationship between PM components and sources to assess whether there is evidence that a component, group of components, or source is more closely related to health effects than PM mass (see Preface). Additionally, the ISA evaluates whether specific populations or lifestyles are at increased risk of PM-related health effects. The ISA also determines the causal nature of relationships between PM and welfare effects. In the evaluation of the welfare-based evidence ([Chapter 13](#)), the PM ISA focuses specifically on the nonecological welfare effects of PM (i.e., visibility, materials effects, and climate) because the ecological effects are assessed in the ISA for Oxides of Nitrogen, Oxides of Sulfur and Particulate Matter – Ecological Criteria as a result of these criteria pollutants being inter-related through complex chemical and physical atmospheric processes and all contributing to nitrogen (N) and sulfur (S) deposition ([U.S. EPA, 2018](#)). However, in the assessment of effects on materials the PM ISA summarizes soiling and deterioration of materials attributable to PM and related nitrogen (N) and sulfur (S) components because of the difficulty associated with isolating the effects of gaseous and particulate N and S wet deposition and because the ISA for Oxides of Nitrogen, Oxides of Sulfur and Particulate Matter – Ecological Criteria focuses only on ecological effects ([U.S. EPA, 2018](#)).

Key to interpreting the health and welfare effects evidence is understanding the sources, chemistry, and distribution of PM in the ambient air ([CHAPTER 2](#)). It is these atmospheric relationships and processes that influence human exposure ([CHAPTER 3](#)) and the uptake of inhaled PM in the respiratory tract ([CHAPTER 4](#)). The uptake of PM and its deposition in the body directly influences the biological mechanisms by which PM could potentially result in a health effect ([CHAPTER 5](#), [CHAPTER 6](#), [CHAPTER 7](#), [CHAPTER 8](#), [CHAPTER 9](#), [CHAPTER 10](#), and [CHAPTER 11](#)). Further, the ISA aims to characterize the independent effect of PM (i.e., PM_{2.5}, PM_{10-2.5}, and UFP) on health ([CHAPTER 5](#), [CHAPTER 6](#), [CHAPTER 7](#), [CHAPTER 8](#), [CHAPTER 9](#), [CHAPTER 10](#), and [CHAPTER 11](#)). The ISA also informs policy-relevant issues ([Section 1.6](#) and [CHAPTER 5](#), [CHAPTER 6](#), [CHAPTER 7](#), [CHAPTER 8](#), [CHAPTER 9](#), [CHAPTER 10](#), [CHAPTER 11](#), and [CHAPTER 12](#)), such as (1) potential copollutant confounding ([Section 1.5.1](#)); (2) timing of effects (i.e., averaging time of exposure metric and lag at which associations are observed in epidemiologic studies ([Section 1.5.2](#)); (3) PM concentration-response relationship(s), and evaluation of potential thresholds for effects ([Section 1.5.3](#)); (4) PM components and sources and relationships with health effects ([Section 1.5.4](#)); and (5) populations or lifestyles at increased risk for health effects related to PM exposure ([Section 1.5.5](#)).


Sources and Exposure to PM

The main objective of the ISA is to characterize health and welfare effects related to ambient PM exposure. This requires understanding PM sources, atmospheric formation, measurement methods, and concentrations. Additionally, with respect to characterizing the health effects of PM it requires understanding the factors that affect both exposure to ambient PM and the uncertainty in estimating exposure. These factors include unmeasured variability in PM_{2.5}, PM_{10-2.5}, and UFP concentrations and size distributions, exposure to copollutants, and uncharacterized PM composition.

Particulate matter is comprised of components that are directly emitted (primary PM) as well as formed through atmospheric chemical reactions involving gaseous precursors (secondary PM) (Section 2.3). Both primary and secondary PM contribute substantially to overall PM mass in ambient air. Within an urban environment most primary PM_{2.5} emissions are from anthropogenic sources, and include some combination of industrial activities, motor vehicles, cooking, and fuel combustion. However, in many locations secondary PM formed from the precursors sulfur dioxide (SO₂), oxides of nitrogen (NO_x), ammonia (NH₃), and volatile organic compounds (VOCs), accounts for the majority of PM_{2.5} mass. Direct emissions of primary PM_{2.5} have decreased slightly (~9% since 2002) over the past decade, along with a substantial decrease in emissions since 2006 of the major PM_{2.5} precursors SO₂ and NO_x, 65% and 30%, respectively. PM_{10-2.5} is almost entirely primary in origin, composed largely of crustal material, sea salt, and biological material. National average PM_{10-2.5} concentrations have changed little over the past decade. Ambient UFPs originate from two distinct processes, primary particles directly emitted from specific sources like motor vehicles and new particle formation by photochemical processes under favorable atmospheric conditions.

There are well-established federal reference methods (FRM) and national monitoring networks for PM_{2.5}, PM₁₀, and PM_{10-2.5} (Section 2.4). Recent monitoring initiatives include the implementation of the National Core multipollutant monitoring network, which includes PM_{2.5} and PM_{10-2.5} measurements along with a suite of other pollutants, a new near road monitoring network that includes PM_{2.5} monitors at 36 sites, and the first routine monitoring of particle number count at 23 sites. Satellite-based measurements in conjunction with chemical transport models have also become increasingly used for estimating PM_{2.5} concentrations. In general, the fraction of PM₁₀ accounted for by PM_{2.5} is higher in the eastern U.S. than in the western U.S. Compared to PM_{2.5}, PM_{10-2.5} concentrations are more spatially variable. The limited amount of available UFP measurements data indicated that the highest UFP concentrations occur in the winter and near roads with heavy traffic, often over short time periods. Overall, UFP concentrations are more spatially variable than PM_{2.5}. As Figure 2-22 shows, national average PM_{2.5} concentrations decreased by about 5 µg/m³ from 2000 to 2015. Much of this decrease is accounted for by a corresponding decrease in sulfate concentrations, especially in the eastern U.S., attributed to reduced SO₂ emissions. Sulfate concentrations are mainly associated with PM_{2.5} and have historically been highest in summer. The reduction in PM_{2.5} and sulfate concentrations has coincided with shifts from summer, as the season with the highest national average concentration, to a more even

distribution of PM_{2.5} concentrations between summer and winter, and to an increase in the contribution of PM_{10-2.5} to PM₁₀ concentrations.



Black = mean, gray = 90th percentile.

Source: Permission pending, [Chan et al. \(2018\)](#).

Figure ES-2 Long-term trend in national monthly and annual average PM_{2.5} concentrations (µg/m³) from 2000–2015.

Fixed-site monitoring is frequently used for obtaining PM_{2.5} exposure surrogates in both short-term and long-term exposure epidemiologic studies (Section 3.3), given that spatial variability in PM_{2.5} concentration tends to be lower than for other size fractions. Fixed-site monitoring for PM_{10-2.5} has been performed by different methods. It is important to consider the method used in order to characterize errors and uncertainties in the data that are related both to the monitoring method and the proximity of the individual receptor to the monitor because PM_{10-2.5} is typically more spatially variable than PM_{2.5}. Condensation particle counter (CPC) is most commonly used to measure UFP. However, some portion of the UFP size distribution may be omitted using CPC, since they do not typically measure particles smaller than 10 nm. UFP also tends to be more spatially variable than PM_{2.5}, contributing to uncertainties in exposure assignments.

Modeling approaches, such as spatial interpolation methods, land use regression, dispersion models, and chemical transport models (CTMs), have for years provided estimates of exposure concentration where no measurements are available. More recently, hybrid models drawing input from CTMs, satellite observations of aerosol optical density, surface measurements of PM concentration, and land use variables have become available. Most studies using hybrid methods are applied to model PM_{2.5} and have out-of-sample cross-validations with $R^2 > 0.8$. Models are employed less frequently to estimate

PM_{10-2.5} and UFP exposure concentration, despite PM_{10-2.5} and UFP typically being more spatially variable than PM_{2.5}. This is related in part to less availability of input data.

When particles enter a building envelope, they may be lost during the process of infiltration to indoor, to produce an infiltration factor (F_{inf}) < 1 (Section 3.4). F_{inf} varies with season, window opening, building age, wind speed and particle size distribution (with F_{inf} lower for PM_{10-2.5} and UFP compared with PM_{2.5}). When examining the influence of estimated exposure concentrations on health effect estimates in a time-series study of short-term PM exposure, use of a fixed-site monitor in lieu of a microenvironmental model that accounted for infiltration produced considerably attenuated health effect estimates, which resulted in an underestimation of the health effect. Infiltration of PM through a building envelope may change the temporal variability of the indoor PM concentration time-series, resulting in reduced correlation between the health effect of interest and the estimated exposure concentration. In the examination of how exposure concentration estimates influence health effect estimates in an epidemiologic study of long-term PM exposure, simulating indoor concentrations produced unbiased health effect estimates.

In summary, exposure error tends to produce underestimation of health effects in epidemiologic studies of PM exposure, although bias in either direction can occur. Recent improvements in estimating spatial resolution of the PM_{2.5} concentration surface have reduced bias and uncertainty in health effects estimates. PM_{10-2.5} and UFP concentrations tend to be more spatially variable than PM_{2.5} concentrations, but data are either unavailable or less often available to fit or validate hybrid models for those size fractions. As a result, there is typically less uncertainty in health effect estimates derived from both monitored and modeled exposure estimates for PM_{2.5} compared with either PM_{10-2.5} or UFP.

Dosimetry of Inhaled PM

Particle dosimetry characterizes the intake, deposition, and retention of PM in the respiratory tract (CHAPTER 4). The basic understanding of particle dosimetry has not changed since the last review. Quantification of the fraction of inhaled particles reaching the lung and the small fraction of deposited particles that enter the blood, distribute around the body, and accumulate in organs and tissues has improved. Understanding the dosimetry of particles is crucial to providing evidence that supports whether it is biologically plausible that PM exposure can lead to a range of health effects spanning multiple organ systems.

A variety of factors influence the amount of inhaled particles deposited and retained in the respiratory tract and include exposure concentration and duration, activity and breathing conditions (e.g., nasal vs. oronasal route and minute ventilation), and particle properties (e.g., particle size, hygroscopicity, and solubility in airway fluids and cellular components). Inhalability is particularly important for between species extrapolation since it decreases more rapidly as particle size increases in rodents (commonly used in laboratory studies) compared to humans. In people, the fraction of oral versus nasal breathing is influenced by age, activity level, sex, disease status (e.g., allergies, upper respiratory

infections), and perhaps body mass index, which ultimately contributes to the fraction of particles inhaled and reaching the lower respiratory tract.

Recent evidence shows that in both humans and rodents, a small fraction of gold nanoparticles depositing in the peripheral lung may move into circulation. The fraction of deposited particles that move into circulation is dependent on particle size and is in the range of 0.2% or less for particles between 5 nm and 200 nm, but may reach a few percent for smaller particles. The translocated particles are distributed around the body and may be retained in other organs or eliminated via urine. Some more limited data show that particles may also reach the fetus in a size dependent manner. Although translocation in humans has only been demonstrated for gold nanoparticles and to some degree for titanium dioxide, the translocation of several types of nanoparticles has been demonstrated in rodents. The importance of compound type on particle translocation has not yet been ascertained. These studies suggest that, following deposition in the lung, a small fraction of ambient particles under 200 nm may translocate into circulation.

Health and Welfare Effects of PM Exposure

This ISA integrates information on PM exposure and health effects from epidemiologic, controlled human exposure, and toxicological studies to determine the causal nature of relationships between exposure to PM of various size fractions (i.e., PM_{2.5}, PM_{10-2.5}, and UFPs) and broad health effect categories. For most health effect categories, except for reproductive and developmental effects, effects are evaluated separately for short-term exposures (i.e., hours up to approximately one month) and long-term exposures (i.e., one month to years). For welfare effects the ISA evaluates evidence as it pertains to the welfare effects of visibility impairment, climate effects, and effects on materials. A consistent and transparent framework [Preamble to the ISA (U.S. EPA, 2015), Table II] is applied to classify the health and welfare effects evidence according to a five-level hierarchy:

1. Causal relationship
2. Likely to be a causal relationship
3. Suggestive of, but not sufficient to infer, a causal relationship
4. Inadequate to infer the presence or absence of a causal relationship
5. Not likely to be a causal relationship

The causality determinations presented in Table ES-1, reflect those PM size fraction, exposure duration, and broad health category combinations for which a "*causal relationship*" or "*likely to be causal relationship*" was concluded in this ISA. The conclusions presented are informed by recent findings in combination with the evidence detailed in the 2009 PM ISA. Important considerations include: (1) determining whether laboratory studies of humans and animals, in combination with epidemiologic studies, inform the biological mechanisms by which PM can impart health effects and provide evidence demonstrating that PM exposure can independently cause a health effect; (2) determining whether there is consistency in epidemiologic evidence across various geographic locations, populations, and methods

used to estimate PM exposure; (3) evaluating epidemiologic studies that examine potential influence of factors (i.e., confounders) that could bias associations observed with PM exposure; (4) determining the coherence of findings integrated across controlled human exposure, epidemiologic, and toxicological studies; and (5) making judgments regarding the influence of error and uncertainty on the relationship between PM exposure and health effects in the collective body of available studies. [Table ES-2](#) details the causality determinations for the welfare effects.

Table ES-1 Summary of "causal relationship" and "likely to be causal relationship" causality determinations for PM exposure and health effects from the current draft PM ISA and corresponding causality determinations from the 2009 PM ISA.

Size Fraction	Health Effect Category ^a and Exposure Duration	Causality Determination	
		2009 PM ISA	Current Draft PM ISA
PM _{2.5}	Respiratory Effects—Short-term exposure Section 5.1.12 , Table 5-18	Likely to be a causal relationship	Likely to be a causal relationship
	Respiratory Effects—Long-term exposure Section 5.2.13 , Table 5-28	Likely to be a causal relationship	Likely to be a causal relationship
	Cardiovascular Effects—Short-term exposure Section 6.1.16 , Table 6-33	Causal relationship	Causal relationship
	Cardiovascular Effects—Long-term exposure Section 6.2.18 , Table 6-52	Causal relationship	Causal relationship
	Nervous System Effects—Long-term exposure Section 8.2.9 , Table 8-20	Not evaluated	Likely to be a causal relationship
	Cancer—Long-term exposure Section 10.2.6 , Table 10-8	Suggestive of, but not sufficient to infer, a causal relationship	Likely to be a causal relationship
	Total mortality—Short-term exposure Section 11.1.12 , Table 11-4	Causal relationship	Causal relationship
	Total mortality—Long-term exposure Section 11.2.7 , Table 11-8	Causal relationship	Causal relationship

Table ES-1 (Continued): Summary of "Causal Relationship" and "Likely to be Causal Relationship" causality determinations for PM exposure and health effects from the current draft PM ISA and corresponding causality determinations from the 2009 PM ISA.

Size Fraction	Health Effect Category ^a and Exposure Duration	Causality Determination	
		2009 PM ISA	Current Draft PM ISA
UFP	Nervous System Effects— Long-term exposure Section 8.6.7, Table 8-34	Not evaluated	Likely to be a causal relationship

ISA = Integrated Science Assessment; PM = particulate matter; PM_{2.5} = fine particulate matter; UFP = ultrafine particles.

Previous causality determinations taken from the 2009 PM ISA (U.S. EPA, 2009).

^aAn array of outcomes is evaluated as part of a broad health effect category: physiological measures (e.g., airway responsiveness), clinical outcomes (e.g., hospital admissions), and cause-specific mortality. Total mortality includes all nonaccidental causes of mortality and is informed by findings for the spectrum of morbidity effects (e.g., respiratory, cardiovascular) that can lead to mortality. The sections and tables referenced include a detailed discussion of the evidence that supports the causality determinations and the PM_{2.5} and UFP concentrations with which health effects have been associated.

1

Health Effects of PM_{2.5} Exposure

2 Across the PM size fractions evaluated within this ISA, the most substantial scientific evidence
3 indicating relationships between short- and long-term PM exposure is for PM_{2.5}. The causality
4 determinations for PM_{2.5} reflect the total body of scientific evidence, building off the conclusions
5 presented in the 2009 PM ISA. The following sections detail those exposure duration and broad health
6 effect categories where this ISA concluded a "causal" or "likely to be causal" causality determination,
7 reflecting the highest degree to which the evidence reduces chance, confounding, and other biases in the
8 exposure—health effect relationship. Those health effect categories where there is still a large degree of
9 uncertainty or limited examination of the relationship between PM_{2.5} exposure and health effects resulting
10 in the causality determination of "suggestive of, but not sufficient to infer, a causal relationship" and
11 "inadequate to determine the presence or absence of a causal relationship" are summarized in
12 CHAPTER 1, Table 1-5.

Respiratory Effects

13 As in the 2009 PM ISA, the current ISA concludes there is a "likely to be causal relationship"
14 between *short-term PM_{2.5} exposure and respiratory effects* (Section 5.1). Recent epidemiologic studies
15 continue to provide strong evidence for a relationship between short-term PM_{2.5} exposure and several
16 respiratory-related endpoints, including asthma exacerbation, chronic obstructive pulmonary disease
17 (COPD) exacerbation, and combined respiratory-related diseases, particularly from studies examining
18 emergency department visits and hospital admissions. The consistent, positive associations observed for
19 asthma and COPD emergency department visits and hospital admissions are further supported by
20 evidence of increased symptoms and medication use in response to short-term PM_{2.5} exposure, which is

indicative of asthma and COPD exacerbations. Animal toxicological studies of short-term PM_{2.5} exposure provide coherence and biological plausibility for asthma and COPD exacerbations by demonstrating asthma-related responses in an animal model of allergic airways disease and enhanced lung injury and inflammation in an animal model of COPD. Animal toxicological evidence also demonstrates altered host defense, greater susceptibility to bacterial infection, respiratory irritant effects, and other effects. This broad body of experimental evidence indicating PM_{2.5}-related respiratory effects in healthy populations generally provides biological plausibility for respiratory effects in association with short-term PM_{2.5} exposure, but does not inform the relationship with asthma or COPD exacerbation. In addition, controlled human exposure studies provide minimal evidence of effects due to short-term PM_{2.5} exposure, such as decrements in lung function and pulmonary inflammation. Recent epidemiologic studies build upon the limited number of studies that previously examined potential copollutant confounding and indicate that PM_{2.5} associations with asthma exacerbation, combined respiratory-related diseases, and respiratory mortality remain relatively unchanged in copollutant models with gaseous pollutants (i.e., O₃, NO₂, SO₂, with more limited evidence for CO) and other particle sizes (i.e., PM_{10-2.5}). Animal toxicological studies further support an independent effect of PM_{2.5} on respiratory health by demonstrating asthma- and COPD-related responses in animal models of disease. Evidence of consistent, positive associations between PM_{2.5} and respiratory mortality demonstrate a continuum of respiratory-related effects.

Both the 2009 PM ISA, and the current ISA concluded there is a "*likely to be causal relationship*" between *long-term PM_{2.5} exposure and respiratory effects* (Section 5.2). There is strong evidence from multiple cohorts that varied in study location, exposure assessment methods, and time periods examined that demonstrated an effect of long-term PM_{2.5} exposure on lung development (i.e., lung function growth). Additional, although more limited, evidence from epidemiologic studies indicates associations between long-term PM_{2.5} exposure and asthma development in children, asthma prevalence in children, childhood wheeze, and pulmonary inflammation. Animal toxicological studies demonstrating impaired lung development resulting from pre- and post-natal PM_{2.5} exposure and the development of an allergic phenotype along with an increase in airway responsiveness following long-term PM_{2.5} exposure provide biological plausibility for these findings. Animal toxicological studies also demonstrate PM_{2.5} exposure-induced oxidative stress, inflammation, and morphological changes in both upper and lower airways. There is limited assessment of potential copollutant confounding of respiratory morbidity outcomes, but recent animal toxicological studies partially address the independence of PM_{2.5} effects by demonstrating PM_{2.5} induced oxidative stress, inflammation, and morphologic changes. This broad body of experimental evidence indicating PM_{2.5}-related respiratory effects in healthy populations generally provides biological plausibility for respiratory effects in association with long-term PM_{2.5} exposure. Additional epidemiologic evidence, indicates an acceleration of lung function decline in adults, as well as consistent evidence for respiratory mortality and cause-specific respiratory mortality, providing evidence of a continuum of effects in response to long-term PM_{2.5} exposure. The relationship between long-term PM_{2.5} exposure and respiratory effects is further supported by epidemiologic studies demonstrating improvements in lung function growth and bronchitic symptoms in children and improvement in lung function in adults in association with declining PM_{2.5} concentrations.

Cardiovascular Effects

Consistent with the 2009 PM ISA, this ISA concludes there is a "*causal relationship*" between short-term PM_{2.5} exposure and cardiovascular effects (Section 6.1). The strongest evidence comes from epidemiologic studies that reported consistent, positive associations between short-term PM_{2.5} exposure and cardiovascular-related emergency department visits and hospital admissions particularly for ischemic heart disease (IHD) and heart failure (HF), as well as cardiovascular-related mortality. Recent examinations of potential copollutant confounding generally indicate that the associations observed with PM_{2.5} and cardiovascular effects in single pollutant models remain relatively unchanged in copollutant models, providing evidence that the observed associations with PM_{2.5} are not artefacts due to confounding by another air pollutant. The independence of a PM_{2.5} cardiovascular effect is further supported by recent experimental studies. Recent controlled human exposure studies expand upon previous findings and demonstrate PM_{2.5}-induced changes in endothelial function and blood pressure, which is coherent with animal toxicological studies demonstrating the same effects. Moreover, experimental evidence demonstrating decreased cardiac contractility and left ventricular pressure is coherent with epidemiologic studies observing positive associations between ambient PM_{2.5} and ED visits and hospital admissions for HF. Thus, the collective body of experimental evidence supports and provides biological plausibility for epidemiologic studies reporting associations particularly between short-term PM_{2.5} exposure and IHD and HF outcomes, as well as a range of other cardiovascular-related effects (e.g., arrhythmia, thrombosis) that can result in more severe outcomes possibly leading to death.

The 2009 PM ISA, as well as the current PM ISA, concluded there is a "*causal relationship*" between long-term PM_{2.5} exposure and cardiovascular effects (Section 6.2). Epidemiologic studies of multiple recent U.S.-based cohorts along with reanalyses of these cohorts provide strong evidence of consistent, positive associations between long-term PM_{2.5} exposure and cardiovascular mortality. These studies used a variety of exposure assessment and statistical techniques and examined various spatial domains (e.g., 1 × 1 km grid cells, census tract, etc.) in many locations where mean annual average PM_{2.5} concentrations are ≤12 µg/m³. Recent epidemiologic studies of cardiovascular morbidity have greatly expanded upon the body of evidence available at the completion of the 2009 PM ISA by focusing on populations with distinct demographic characteristics (e.g., post-menopausal woman, male doctors, etc.) and extensively considering potential confounders (e.g., socioeconomic status [SES]). While an extended analysis of the Women's Health Initiative (WHI) cohort strengthened the initial observation of a relationship between long-term PM_{2.5} exposure and coronary events among post-menopausal women, additional cohorts of women similar to the WHI cohort did not report consistent, positive associations with coronary heart disease (CHD), myocardial infarction or stroke. Longitudinal studies examining the progression of atherosclerosis in relation to long-term exposure to PM_{2.5} reported inconsistent results that were dependent upon the vascular bed examined, but there was evidence of PM_{2.5}-associated coronary artery calcification, a strong predictor of CHD, within a study focusing on the progression of atherosclerosis in a healthy population, i.e., Multi-Ethnic Study of Artherosclerosis and Air Pollution (MESA—Air). A limited number of epidemiologic studies examining other cardiovascular effects,

1 provide some evidence of associations with HF, blood pressure, and hypertension as well as subclinical
2 cardiovascular biomarkers. Recent studies also reduce the uncertainty associated with potential
3 copollutant confounding by reporting that associations between long-term PM_{2.5} exposure and
4 cardiovascular mortality remained relatively unchanged or increased in copollutant models adjusted for
5 O₃, NO₂, SO₂, and PM_{10-2.5}. Evidence from animal toxicological studies further supports a direct PM_{2.5}
6 effect on the cardiovascular system and provides coherence with effects observed in epidemiologic
7 studies. For example, animal toxicological studies demonstrating atherosclerotic plaque progression in
8 mice is coherent with epidemiologic studies of atherosclerosis, while animal toxicological studies
9 reporting increased coronary artery wall thickness, decreased cardiac contractility and output, and
10 changes in blood pressure are coherent with epidemiologic studies of HF. Furthermore, when considering
11 the collective body of evidence there are biologically plausible pathways by which long-term exposure to
12 PM_{2.5} could lead to a continuum of effects potentially resulting in death.

Nervous System Effects

13 The 2009 PM ISA did not make a causality determination for long-term PM_{2.5} exposure and
14 nervous system effects due to the paucity of data available. Since the 2009 PM ISA, the literature base has
15 greatly expanded and the combination of animal toxicological and epidemiologic evidence supports a
16 *"likely to be causal relationship"* between *long-term PM_{2.5} exposure and nervous system effects*
17 (Section 8.2). Animal toxicological studies provide evidence for a range of nervous system effects
18 including neuroinflammation and oxidative stress, neurodegeneration, cognitive effects, and effects on
19 neurodevelopment. Epidemiologic studies, although fewer in number, generally support associations
20 between long-term PM_{2.5} exposure and changes in brain morphology, cognitive decrements, and
21 dementia. Both experimental and epidemiologic evidence is well substantiated and coherent, supporting a
22 pathway involving neuroinflammation in specific regions of the brain (i.e., the hippocampus, cerebral
23 cortex and hypothalamus) and morphologic changes in the brain indicative of neurodegeneration. Overall,
24 the lack of consideration of copollutant confounding introduces some uncertainty in the interpretation of
25 the epidemiologic studies but this uncertainty is addressed, in part, by the direct evidence of effects
26 provided by experimental animal studies. In addition to the nervous system effects primarily observed in
27 adults, there is initial and limited epidemiologic evidence of neurodevelopmental effects, specifically
28 autism spectrum disorder (ASD), which is supported by an animal toxicological study demonstrating
29 PM_{2.5}-induced inflammatory and morphologic changes in regions of the brain consistent with ASD.

Cancer

30 The 2009 PM ISA concluded that evidence was *"suggestive of a causal relationship"*³⁰ between
31 *long-term PM_{2.5} exposure and cancer* (Section 10.2). Building upon the decades of research on whole PM

³⁰ Since the 2009 PM ISA, the causality determination language has been updated and this category is now stated as *"suggestive of, but not sufficient, to infer a causal relationship"*.

exposures and evidence presented in the 2009 PM ISA, recent experimental and epidemiologic evidence indicating genotoxicity, epigenetic effects (i.e., hypo- and hyper-methylation of DNA), and increased carcinogenic potential due to PM_{2.5} exposure, along with strong epidemiologic evidence for increases in lung cancer incidence and mortality supports a "*likely to be causal relationship*" between long-term PM_{2.5} exposure and cancer. PM_{2.5} exhibits various characteristics of carcinogens, as shown in studies demonstrating genotoxic effects (e.g., DNA damage), epigenetic alterations, oxidative stress, and electrophilicity. Studies of cancer development have often focused on whole PM exposures³¹, not individual PM size fractions, or individual components often found to encompass PM_{2.5} (e.g., hexavalent chromium, arsenic). Ames *Salmonella*/mammalian-microsome mutagenicity assays of PM_{2.5} and PM_{2.5} extracts demonstrate that PM contains mutagenic agents. In vitro and in vivo toxicological studies demonstrate the potential for PM_{2.5} exposure to result in DNA damage, which is supported by limited human evidence. Cytogenic effects (e.g., chromosomal aberrations), and differential expression of genes potentially relevant to genotoxicity or cancer pathogenesis have also been demonstrated. There is also limited evidence for cellular and molecular changes that could lead to genomic instability as well as for the carcinogenic potential of PM_{2.5}, as demonstrated by enhanced tumor formation in animals treated with urethane. The experimental and epidemiologic evidence of genotoxicity, epigenetic effects, and carcinogenic potential provides biological plausibility for the results from multiple epidemiologic studies conducted in diverse cohorts in terms of geographic coverage and population demographics reporting primarily consistent, positive associations between long-term PM_{2.5} exposure and lung cancer incidence and mortality, particularly in never smokers. In the limited assessment of potential copollutant confounding, PM_{2.5}-lung cancer incidence and mortality associations were found to be relatively unchanged in models with O₃.

Mortality

As in the 2009 PM ISA, the current ISA concludes there is a "*causal relationship*" between short-term PM_{2.5} exposure and total (nonaccidental) mortality (Section 11.1). Recent multicity studies conducted in the U.S., Canada, Europe, and Asia in combination with the single- and multicity studies evaluated in the 2009 PM ISA continue to provide evidence of consistent, positive associations between short-term PM_{2.5} exposure and total mortality. The positive associations reported across studies reflect both traditional analyses using ambient monitors as well as analyses conducted in both urban and rural locations that use new exposure assignment techniques and rely on multiple sources of PM_{2.5} data (e.g., ambient monitors, statistical models, and satellite images). Recent studies also expand upon the assessment of potential copollutant confounding and indicate that PM_{2.5}-mortality associations are relatively unchanged in copollutant models with gaseous pollutants and PM_{10-2.5}. The positive associations reported for total mortality are supported by positive associations for cause-specific mortality (i.e., cardiovascular- and respiratory-related mortality). The consistent and coherent evidence across

³¹ Whole PM exposures represent exposures that contain both PM and gaseous pollutants.

1 scientific disciplines for cardiovascular morbidity, particularly ischemic events and HF (CHAPTER 6),
2 and to a lesser degree for respiratory morbidity, with the strongest evidence for exacerbations of COPD
3 and asthma (CHAPTER 5), provide biological plausibility for cause-specific mortality and ultimately
4 total mortality. Recent studies also further reduce chance, confounding, and other biases in the
5 relationship between short-term PM_{2.5} exposure and total mortality.

6 Both the 2009 PM ISA and the current ISA concludes there is a "*causal relationship*" between
7 *long-term PM_{2.5} exposure and total (nonaccidental) mortality* (Section 11.2). Additional reanalyses and
8 extensions of the American Cancer Society and Harvard Six Cities cohorts as well as new cohorts
9 consisting of Medicare participants, people that live in Canada, or people employed in a specific job
10 (e.g., teacher, nurse, etc.) further support a positive association between long-term PM_{2.5} exposure and
11 total mortality, particularly in areas with annual mean concentrations <20 µg/m³, and in some cases below
12 12 µg/m³. Positive associations persist regardless of the exposure assignment approach used (i.e., ambient
13 monitors or the combination of monitoring, modeling, and satellite data) and in copollutant models,
14 particularly with O₃ and more limited evidence for NO₂ and PM_{10-2.5}. The evidence for total mortality is
15 supported by positive associations for cause-specific mortality, including cardiovascular, respiratory, and
16 lung cancer mortality. The coherence of effects across scientific disciplines for cardiovascular morbidity,
17 particularly for CHD, stroke and atherosclerosis, and respiratory morbidity for the development of COPD,
18 contribute to the biological plausibility for mortality due to long-term PM_{2.5} exposure. Additionally,
19 recent studies demonstrating increases in life expectancy due to decreases in long-term PM_{2.5}
20 concentrations further support a relationship between long-term PM_{2.5} exposure and total mortality.

Health Effects of UFP Exposure

21 Since the completion of the 2009 PM ISA recent studies further explored the relationship between
22 UFP exposure and health effects. The interpretation of epidemiologic study results is complicated by most
23 studies relying on a single monitor to measure UFPs, which is inadequate as has been reflected in some
24 monitoring campaigns that demonstrate a high degree of spatial variability in UFP concentrations and that
25 the size distribution of UFPs changes with distance from source (Section 2.5). Additionally, experimental
26 studies often include size ranges up to 200 nm or higher, which complicates the examination of coherence
27 and biological plausibility of UFP-related health effects. These uncertainties in addition to the
28 inconsistency across studies in the characterization of UFP with respect to size distribution and exposure
29 metric contributed to causality determinations that did not exceed "*suggestive of, but not sufficient to*
30 *infer, a causal relationship*" for most exposure and health effect category combinations.

Nervous System Effects

31 Due to the few studies that examined long-term UFP exposure and nervous system effects, the
32 2009 PM ISA did not make a causality determination; however, it was hypothesized that ambient UFPs
33 may reach the brain via olfactory transport based on a few animal toxicological studies of

laboratory-generated UFPs. Since then, additional strong animal toxicological evidence of neurotoxicity and altered neurodevelopment, in combination with initial evidence suggesting potential translocation of UFPs into the brain via olfactory transport and from a single epidemiologic study indicating effects on attention and memory support a "*likely to be causal relationship*" between *long-term UFP exposure and nervous system effects* (Section 8.6). Animal toxicological studies provide consistent evidence of brain inflammation and oxidative stress in multiple regions of the brain, morphologic changes that are characteristic of neurodegeneration and Alzheimer's disease. Additionally, there is evidence of neurodevelopmental effects, including behavioral, neuroinflammatory, and morphological changes consistent with ASD. The animal toxicological study results are supported by an epidemiologic study reporting evidence of decrements on tests of attention and memory in children. However, epidemiologic studies of long-term UFP exposure are sparse due to difficulties in capturing the spatial variation in long-term UFP concentrations that can result in substantial exposure measurement error.

Policy-Relevant Considerations for Health Effects Associated with Particulate Matter Exposure

This section describes issues relevant for considering the potential significance of impacts of ambient PM, particularly PM_{2.5}, exposure on public health (Section 1.6)³², including potential copollutant confounding of PM_{2.5}-health effects associations, the relationship between PM_{2.5} exposure and the timing of health effects, the shape of the concentration-response (C-R) relationship, whether PM_{2.5} components and sources are more closely associated with health effects than PM_{2.5} mass, and the identification of populations and lifestages potentially at increased risk of a PM_{2.5}-related health effect.

Recent epidemiologic studies greatly expand upon the evidence informing whether associations observed between short- and long-term PM_{2.5} exposure and health are confounded by other pollutants observed in the air pollution mixture. The examination of potential copollutant confounding in studies of respiratory and cardiovascular effects are primarily limited to studies of emergency department visits and hospital admissions. Across studies of short-term PM_{2.5} exposure and respiratory and cardiovascular effects and mortality, correlations between PM_{2.5} and gaseous (i.e., SO₂, NO₂, CO, and O₃) and particulate pollutants (i.e., PM_{10-2.5}) varied across studies, with low-to-moderate correlations (i.e., <0.7). Collectively, studies of short-term PM_{2.5} exposure that examined potential copollutant confounding indicated that associations remained relatively unchanged in copollutant models, and in instances where associations were attenuated they remained positive. Far fewer studies examined potential copollutant confounding and long-term PM_{2.5} exposure, but there has been an expansion of studies focusing on mortality. Studies focusing on respiratory (i.e., lung function and asthma development) and cardiovascular effects (i.e., cardiovascular mortality), along with lung cancer incidence and mortality, provide initial evidence that associations with PM_{2.5} are relatively unchanged in copollutant models with primarily traffic-related pollutants (i.e., NO₂, NO_x, and CO) and O₃. For mortality, the most extensive

³² Section 1.6 in Chapter 1 integrates the evidence across all health chapters, but each health chapter has individual discussions on the topics discussed within this section.

1 analyses occurred for O₃, with more limited assessments of other pollutants, but overall associations were
2 reported to remain unchanged in copollutant models for total (nonaccidental) mortality, cardiovascular,
3 and respiratory mortality.

4 An important question that informs different aspects of the PM NAAQS is the timing of observed
5 effects due to short-term PM_{2.5} exposure, specifically the averaging time of the exposure metric in
6 epidemiologic studies and the lag days over which health effects are observed. Some recent
7 epidemiologic studies focusing on respiratory- and cardiovascular-related emergency department visits
8 and hospital admissions, cardiovascular effects (e.g., ST-elevation, myocardial infarction, and
9 out-of-hospital cardiac arrest), and mortality examined associations between subdaily exposure metrics
10 and the widely used 24-hour average exposure metric. Across the studies evaluated, the available
11 evidence does not indicate that sub-daily averaging periods for PM_{2.5} are more closely associated with
12 health effects than the 24-hour average exposure metric. In addition to examining potential differences in
13 associations by averaging time of the exposure metric, recent epidemiologic studies expanded the
14 assessment of examining the timing of effects by systematically examining lag days by focusing on
15 whether there is evidence of an immediate (e.g., lag 0–1 days), delayed (e.g., lag 2–5 days), or prolonged
16 (e.g., lag 0–5 days) effect of PM on health. Epidemiologic studies examining potential differences in
17 associations in relation to short-term PM_{2.5} exposure focused on respiratory- and cardiovascular-related
18 emergency department visits and hospital admissions as well as mortality. While recent studies provided
19 evidence of associations in the range of 0–5 days for respiratory effects, there was evidence of an
20 immediate effect for cardiovascular effects and mortality (i.e., 0–1 days) with some initial evidence of
21 associations occurring over longer exposure durations (e.g., 0–4 days).

22 An examination of the C-R relationship between short- and long-term PM_{2.5} exposure and health
23 effects can inform both the shape of the C-R curve and whether there is a threshold (i.e., concentration
24 level) below which there is no evidence of an effect of PM_{2.5} on health. Studies of short-term PM_{2.5}
25 exposure and health are limited to studies of respiratory-related emergency department visits and hospital
26 admissions, and mortality. Epidemiologic studies of respiratory disease and asthma emergency
27 department visits and hospital admissions focusing on the shape of the C-R curve provide initial evidence
28 of a log-linear relationship with less certainty at concentrations below 10 µg/m³. However, studies
29 focusing on whether the PM_{2.5} association changes at different concentration ranges (i.e., cut-point
30 analyses) provide some evidence of potential nonlinearities in the C-R relationship. Epidemiologic studies
31 of mortality greatly expand upon the evidence evaluated in the 2009 PM ISA where C-R analyses were
32 limited to studies of PM₁₀. Evidence from U.S. studies examining short-term PM_{2.5} exposure and
33 mortality indicate a log-linear relationship at concentrations as low as 5 µg/m³ with cut-point analyses
34 providing no evidence of a threshold. For long-term PM_{2.5} exposure, most of evidence on the shape of the
35 C-R curve and whether a threshold exists comes from studies of mortality with some initial recent
36 evidence from studies of respiratory and cardiovascular effects, as well as lung cancer mortality and
37 incidence. Epidemiologic studies of long-term PM_{2.5} exposure and mortality used a variety of statistical
38 approaches and cut-point analyses, which support a linear, no-threshold relationship for total

(nonaccidental) mortality, especially at lower ambient PM_{2.5} concentrations, with confidence in some studies in the range of 5–8 µg/m³. Additionally, there is initial evidence indicating that the slope of the C-R curve may be steeper (supralinear) at lower concentrations for cardiovascular mortality. Evaluation of the C-R relationship is more limited for respiratory and cardiovascular effects, but overall initial assessments support a linear relationship specifically at long-term PM_{2.5} concentrations ranging from 10 to 12 µg/m³ and 5–10 µg/m³, respectively.

Recent epidemiologic and experimental studies extensively build upon those studies evaluated in the 2009 PM ISA that examined relationships between exposure to PM_{2.5} components and sources and health effects. As detailed in the Preface, this ISA focuses on specific study criteria to thoroughly evaluate whether there is evidence that an individual component(s) and/or source(s) is more closely related to health effects than PM mass. Across the health effects categories evaluated in this ISA, most studies that examine PM sources and components focused on PM_{2.5}. In studies examining both short- and long-term exposure a variety of health effects were examined ranging from subclinical (e.g., changes in lung function, respiratory symptoms) to more overt e.g., emergency department visits, hospital admissions, and mortality). Across exposure durations and health effects categories it was concluded that many PM_{2.5} components and sources are associated with many health effects, and the evidence does not indicate that any one source or component is consistently more strongly related with health effects than PM_{2.5} mass.

Lastly, an important consideration in evaluating whether the NAAQS provides public health protection with an adequate margin of safety is assessing whether there are specific populations or lifestages at increased risk of a PM-related health effect. While the ISA provides substantial evidence of health effects due to short- and long-term exposure to PM_{2.5} across populations with diverse characteristics (e.g., children, older adults, people with pre-existing cardiovascular diseases, etc.), an evaluation of whether any of these populations are at increased risk of a PM-related health effect relies on evidence from specific types of studies that can directly inform this question as detailed in Section 1.6 and CHAPTER 12. Based on the framework for characterizing the evidence for populations potentially at increased risk of an air pollutant-related health effect detailed in the 2013 O₃ ISA (U.S. EPA, 2013), this ISA concludes there is adequate evidence that children are at increased risk of a PM_{2.5}-related health effect based off strong evidence of impaired lung function growth and additional evidence of decrements in lung function and asthma development. Additionally, there is adequate evidence that nonwhite people are at increased of PM_{2.5}-related health effects based on studies of long-term PM_{2.5} exposure and mortality and studies demonstrating differential exposure by race. There was also suggestive evidence that populations with pre-existing cardiovascular and respiratory disease, that are overweight or obese, with genetic variants in genes in the glutathione pathway and oxidant metabolism, or that are of low SES are at increased risk for PM_{2.5}-related health effects.

PM Exposure and Welfare Effects

Compared to the evaluation of the health effects evidence, the evaluation of the welfare effects evidence focuses broadly on PM and not individual size fractions or exposure durations. Additionally, the evaluation, as noted previously, focuses on the welfare effects of visibility impairment, climate effects, and effects on materials due to the ecological effects of PM being evaluated in the ISA for Oxides of Nitrogen, Oxides of Sulfur and Particulate Matter–Ecological Criteria (U.S. EPA, 2018).

Table ES-2 Summary of causality determinations for relationships between PM exposure and welfare effects from the 2009 and current draft PM ISA.

Welfare Effect Category	Causality Determination	
	2009 PM ISA	Current Draft PM ISA
Visibility Impairment Section 5.1.12, Table 5-18	Causal relationship	Causal relationship
Climate Effects Section 5.2.13, Table 5-28	Causal relationship	Causal relationship
Effects on Materials Section 6.1.16, Table 6-33	Causal relationship	Causal relationship

ISA = Integrated Science Assessment; PM = particulate matter.

Previous causality determinations taken from the 2009 PM ISA (U.S. EPA, 2009).

As noted in Table ES-2, this ISA concludes a "causal relationship" between PM visibility impairment, climate effects, and effects on materials which is consistent with the 2009 PM ISA. For visibility impairment (Section 13.2), the relationship between PM and light extinction has been well characterized. The rapid decline in PM_{2.5} sulfate that has occurred from 2002–2012 (i.e., –4.6% per year in rural areas and –6.2% per year in urban areas) has contributed to improvements in visibility in many areas, but an increasing amount of light extinction is now due to nitrate and organic matter. There have been no recent visibility preference studies; however, a recent meta-analysis demonstrates that scene-dependent haze metrics better account for preference compared to only using the deciview scale as a metric. For climate (Section 13.3), there is substantial evidence indicating that PM affects the radiative forcing of the climate system, both through direct scattering and absorption of radiation, and indirectly, by altering cloud properties. However, it is important to note there are still substantial uncertainties with respect to key processes linking PM and climate, specifically clouds and aerosols because of the scale between PM-relevant cloud processes and the resolution of state-of-the-art models and the indirect impacts and feedbacks in the climate system due to an initial radiative effect due to PM. Lastly, for effects on materials (Section 13.4), most of the evidence has often focused on examining PM impacts on stone

- 1 used for historic monuments and buildings. Recent evidence further expands the understanding of soiling
- 2 and corrosion process for glass and metals, and demonstrates that atmospheric soiling can impact energy
- 3 efficiency of photovoltaic systems and some buildings.

References

- Chan, EAW; Gantt, B; McDow, S. (2018). The reduction of summer sulfate and switch from summertime to wintertime PM_{2.5} concentration maxima in the United States. *Atmos Environ* 175: 25-32.
<http://dx.doi.org/10.1016/j.atmosenv.2017.11.055>
- U.S. EPA (U.S. Environmental Protection Agency). (2009). Integrated science assessment for particulate matter [EPA Report]. (EPA/600/R-08/139F). Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment- RTP Division. <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=216546>
- U.S. EPA (U.S. Environmental Protection Agency). (2013). Integrated science assessment for ozone and related photochemical oxidants [EPA Report]. (EPA/600/R-10/076F). Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment-RTP Division. <http://cfpub.epa.gov/ncea/isa/recordisplay.cfm?deid=247492>
- U.S. EPA (U.S. Environmental Protection Agency). (2015). Preamble to the integrated science assessments [EPA Report]. (EPA/600/R-15/067). Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment, RTP Division. <https://cfpub.epa.gov/ncea/isa/recordisplay.cfm?deid=310244>
- U.S. EPA (U.S. Environmental Protection Agency). (2018). Integrated science assessment for oxides of nitrogen, oxides of sulfur and particulate matter -Ecological criteria (2nd external review draft). (EPA/600/R-18/097). Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment. <http://cfint.rtpnc.epa.gov/ncea/prod/recordisplay.cfm?deid=340671>

CHAPTER 1 INTEGRATED SYNTHESIS

Overall Conclusions of the Particulate Matter (PM) Integrated Science Assessment (ISA)

- Recent evidence spanning the scientific disciplines (i.e., atmospheric chemistry, exposure science, dosimetry, epidemiology, controlled human exposure, and animal toxicology) builds upon evidence detailed in the 2009 PM ISA and reaffirms that for short- and long-term PM_{2.5} exposure there is a “*causal relationship*” for cardiovascular effects and total (nonaccidental) mortality and a “*likely to be causal relationship*” for respiratory effects.
- Recent experimental and epidemiologic evidence supports a “*likely to be causal relationship*” for long-term PM_{2.5} exposure and nervous system effects.
- Recent evidence, primarily from studies of lung cancer incidence and mortality, in combination with the decades of research on the mutagenicity and carcinogenicity of PM supports a “*likely to be causal relationship*” between long-term PM_{2.5} exposure and cancer.
- Recent evidence from primarily animal toxicological studies supports a “*likely to be causal relationship*” for long-term ultrafine particle (UFP) exposure and nervous system effects.
- Remaining uncertainties and limitations in the scientific evidence contribute to a “*suggestive of, but not sufficient to infer, a causal relationship*” and “*inadequate to infer the presence or absence of a causal relationship*” for all other exposure, size fraction, and health effects combinations.
- Recent evidence builds upon and reaffirms that there is a “*causal relationship*” between PM and the nonecological welfare effects: visibility impairment, climate effects, and materials effects.
- The assessment of PM sources and components confirms and continues to support the conclusion from the 2009 PM ISA: *Many PM_{2.5} components and sources are associated with many health effects, and the evidence does not indicate that any one source or component is more strongly related with health effects than PM_{2.5} mass.*
- Many populations (e.g., healthy, diseased, etc.) and lifestages (e.g., children, older adults, etc.) have been shown to be at-risk of a health effect in response to short- or long-term PM exposure, particularly PM_{2.5}. However, of the populations and lifestages examined, current scientific evidence indicates that only some populations may be at *disproportionately increased risk* of a PM_{2.5}-related health effect, including nonwhite populations, children, people with specific genetic variants in genes in the glutathione pathway, people who are overweight or obese, people with pre-existing cardiovascular and respiratory diseases, and people of low socioeconomic status (SES).

1.1 Introduction

1.1.1 Purpose

1 The subsequent chapters of this ISA provide a detailed evaluation and characterization of the
2 current state of the science with respect to the health and nonecological welfare effects³³ due to exposure
3 to particulate matter (PM). The overall scope of the ISA, which governs the types of studies considered in
4 the evaluation of the scientific evidence, is detailed in the Preface. Aspects specific to evaluating studies
5 of PM that form the basis of the causality determinations detailed within this ISA are described in the
6 Appendix. The main chapters of the ISA provide both the scientific basis for causality determinations³⁴
7 and policy-relevant scientific information that supports the review of the National Ambient Air Quality
8 Standards (NAAQS) for PM. The purpose of this CHAPTER 1 is not to summarize each of the chapters,
9 but to synthesize the key findings on each topic considered in characterizing PM exposure and
10 relationships with health and welfare effects. This ISA draws forward and integrates evidence evaluated
11 in prior assessments including the 2009 PM ISA (U.S. EPA, 2009) and earlier assessments e.g., 2004 PM
12 Air Quality Criteria Document (AQCD) (U.S. EPA, 2004) and 1996 PM AQCD (U.S. EPA, 1996).

1.1.2 Organization of the ISA

13 The ISA consists of the Preface (legislative requirements and history of the primary and
14 secondary PM NAAQS; and purpose and overview of the ISA along with the overall scope, and process
15 for evaluating evidence), Executive Summary, and thirteen chapters. CHAPTER 1 synthesizes the
16 scientific evidence that best informs the policy-relevant questions detailed within the *Integrated Review*
17 *Plan for the Primary National Ambient Air Quality Standards for Particulate Matter* (PM IRP; (U.S.
18 EPA, 2016)) that frame this review of the primary (health-based) and secondary (welfare-based) PM
19 NAAQS. CHAPTER 2 characterizes the sources, atmospheric processes related to PM formation, and
20 trends in ambient PM concentrations, for specifically PM_{2.5} (fine PM; PM with a nominal mean
21 aerodynamic diameter less than or equal to 2.5 µm), PM_{10-2.5} (thoracic coarse or coarse PM; PM with a
22 nominal mean aerodynamic diameter greater than 2.5 µm and less than or equal to 10 µm), and ultrafine
23 particles [UFPs, generally considered as particulates with a diameter less than or equal to 0.1 µm
24 (typically based on physical size, thermal diffusivity or electrical mobility)]. CHAPTER 3 describes

³³ Hereafter welfare effects refers to nonecological welfare effects, unless otherwise noted. The ecological effects resulting from the deposition of PM and PM components are being considered in a separate assessment as part of the review of the secondary (welfare-based) NAAQS for oxides of nitrogen, oxides of sulfur, and PM (U.S. EPA, 2018)

³⁴ The general process for developing an ISA, including the framework for evaluating weight of evidence and drawing scientific conclusions and causal judgments, is described in a companion document, Preamble to the Integrated Science Assessments (U.S. EPA, 2015).

1 methods to estimate human exposure to PM and the impact of exposure measurement error on
2 associations with health effects. CHAPTER 4 describes the dosimetry of the various size fractions of PM.
3 CHAPTER 5, CHAPTER 6, CHAPTER 7, CHAPTER 8, CHAPTER 9, CHAPTER 10, and CHAPTER
4 11 evaluate and integrate epidemiologic, controlled human exposure, and animal toxicological evidence
5 and characterize the biological plausibility for health effects related to short-term and long-term exposure
6 to PM_{2.5}, PM_{10-2.5}, and UFPs for respiratory effects, cardiovascular effects, metabolic effects, nervous
7 system effects, reproductive and developmental effects, cancer, and mortality, respectively. CHAPTER
8 12 evaluates the scientific evidence on populations and lifestages potentially at increased risk of a PM-
9 related health effect. Lastly, CHAPTER 13 evaluates the scientific evidence for welfare effects, focusing
10 specifically on the nonecological welfare effects of visibility impairment, climate effects, and effects on
11 materials.

12 A key consideration in the health effects assessment is the extent to which evidence indicates that
13 PM_{2.5}, PM_{10-2.5}, and UFPs exposures independently cause health effects. To that end, this chapter draws
14 upon information about the sources, atmospheric chemistry, distribution, background sources of ambient
15 PM, as well as exposure to ambient PM of different size fractions and identifies pollutants and other
16 factors related to the distribution of or exposure to ambient PM that can potentially influence
17 epidemiologic associations observed between health effects and PM_{2.5}, PM_{10-2.5}, and UFP exposures
18 (Section 1.2). The chapter also summarizes information on the dosimetry of inhaled PM of different size
19 fractions (Section 1.3). The discussions of the health effects evidence and causality determinations
20 (Section 1.4) details the extent to which there is biological plausibility for the various PM exposure
21 duration-health effects relationships evaluated, and provides an integrated summary of the epidemiologic
22 and experimental (i.e., animal toxicological and controlled human exposure) evidence and whether it
23 collectively supports independent relationships between PM_{2.5}, PM_{10-2.5}, or UFPs exposure and health
24 effects.³⁵ This chapter also integrates evidence across the ISA for specific policy-relevant issues that are
25 informative in the PM NAAQS review (Section 1.5), specifically: potential copollutant confounding
26 (Section 1.5.1); the timing of effects, which includes the lag structure of associations and averaging time
27 for exposure metrics (Section 1.5.2); the shape of the concentration-response relationship and whether a
28 threshold exists (Section 1.5.3); and whether individual PM components or exposure metrics representative
29 of PM sources are a better indicator for the PM-health effects relationship than PM mass (Section 1.5.4).
30 Additionally, within the policy-relevant considerations discussion, this chapter summarizes the evidence
31 as to whether specific populations or lifestages are at increased risk of a PM-related health effect, which is
32 an important consideration in the context of the NAAQS and ensuring public health is protected with an
33 adequate margin of safety (Section 1.5.5). This chapter also characterizes the welfare effects evidence and
34 the role of PM, specifically non-ecological effects on visibility, climate, and materials (Section 1.6).

³⁵ When discussing epidemiologic evidence, as detailed in the Preface, risk estimates are for a 10 µg/m³ increase in 24-hour average PM_{2.5} and PM_{10-2.5} concentrations and a 5 µg/m³ increase in annual PM_{2.5} and PM_{10-2.5} concentrations.

1 Lastly, Section 1.7, summarizes the causality determinations for all PM size fraction, exposure duration,
2 and health and welfare effects combinations evaluated within this ISA.

1.2 From Emissions Sources to Exposure to Particulate Matter

3 The characterization of human exposure is key to understanding the relationships between
4 ambient PM (i.e., PM_{2.5}, PM_{10-2.5}, and UFP) and health effects. Exposure to PM is influenced by a variety
5 of factors including, but not limited to, time-activity patterns, building characteristics, and amount of PM
6 in the ambient air. The latter is influenced by sources and atmospheric processes contributing to ambient
7 PM concentrations that together can influence the spatial and temporal patterns of PM. These patterns
8 have implications for variation in exposure in the population, the adequacy of methods used to estimate
9 exposure, and in turn, the strength of inferences that can be drawn about the health and welfare effects
10 related to PM exposure.

1.2.1 Emission Sources and Distribution of Ambient Concentrations

11 PM is well defined as a complex mixture of solid and liquid droplets that is often characterized by
12 distinct size fractions, i.e., PM_{2.5}, PM_{10-2.5}, and UFPs. The characteristics of each PM size fraction can
13 vary in terms of: sources and emissions, atmospheric processes that result in PM formation, variability in
14 concentrations over time and space, and monitoring.

15 Observations and new developments in the characterization of ambient PM build on the
16 conclusions reported in the 2009 PM ISA, as summarized in CHAPTER 2. In the 2009 PM ISA, a
17 decreasing trend in PM_{2.5} concentrations were reported between 1999–2007, and a decreasing trend in
18 PM₁₀ concentrations between 1988–2007. In addition, for the years 2005–2007, there was considerable
19 variability in daily average concentrations of PM_{2.5}. PM size was also observed to vary with location, with
20 a generally larger fraction of PM₁₀ mass accounted for by PM_{10-2.5} size in western cities (e.g., Phoenix and
21 Denver) and by PM_{2.5} mass in eastern U.S. cities (e.g., Pittsburgh and Philadelphia). Compared to the
22 larger PM size fractions, there was more limited information on the regional and temporal variability of
23 UFPs. The composition of PM_{2.5} nationally was also observed to vary, with higher sulfate concentrations
24 in the summer and in the eastern U.S., and higher particulate organic carbon (OC) concentrations in the
25 western and southeastern U.S. Little information was available on PM_{10-2.5} or UFP composition. In urban
26 areas, PM_{2.5}, PM₁₀, and UFPs were all observed to peak during morning rush hour and exhibited an
27 evening rush hour peak that was broader than the morning peak and extended into the overnight period,
28 reflecting the collapse of the mixing layer after sundown. In terms of measuring PM, notable advances
29 had taken place in real-time PM mass measurement methods, single particle aerosol mass spectrometry
30 methods, organic speciation methods, and dichotomous samplers for distinguishing PM_{2.5} and PM_{10-2.5}.
31 Major PM sources identified included combustion of fossil fuel, either by stationary sources or by

1 transportation for primary PM, and formation of sulfates from SO₂ emitted mainly by electric power
2 generating units (EGUs). Progress was also noted in understanding the chemistry of new particle
3 formation and of secondary organic aerosol (SOA) formation. Background PM typically accounts for a
4 small fraction of urban PM_{2.5} or PM₁₀, but high PM concentrations can occur during episodic events like
5 wildfires or dust storms.

6 Changes in ambient PM characteristics as well as new research developments have occurred since
7 the 2009 PM ISA. Ambient annual average PM_{2.5} concentrations in the U.S. on average were 3.4 µg/m³
8 lower in the period from 2013–2015 than in the period from 2005–2007 decreased from a 3-year average
9 of 12 µg/m³ for 2013–2015 to 8.6 µg/m³ for 2005–2007, continuing the downward trend in national
10 ambient PM_{2.5} concentrations. However, while PM_{2.5} concentrations were observed to decline, national
11 average PM_{10–2.5} concentrations were similar in both time periods. While monthly national average PM_{2.5}
12 concentrations were higher in summer than in winter from 2002–2008, this pattern is reversed from
13 2012–2015, when monthly average PM_{2.5} concentrations became higher in winter than in summer. A
14 greater reduction in sulfate concentrations than other component concentrations resulted in smaller sulfate
15 contributions to PM_{2.5} mass in 2013–2015 compared to 2005–2007, especially in the Eastern U.S. At
16 many locations sulfate has been replaced by organic material as the greatest contributor to PM_{2.5} mass.
17 Much of the organic material is SOA, and there has been continued progress in understanding SOA
18 precursors, formation processes, and components. The declines in PM_{2.5} and sulfate concentrations are
19 consistent with a large reduction in SO₂ emissions, mainly from decreased EGU coal combustion.
20 Monitoring network changes have provided a more extensive set of observations for understanding the
21 contributions of PM_{2.5} and PM_{10–2.5} to PM₁₀. The decrease in PM_{2.5} concentrations has resulted in smaller
22 PM_{2.5}/PM₁₀ ratios in many locations. PM₁₀ in the East and Northwest is in the range of 50–60% PM_{2.5},
23 while PM₁₀ in the Western U.S. is generally less than 50% PM_{2.5}. Routine measurement of UFPs is in its
24 beginning stages, with only a few monitors beginning to report data.

1.2.1.1 Sources and Emissions of PM

25 PM is comprised of components that are directly emitted (primary particles) as well as formed
26 through atmospheric chemical reactions involving gaseous precursors (secondary particles). The sources
27 of PM vary with PM size fraction.

28 PM_{2.5} can be generated from both natural and anthropogenic sources. The greatest contributors to
29 primary PM_{2.5} at the national level are agricultural dust, dust resuspended through on-road activities, and
30 fires (i.e., wildfires, prescribed fires, and agricultural fires; see Section 2.3.1.1 and Figure 2-2). On a
31 national scale, anthropogenic emissions have been estimated to account for 40% of total primary PM_{2.5}
32 emissions and 16% of total PM₁₀ emissions (U.S. EPA, 2017). However, this does not account for
33 secondary PM, most of which is derived from anthropogenic precursors. On an urban scale, sources that
34 emit PM_{2.5} vary from city-to-city. Generally, anthropogenic sources account for nearly all urban primary

PM_{2.5} emissions, and they include some combination of industrial activities, motor vehicles, cooking, and fuel combustion, and often wood smoke as well as construction and road dust. (Section 2.3.1.2). These urban anthropogenic primary sources and more regional secondary generation both contribute substantially to PM_{2.5} mass in urban locations.

Source contributions to primary PM_{2.5} emissions have changed over time. For example, changes in both gasoline and diesel emissions controls have led to reductions in primary PM_{2.5} emitted from newer vehicles, and primary emissions from stationary fuel combustion, industrial activities, and nonroad vehicles have also decreased (Section 2.3.1.2). Natural and international sources are generally minor contributors to PM_{2.5} in urban areas. In many locations secondary PM accounts for the majority of PM_{2.5} mass. The major PM precursors that can ultimately contribute to PM_{2.5} mass include sulfur dioxide (SO₂), oxides of nitrogen (NO_x), ammonia (NH₃), and volatile organic compounds (VOCs) (Section 2.3.2.1). SO₂ emissions are mainly from electricity generating units (EGUs, 67%) while NO_x is emitted by several combustion sources, including on-road vehicles (34%), off-road vehicles (21%), and EGUs (13%). NH₃ emissions are dominated by livestock waste (55%) and fertilizer application (26%), and VOCs, on a national scale, mainly biogenic in origin (70%) (Section 2.3.2.1). Emissions of some PM_{2.5} precursors, and subsequently their overall contribution to PM_{2.5} mass, have changed over time (Section 2.3.2.1). Since the 2009 PM ISA, SO₂ emissions have been reduced from 13.9 million metric tons (MMT) in 2006 to 4.8 MMT in 2014, representing a 65% reduction and the greatest reduction among all precursor emissions (Section 2.3.2.1). NO_x emissions were also substantially reduced during the same time, decreasing from 19.4 MMT in 2006 to 13.5 MMT in 2014, representing an overall reduction of 30%. NH₃ emissions, however, have remained relatively constant over time, with estimates of 3.8 MMT in 2006 and 3.9 MMT in 2014 (Section 2.3.2.1).

While PM_{2.5} is comprised of both primary PM, generated mostly from combustion-related activities, and secondary PM from atmospheric chemical reactions of precursor emissions, PM_{10-2.5} is almost entirely primary in origin. PM_{10-2.5} is produced by surface abrasion or by suspension of sea spray or biological material (e.g., microorganisms, pollen, plant and insect debris) (Section 2.3.3). Major sources on a national scale are unpaved road dust and agricultural dust, and in urban areas paved road dust and construction dust are usually major sources. Dust events can also result from international transport, and some of the dust particles in these events fall into the PM_{10-2.5} size range. Primary biological aerosol particles can also be an important contributor to PM_{10-2.5}, including fungal spores, bacteria, viruses, and plant debris.

Ambient UFPs originate from two distinct processes, primary particles directly emitted from specific sources and new particle formation (NPF), which occurs because of particular atmospheric conditions that allow for particle nucleation (Section 2.3.4). UFP and PM_{2.5} primary sources are largely indistinguishable because UFP is usually emitted by the same sources as PM_{2.5}, and grow out of the ultrafine size range through coagulation or gas-to-particle condensation over a short duration to form particles within the PM_{2.5} size range. (Section 2.3.4.1). However, differences in the impact of various

sources while particles are still mostly in the UFP size range can lead to differences in sources of greatest concern in both size ranges. For example, freshly emitted motor vehicle exhaust often occurs on busy urban streets in residential neighborhoods, while emissions from electric power generation occur further away from human activity, and particles are likely to grow out of the UFP size range to a greater extent before reaching populated areas. It typically takes between about half a day and three days before newly-formed particles grow larger than 100 nm in diameter. As a result, although UFP size increases from 10 nm to 25 nm within 100 m, vehicle-related PM components are still mainly in the UFP size range as far as 1 km from a major highway.

Although relatively limited information is available on a source-by-source basis to capture changes in UFP emissions over time, analyses of individual sources where new source requirements have been instituted allow for an assessment of source contributions to UFP emissions. Most new research on UFP emissions has been focused on automobile exhaust, in part because of some of the highest observed UFP concentrations have been observed in near-road environments. For example, new requirements on heavy-duty diesel highway engines that were phased in from 2007–2010 and focused on reducing PM and NO_x emissions have led to reductions in UFP number concentration (NC) of more than 90% compared to earlier diesel engine models (Section 2.3.4.1). Although these newer diesel highway engines generate, on average, a smaller amount of UFP emissions compared to earlier models, there can still be discrete periods of extremely high UFP formation. This is due to thermal desorption of adsorbed sulfates that build up within the exhaust catalyst system and then can be released in a single burst (Section 2.3.4.1). Motor vehicles are a leading source of UFP emissions especially near roadways and recently similar observations of high UFP levels downwind of airports have also been reported. However, stationary point sources are also important, particularly at further distances from roadways. Gasoline and diesel-powered highway vehicles, nonroad diesel engines, and industrial sources are likely the largest sources of UFP in populated areas, where relative contributions of mobile and stationary sources of UFP are likely to vary considerably depending on location, season, and time of day.

1.2.1.2 Atmospheric Processes and PM Formation

The atmospheric processes that result in PM formation, specifically oxidation reactions to form ammonium sulfate and ammonium nitrate, have been well characterized in previous assessments (U.S. EPA, 2009, 2004) (Section 2.3.2.2). As a result, recent research has focused primarily on the formation of SOA, and has shown that SOA is a sizeable contributor to PM_{2.5} mass under a variety of atmospheric conditions (Section 2.3.2.3). New research has increased our understanding of how a substantial amount of SOA is produced by several important processes: reactions of the biogenic VOC isoprene; cloud processing; and further oxidation of gas phase products formed from atmospheric VOC oxidation. Additionally, PM formation from biogenic VOC reactions has been reported to be enhanced by anthropogenic influences, including NO_x and SO₂ precursor emissions. (Section 2.3.2.3). Compositional analyses have shown that organosulfates and organonitrates often account for a large fraction of SOA, up

to 5–10% for organosulfates and up to 10–20% for organic nitrates (Section 2.3.2.3). Examination of atmospheric processes that lead to SOA formation has led to observations that atmospheric aging (oxidation) of organic aerosols increases reactive oxygen species activity of ambient PM (Section 2.5.1.1.7). Reactive oxygen species (ROS) have been shown to contribute to cellular oxidative stress in respiratory tract cells (Section 5.1.1).

In addition to exploring SOA formation, recent studies have further examined particle nucleation. New instrumentation has made it possible to measure atmospheric molecular clusters and to directly observe the process of particle nucleation (Section 2.3.4). This research has also focused on identifying the chemical species important in the particle nucleation process. Previous research had focused mainly on the role of sulfate and water, with increasing evidence that organic species were also involved. More recent research identified the importance of additional species, including ammonia and amines as well as extremely low volatility organic compounds in particle nucleation. (Section 2.3.4.2).

1.2.1.3 Monitoring and Modeling of PM

Broadly, PM is measured through the following: well-established long-term national monitoring networks based on well-established monitoring methods; individual monitors established for a specific period for the purposes of characterizing air quality or conducting an epidemiologic study using a variety of established or experimental methods; and satellite measurements. Depending on the PM size fraction, the extent to which information is available on ambient concentrations will vary as a direct result of the monitoring capabilities currently available.

For PM_{2.5} and PM₁₀, extensive national air monitoring networks have been established based on Federal Reference Methods (FRMs) for supporting air quality analyses for the purposes of monitoring for compliance with the PM NAAQS, measurement of spatial and temporal trends of air pollutants, and to support research to assess exposure and health risks from PM exposures (Section 2.4.6). Because PM itself is a complex mixture, additional monitoring networks have been established to capture information on PM_{2.5} components. Specifically, the Chemical Speciation Network (CSN), and the Interagency Monitoring of Protected Visual Environments (IMPROVE) network, which was established for the specific purpose of understanding the relationship between PM composition and atmospheric visibility impairment, both monitor PM_{2.5} components (Section 2.4.6).

Two new national monitoring networks provided additional monitoring of PM_{2.5} and/or PM_{10–2.5} (Section 2.4.6). The first national monitoring network was established as a result of the 2010 NO₂ NAAQS. This network instituted near-road monitors that were placed within 50 m of heavily trafficked roads in urban areas, and many of these near-road monitoring sites also conducted routine monitoring of PM_{2.5}. The NCore monitoring network was deployed starting in January 2011 and included measurements for PM_{2.5} and PM_{10–2.5}. The PM_{10–2.5} measurements were based on improved monitoring methods specified for PM_{10–2.5} measurement methods to qualify as FRMs and Federal Equivalence Methods

(FEMs), and compared to previously used methods that relied on taking the difference between PM₁₀ and PM_{2.5} FRM measurements (Section 2.4.6). The new PM_{10-2.5} monitoring requirements are met by using identical instrumentation for both PM_{2.5} and PM₁₀ except for the sampler cut-point; i.e., using the same sampler design, filter type, and filter face velocity for both PM_{2.5} and PM_{10-2.5} in the same sampler.

To date, most monitoring efforts with respect to PM focus on mass-based measurements of PM_{2.5}, PM₁₀, and PM_{10-2.5}. Recently, some monitors have been deployed to measure UFP concentrations. Routine network particle number concentration (NC) measurements were initiated at a few sites, mostly in New York state, which were made possible by the recent development of water-based condensation particle counters (CPCs) (Section 2.4.6). In other research, new CPCs have been developed, which are capable of measuring NC of particles with aerodynamic diameter 0.001 µm and larger, and these are especially useful for investigating the atmospheric nucleation of particles. (Section 2.4.3.1). Analysis of particle number count data from field studies shows that UFPs are likely to vary considerably among widely used methods, reflecting differences in the size ranges measured. While size ranges of ambient UFP measurements can vary depending on the monitor used, it is important to note that the ambient UFP size range varies from that used in experimental (i.e., animal toxicological and controlled human exposure) studies that rely on concentrated ambient particle (CAP) UFP exposures. Specifically, UFP CAPs result in particle size ranges up to 0.18–0.3 µm, which is larger than the nominal UFP size limit of less than 0.1 µm, which has previously been defined as the upper size cut as detailed in the 2009 PM ISA. Because the contribution to mass from particles less than 0.1 µm is relatively small, much of the mass may be associated with particles greater than 0.1 µm. However, as described in Section 2.4.3.1, the difference in particle number measurements between PM delivered with usual methods in controlled exposure studies and ambient UFP from which it originates is likely to be much less than the difference in mass (Section 2.4.3.3).

Some of the biggest developments since the 2009 PM ISA include the use of satellite-based measurements to estimate PM_{2.5} concentrations and the continued evolution of chemical transport models (CTMs). Satellite-based measurements have become widely used and combined with modeled data and ground level measurements to extend spatial coverage and improve spatial resolution of PM_{2.5} estimates (Section 2.4.5). Although satellite based PM_{2.5} measurements allow for an expansion of the spatial coverage of epidemiologic studies, they are subject to measurement errors not encountered with FRM or other ground-based measurements, particularly due to data availability because of the inability to provide measurements during days with cloud or snow cover. This is because PM_{2.5} is not directly measured and its estimation is based on computational algorithms involving a range of assumptions, such as vertical distribution and particle composition (Section 2.4.5). With respect to CTMs, advances have included the addition of biogenic VOC chemistry, organic aerosol aging, cloud chemistry, dry deposition, meteorological processes, wind-blown dust, and ammonia emissions. Collectively, these additions have resulted in demonstrable improvements in the prediction of seasonal variation and long-term changes in PM_{2.5} concentrations (Section 2.4.7).

1.2.1.4 National PM Concentrations

Recent assessments of ambient PM concentrations have shown a general decline over time. PM_{2.5} concentrations are generally lower than those reported in the 2009 PM ISA, decreasing from a national 3-year average of 12 µg/m³ for 2005–2007 to 8.6 µg/m³ for 2013–2015 (Section 2.5.1.1.1 and Section 2.5.2.1.1). Similar to the trend in PM_{2.5} concentrations, national 3-year average PM₁₀ concentrations have declined by 15% compared to those reported for 2005–2007, and are estimated at 21.1 µg/m³ for 2013–2015, at least in part reflecting decreases in PM_{2.5} concentrations. As detailed in Section 1.2.1.3, limited data are available from national monitors for PM_{10–2.5} and UFP. As a result, it is difficult to assess trends in UFP and PM_{10–2.5} concentrations over time (Section 2.5.1.1.5 and Section 2.5.2.1.3).

An examination of PM_{2.5} composition trends further informs the overall reductions in PM_{2.5} concentrations that have occurred over time. The biggest change in PM_{2.5} composition that has occurred since the 2009 PM ISA, is the reduction in sulfate concentrations. Between 2000 and 2015 nationwide annual average sulfate concentration decreased by 17% at urban sites and 20% at rural sites. This change in sulfate concentrations is most evident in the eastern U.S., and has resulted in organic matter or nitrate now being the greatest contributor to PM_{2.5} mass in most locations (Section 2.5.1.1.6). The observed decline in PM_{2.5} sulfate concentrations can be attributed to a similar decline in SO₂ emissions. The overall reduction in sulfate concentrations likely contributed substantially to the decrease in national average PM_{2.5} concentrations as well as the decline in the fraction of PM₁₀ accounted for by PM_{2.5}, when compared to the years 2005–2007 (Section 2.5.1.1.6).

1.2.1.5 Spatial and Temporal Variability in PM Concentrations

Although there has been an overall reduction in national PM concentrations over time, there are distinct spatial and temporal patterns in PM concentrations. At a macro scale, PM_{2.5} concentrations are generally higher and more spatially uniform in the eastern U.S. than in the western U.S. (Section 2.5.1.1.1). While PM_{2.5} concentrations are generally higher in the eastern U.S., the highest reported concentrations are an exception to this trend, occurring in California. Especially high PM_{2.5} concentrations are observed in the San Joaquin Valley, where multiple monitors recorded 3-year average concentrations greater than 14 µg/m³, and in the Los Angeles basin, where 3-year average concentrations exceeded 12 µg/m³ at several monitors. In the Eastern U.S., the highest PM_{2.5} concentrations are in or near the Ohio Valley, extending eastward into Pennsylvania, where 3-year average concentrations for numerous monitors exceeded 10 µg/m³. On a national scale there are distinct east and west patterns in long-term average PM_{2.5} concentrations, but on an urban scale there is not a clear pattern of PM_{2.5} spatial variability with some observations indicating relatively uniform concentrations while others depict a high degree of variability (Section 2.5.1.2.1).

Seasonal analyses have shown a change in the season with the highest PM_{2.5} concentrations. Compared to the 2009 PM ISA, where the examination of seasonal PM_{2.5} concentrations depicted higher concentrations in the summer, recent data indicate higher average PM_{2.5} concentrations in the winter, which reflects lower SO₂ emissions and subsequently sulfate concentrations in the summer (Section [2.5.1.1.1](#) and Section [2.5.2.2.1](#)). Within most urban areas, PM_{2.5} exhibit a rush hour peak in the morning and evening (Section [2.5.2.3](#)).

In general, the fraction of PM₁₀ accounted for by PM_{2.5} is higher in the eastern U.S. than in the western U.S. (Section [2.5.1.1.4](#)). Compared to PM_{2.5}, PM_{10-2.5} concentrations are more spatially variable (Section [2.5.1.2.3](#)). Ninety-eighth percentile PM_{10-2.5} concentrations greater than 40 µg/m³ were observed in multiple locations in California, as well as in the southwestern states of Nevada, Arizona, New Mexico, Texas, and the central plains states of Oklahoma, Missouri, and Iowa, and the urban areas of St. Louis, MO, Cleveland, OH, and south Florida. While not directly comparable, PM₁₀ concentrations, monitoring data for which are available for many more years, can inform, and are often consistent with, the observed spatial and temporal pattern of PM_{10-2.5} concentrations. Compared to the 2004 AQCD (U.S. EPA, 2004), more PM₁₀ in the eastern U.S. is now accounted for by PM_{10-2.5} than before based on examining the fraction of PM₁₀ comprised of PM_{2.5}. The PM_{2.5} fraction of PM₁₀ appears to have decreased from about 60–70% in the 2004 PM AQCD to about 50–60% in 2013–2015 reported in this document, although the 2013–2015 observations are based on national network data and the 2004 data are based on a limited number of field study samples (Section [2.5.1.1.4](#)). All U.S. regions display clear seasonal variations in PM_{10-2.5} concentrations, with the lowest concentrations occurring around January and the highest occurring in the summer months (Section [2.5.2.2.2](#)). Most PM_{10-2.5} measurements have been based on 24-hour monitoring, however, considerably higher PM_{10-2.5} concentrations have been observed using monitors capable of recording higher time resolution measurements, potentially indicating a tendency for intense PM_{10-2.5} short-term episodes not captured by 24-hour monitoring (Section [2.5.1.1.3](#)).

Data on the spatial and temporal variability in UFP concentrations is rather limited, particularly in the U.S. However, a single U.S. study that measured a full year of urban size-resolved particle number count measurements indicated about 90% of particles were smaller than 0.1 µm. (Section [2.5.1.1.5](#)). The limited amount of available UFP measurements data indicated that the highest UFP concentrations occur in the winter and near roads with heavy traffic, often over short time periods (Section [2.5.1.2.4](#) and Section [2.5.2.2.3](#)). Overall, UFP concentrations are more spatially variable than PM_{2.5} (Section [2.5.1.2.4](#)). Examinations of temporal variability show that UFP concentrations typically rise substantially in the morning and remain high into the evening hours when they reach their maximum, with distinct rush hour and early afternoon peaks. Additionally, there is evidence of seasonal impacts on the temporal variability of UFP concentrations, with high afternoon concentrations during warmer months possibly due to photochemical formation, and lower concentrations through the night (Section [2.5.1.1.5](#) and Section [2.5.2.2.3](#)).

1 A detailed evaluation of the composition of PM_{2.5}, PM_{10-2.5}, and UFPs finds that each size
2 fraction is dominated by a few components. For PM_{2.5}, there are clear geographic differences in its
3 composition. In the eastern U.S., sulfate and organic matter are the highest contributors to total mass
4 while in the western U.S. organic matter most often is the highest contributor, although sulfate, nitrate,
5 and crustal material can also be abundant (Section 2.5.1.1.6). When examining the absolute
6 concentrations of specific components, the highest nitrate concentrations are observed in the western
7 U.S., particularly in California, but with some elevated concentrations in the upper Midwest. Seasonally,
8 nitrate concentrations are much higher in the winter than summer in all locations (Section 2.5.1.1.6).
9 Organic and elemental carbon concentrations are both more uniformly distributed in the eastern U.S., but
10 more variable among western U.S. locations. The highest urban concentrations in the western U.S. occur
11 during fall and winter (Section 2.5.1.1.6). Crustal material is a substantial contributor to PM_{2.5} mass in dry
12 areas of the western U.S., such as in Phoenix and Denver (Section 2.5.1.1.6). For PM_{10-2.5}, as noted
13 previously concentrations are highest in southwestern U.S. and are observed to be largely dominated by
14 crustal material, but organic material can also represent a substantial contribution to mass, as well as
15 biological material like bacteria, viruses, fungal spores, pollen, and plant debris (Section 2.5.1.1.6). For
16 UFPs there is still relatively limited information on its composition, but initial data indicate that urban
17 UFPs are rich in organic and elemental carbon, while sulfate and ammonium are likely to be substantial
18 contributors to UFPs in areas where new particle formation occurs (Section 2.5.1.1.6).

19 Background PM generally refers to PM that is formed by sources or processes that cannot be
20 influenced by actions to control PM concentrations. Various background definitions have been used for
21 NAAQS reviews. U.S. background concentration of a pollutant is the concentration resulting from natural
22 primary and precursor sources everywhere in the world plus anthropogenic sources outside of the U.S.,
23 Canada, and Mexico. Similarly, North American background concentrations is the concentration resulting
24 from natural primary and precursor sources everywhere in the world plus anthropogenic sources outside
25 of the U.S., Canada, and Mexico. U.S. background sources of PM include wind erosion of natural
26 surfaces, volcanic production, wildfires, sea salt, biological material like pollen and spores, SOA
27 produced by oxidation of biogenic hydrocarbons, and international transport. Background PM can be
28 episodic, as in the case of volcanic eruptions, forest fires, and dust storms or more consistent, as in the
29 case of a relatively constant, low level contributions from natural and intercontinental sources outside of
30 major events. Nationally, it has been estimated that wildfire smoke contributes between 10% and 20% of
31 primary PM_{2.5} emissions per year, and intercontinental transport contributes 0.05 to 0.15 µg/m³ to annual
32 average PM_{2.5} concentrations in the U.S., but that this contribution varies by region and season. On
33 average, natural sources including soil dust and sea salt have been estimated to account for approximately
34 10% of U.S. urban PM_{2.5} (Section 2.5.4).

1.2.1.6 Summary

1 Since the 2009 PM ISA there are new developments and observations in the characterization of
2 ambient PM. For PM_{2.5}, these include observations of a steep decline in SO₂ precursor concentrations,
3 replacement of sulfate with organic matter as the greatest contributor to PM_{2.5} mass in many locations in
4 the eastern U.S., and a substantial decrease in national average PM_{2.5} concentration. A large body of new
5 research has also refined the overall understanding of SOA formation processes. Improvements in CTM
6 methods have resulted in demonstrable improvements in the prediction of seasonal variation and
7 long-term changes in PM_{2.5}. Extensive new network monitoring for PM_{10-2.5} has greatly increased the
8 amount of data available for assessing relative amounts of PM_{2.5} and PM_{10-2.5}, showing that PM_{10-2.5} as a
9 fraction of PM₁₀ has increased in the eastern U.S. as sulfate and PM_{2.5} have decreased, and that in many
10 western locations the contribution of PM_{10-2.5} to PM₁₀ exceeds the contribution of PM_{2.5} to PM₁₀. This
11 new monitoring effort has further informed the understanding of seasonal and regional differences in
12 PM_{10-2.5} concentrations. Recent studies focusing on UFPs, largely supports observations in the 2009 PM
13 ISA, but new areas of emphasis include instrumentation for measuring particles as small as 1 nm and the
14 initiation of long-term monitoring in a few U.S. locations, which will facilitate future research. However,
15 network data are still sparse, and there is still far less information regarding patterns of spatial and
16 temporal variability of UFP in comparison to PM_{2.5} or PM_{10-2.5}. Differences in monitoring methods and
17 the lack of a consistent definition also make comparison of UFP data difficult between different field
18 studies or methods.

1.2.2 Assessment of Human Exposure

19 Findings from the recent exposure assessment literature build on evidence presented in the 2009
20 PM ISA for the assessment of PM exposures. The 2009 PM ISA found that spatial variability of PM_{10-2.5}
21 and UFP at micro-to-neighborhood scales was greater than that of PM_{2.5}, and primary PM_{2.5} components,
22 such as EC, exhibited greater spatial variability than PM_{2.5} components produced through atmospheric
23 chemical reactions, such as NO₃⁻ or SO₄²⁻. Regional variability in PM composition was also noted and
24 thought to result from differences among sources in different parts of the country. Models, such as land
25 use regression (LUR), were discussed as tools intended to characterize spatially variable components or
26 size fractions, but limitations in the LUR's ability to adequately capture spatial variability were identified
27 in several papers reviewed. Additionally, variability in the PM size distribution, PM composition, and
28 infiltration was identified across regions as factors that could influence individual exposure to PM.
29 Unmeasured variability in ambient PM concentration, size fractions, and composition were noted to cause
30 potential uncertainty in estimates of exposure concentrations and health effect estimates. The recent
31 literature advances the state of exposure science by presenting innovative methodologies to estimate PM
32 exposure, detailing new and existing measurement and modeling methods, and further informing the
33 influence of exposure measurement error due to new and existing exposure concentration estimation
34 methods on associations between PM and health effects reported in the epidemiologic study literature.

1 New evidence supports older findings that appropriate surrogates for exposure concentration may
2 depend on PM size distribution, because spatial variability in PM concentrations varies with particle size
3 (Section 3.4.3.2). Multiple techniques have recently been developed or improved to assign PM exposure
4 concentrations in epidemiologic studies. These methods include personal monitors, data averaging across
5 monitors, interpolation methods, LUR models, spatiotemporal models, CTMs, dispersion models,
6 microenvironmental models, and satellites (Section 3.3). Fixed-site monitors also continue to be used
7 frequently to estimate exposure concentration. Each method has strengths and limitations. Accordingly,
8 errors and uncertainties in the exposure assessment methods can add bias and uncertainty to health effect
9 estimates from epidemiologic studies on the health effects of PM exposure.

10 Ambient PM data from individual sites continue to be used widely in health studies as a surrogate
11 for PM exposure concentration, because fixed-site monitors provide a continuous record of ambient PM
12 concentrations over many years (Section 3.3.1.1). For PM_{2.5}, the concentration profile tends to be more
13 homogeneous across the urban or neighborhood scale, ambient concentrations estimated at fixed-site
14 monitors may reflect exposure concentrations. However, the higher degree of spatial variability in
15 ambient PM_{10-2.5} and UFP across an urban area may not be captured by a fixed-site monitor. As a result,
16 uncharacterized variability in a time-series of exposure concentrations across space, resulting from use of
17 fixed-site monitoring data, in a time-series epidemiologic study of PM_{10-2.5} or UFP exposure may tend to
18 attenuate health effect estimates (Section 3.4.5.1). For long-term exposure studies, bias may occur in
19 either direction depending on whether the fixed-site monitor is over- or underestimating ambient PM_{10-2.5}
20 or UFP exposure concentration for the population of interest (Section 3.4.5.2). In all study types, use of
21 fixed-site monitoring ambient PM_{10-2.5} or UFP concentrations in lieu of the true exposure is expected to
22 widen confidence intervals beyond what would be obtained if the true exposure were used. Personal
23 monitors directly measure PM exposure, but they produce a relatively limited data set, making them most
24 suitable for panel epidemiologic studies (Section 3.4.5.1.2). Without accompanying geographic
25 positioning system (GPS) or time-activity diary data, it is impossible to distinguish ambient PM exposure
26 from exposure to PM of nonambient origin in these studies.

27 Models of PM concentration can be used to develop exposure surrogates for individuals and large
28 populations when personal exposure measurements are unavailable (Section 3.3.2). Recent developments
29 have been made to advance techniques for spatiotemporal modeling, which typically combine universal
30 kriging with variables describing land use, population characteristics, emissions, and geographic features
31 (Section 3.3.2.3). GIS-based spatiotemporal models of concentration that are used as exposure surrogates
32 have produced out-of-sample cross-validation (i.e., out-of-sample $R^2 > 0.8$) for PM_{2.5} and its components,
33 some of which have more spatially varying concentration fields than PM_{2.5} mass concentration.
34 Overly-smoothed exposure concentration surfaces from spatiotemporal models have been shown to bias
35 the health effect estimate towards the null (i.e., underestimating the true health effect) with decreased
36 probability that the confidence intervals contain the true health effect, particularly when the actual spatial
37 variability is much higher than what is represented by the model (Section 3.4.5.2). Bias correction and
38 bootstrap calculation of standard errors have been shown to improve health effect estimate prediction

1 from spatiotemporal models when the exposure estimates have a classical-like error structure. A study of
2 PM_{2.5} mass and components, including EC, OC, Si, and S, where the exposure model errors had a
3 Berkson structure, did not exhibit improvement of the health effect estimate when bootstrap simulation of
4 the standard error was applied. When the exposure estimates have a Berkson-like error structure, health
5 effect estimate predictions would only be expected to improve when model covariates are chosen so that
6 the statistical distribution of the modeled exposure concentrations is close to the distribution of the true
7 exposure concentrations.

8 Recent developments have been made for mechanistic models, such as dispersion models and
9 CTMs, to simulate the transport, dispersion, and (in the case of CTMs) atmospheric chemistry of ambient
10 PM (Section 3.3.2.4). Hybrid approaches to combine exposure concentration predictions from CTMs with
11 those from fixed-site monitoring data or dispersion models have grown since the 2009 PM ISA. CTMs
12 are limited in their spatial resolution, which is typically at length scales of 4 km or 12 km (and sometimes
13 down to 1 km). Data fusion techniques merge CTMs with dispersion model results or fixed-site
14 monitoring data. They are designed to estimate spatial variability of exposure concentrations at the
15 subgrid scale, typically through a hierarchical modeling framework. These models have good cross-
16 validation and have the potential to reduce exposure measurement error and resulting bias and uncertainty
17 in health effect estimates produced by epidemiologic models of long-term exposure to PM, even for
18 spatially-varying size fractions and components.

19 Several advancements to data fusion techniques have been made since the 2009 PM ISA to merge
20 aerosol optical density (AOD) observations from satellite images with surface-level PM measurements
21 from fixed-site monitors (Section 3.3.3). Regression models have been developed to calibrate the AOD
22 observations to surface measurements of PM_{2.5}, and PM_{2.5} exposure concentrations have then been
23 estimated from those models in locations where surface measurements are unavailable. Land use or other
24 geographical variables incorporated in these models have been shown to improve cross-validation and
25 reduce error in estimates of exposure concentrations, and increasing the number of monitors used to fit
26 the model has reduced bias and uncertainty in the exposure estimates. Hence, hybrid modeling approaches
27 combining satellite data with fixed-site monitoring data and LUR or spatiotemporal modeling results have
28 the potential to reduce bias and uncertainty in health effect estimates reported in epidemiologic studies of
29 short- and long-term exposure to PM_{2.5}. Satellite data techniques have not typically been applied to model
30 spatially-variable UFP, PM_{10-2.5}, or PM_{2.5} component exposure concentration fields. Epidemiologic
31 studies where PM exposure concentration is derived from a hybrid satellite-LUR model have reported
32 larger magnitude health effect estimates with increasing spatial resolution (i.e., dividing the spatial
33 domain into many smaller areas in which concentration is modeled) of the exposure concentration
34 surfaces. If the effect estimate derived from the hybrid model was shown by cross-validation to be more
35 accurate than a low-resolution model, then this finding suggests that low spatial resolution (i.e., a spatial
36 domain with a small number of large areas in which concentration is modeled) of the PM exposure
37 concentration surface may cause bias of the health effect estimate towards the null to underestimate the
38 true health effect in a long-term exposure study (Section 3.4.5.2).

1 Among the methods evaluated, only personal monitoring and microenvironmental modeling
2 account for indoor exposure to ambient PM (Section 3.3.1.2). Particles are deposited during the process of
3 infiltration to indoor or vehicle microenvironments, to produce an infiltration factor (F_{inf}) <1
4 (Section 3.4.1.1). As described in the 2009 PM ISA, F_{inf} varies with season, window opening, building
5 age, wind speed and particle size distribution (with F_{inf} lower for $PM_{10-2.5}$ compared with $PM_{2.5}$). Recent
6 studies have reported lower F_{inf} for UFP compared with F_{inf} for $PM_{2.5}$, potentially reflecting diffusion-
7 driven surface deposition losses for UFP during the infiltration process. In a study of the influence of
8 exposure estimates on health effect estimates in a time-series epidemiologic study of PM exposure, use of
9 a fixed-site monitor in lieu of a microenvironmental model that accounted for infiltration produced
10 considerably attenuated health effect estimates (Section 3.4.5.1). Infiltration of PM through a building
11 envelope may change the temporal variability of the indoor PM concentration time-series, resulting in
12 reduced correlation between the health effect of interest and the estimated exposure concentration. In a
13 study of the influence of modeled exposure concentrations on health effect estimates in an epidemiologic
14 study of long-term average PM exposure, simulating indoor concentrations produced unbiased health
15 effect estimates. Furthermore, the health effect estimate was biased towards the null with inflated
16 confidence intervals after omitting a term for infiltration in a LUR or spatiotemporal model. Bias towards
17 the null leads to underestimation of the true health effect (Section 3.4.5.2).

18 Exposure to copollutants may result in some confounding of the PM health effect estimate if
19 exposure to the copollutants and their relationships to the health effect of interest are both correlated with
20 PM exposure (Section 3.4.3). Median correlations of 24-hour ambient $PM_{2.5}$ with concentrations of some
21 ambient gases (CO , NO_2 , O_3) from the U.S. EPA Air Quality System (AQS) during 2013–2015 were as
22 high as Pearson $R = 0.5$, although correlation varied with season (highest for O_3 in summer and for CO
23 and NO_2 in winter). The upper end of the distribution of correlations approached one for these gases.
24 Copollutant correlation data for short-term concentration measurements from the literature since the 2009
25 PM ISA were consistent with the AQS data. For $PM_{10-2.5}$, median correlations of 24-hour ambient
26 concentrations during the same time period were as high as Pearson $R = 0.4$ but with upper correlations
27 typically below Pearson $R = 0.7$ – 0.8 . Median correlations between $PM_{2.5}$ and $PM_{10-2.5}$ range between 0.2
28 and 0.5, with higher values in summer and fall. Data for UFP correlations were very limited, but they
29 indicate correlations as high as Pearson $R = 0.5$ for NO_2 and NO_x . Sites with moderate-to-strong
30 correlations ($R > 0.4$) may introduce a greater degree of confounding into epidemiologic results,
31 depending on the relationship between the copollutants and the health effect of interest.

32 Some epidemiologic studies of the health effects of PM exposure have examined potential
33 associations between health effects and exposure to PM components (Section 3.4.4) since the 2009 PM
34 ISA. An examination of the composition of $PM_{2.5}$ using data from AQS found that the highest Pearson
35 correlations between $PM_{2.5}$ mass and $PM_{2.5}$ component concentrations occurred for OC , SO_4^{2-} , EC , and
36 NO_3^- . A large percentage of $PM_{2.5}$ mass concentration is a product of atmospheric chemistry. The recent
37 peer-reviewed literature showed high correlations of $PM_{2.5}$ mass concentrations with concentrations of
38 secondary SO_4^{2-} and NO_3^- as well as primary V and Zn . Similarly, high correlations between the

quasi-ultrafine $PM_{0.25}$ and V were observed in recent studies for $PM_{0.25}$ exposure concentrations, and correlations near Pearson $R = 1$ during the winter support the notion that heating oil combustion plays a role in these associations. For $PM_{10-2.5}$, the largest correlation was for Si, possibly in dust. Median correlations reported from AQS and the literature for $PM_{10-2.5}$ with all other $PM_{10-2.5}$ components were Pearson $R < 0.5$, indicating that $PM_{10-2.5}$ is not strongly associated with combustion. Generally, $PM_{2.5}$ components reflect the secondary nature of their production, the $PM_{0.25}$ components reflect combustion, and $PM_{10-2.5}$ components reflect mechanical generation.

In summary, exposure error tends to produce underestimation of health effects in epidemiologic studies of PM exposure, although bias in either direction can occur. There are new developments in assessment of PM exposure, including hybrid spatiotemporal models that incorporate satellite observations of AOD, land use variables, surface monitoring data from FRMs, and/or CTMs. Improvements in spatial resolution of the $PM_{2.5}$ concentration surface have reduced bias and uncertainty in health effects estimates. However, high correlations with some gaseous copollutants necessitate evaluation of the impact of confounding on health effects estimates, using two-pollutant models to ascertain robustness of epidemiologic study results. $PM_{10-2.5}$ and UFP concentrations tend to be more spatially variable than $PM_{2.5}$ concentrations, and data are either unavailable or less often available to fit or validate hybrid models for those size fractions. As a result, there is typically less uncertainty in health effect estimates derived from both monitored and modeled exposure estimates for $PM_{2.5}$ compared with $PM_{10-2.5}$ and UFP.

1.3 Dosimetry of PM

Particle dosimetry refers to the characterization of deposition, translocation, clearance, and retention of particles and their components within the respiratory tract and extra-pulmonary tissues. The dose from inhaled particles deposited and retained in the respiratory tract is governed by several factors. These factors include exposure concentration and duration, activity and breathing conditions (e.g., nasal vs. oronasal route and minute ventilation), and particle properties (e.g., particle size, hygroscopicity, and solubility in airway fluids and cellular components). Basic information related to the mechanisms of particle deposition and clearance and the influence of disease severity on these mechanisms has not changed over the last several PM NAAQS reviews. Compared to prior reviews, species similarities and differences in the amounts of inhaled PM reaching the lower respiratory tract is now better understood and quantified. Additionally, some older literature on route of breathing in humans, that was not included in prior reviews, has come to light and shows differences in route of breathing as a function of age and sex. New data on particle translocation across the olfactory mucosa into the brain and from the alveolar epithelium into the blood also now allows for improved estimates of the importance of these processes in humans.

1 To be deposited in the respiratory tract, particles need to first be inhaled. Inhalability refers to the
2 fraction of particles that can enter the upper respiratory tract (i.e., the head) during inhalation and is
3 dependent on the aerodynamic diameter of the particle (d_{ae}). A commonly used occupational criterion of
4 particle inhalability in humans based on the d_{ae} of particles, predicts that as d_{ae} increases from 1–10 μm ,
5 inhalability decreases from ~97 to ~77%, plateauing at 50% for particles ~40 μm in diameter
6 (Section 4.1.5). The occupational criterion is for relatively high wind speeds (>1 m/s). In calm air,
7 inhalability decreases toward zero with increasing d_{ae} above about 20 μm for nasal and 30 μm for oral
8 breathing. There is evidence for much lower particle inhalability in infants than adults. In rodents,
9 inhalability decreases more rapidly than in humans, from 80 to 44%, as d_{ae} of particles increases from 2.5
10 to 10 μm especially for faster breathing rates. Inhalability and nasal deposition are particularly important
11 considerations influencing how much PM makes it into the lower respiratory tract of rodents relative to
12 humans (Section 4.1.6).

13 The route of breathing, breathing pattern (volume and rate), and particle size are among the
14 factors affecting the amount of PM that enters the body and may subsequently deposit in the respiratory
15 tract. With increasing physical activity, there is an increase in minute ventilation and a shift from nasal to
16 oronasal breathing, and depending on the size fraction of PM inhaled, potentially greater PM penetration
17 into the lower respiratory tract (i.e., the lungs). Even at rest, differences have been observed by age, sex,
18 disease status, and body mass index in the fraction of oral versus nasal breathing (Section 4.1.3). Children
19 inhale a larger fraction of air through their mouth than adults, and males tend inhale a larger fraction of air
20 through their mouth than females (across all ages). Individuals with allergies or upper respiratory
21 infections experience increased nasal resistance, and thus, an increased fraction of oral breathing. Obesity,
22 especially in boys, may also contribute to increased nasal resistance and an increased oral fraction of
23 breathing relative to normal weight children. Due to their increased amount of oral breathing, these
24 individuals may be expected to have greater PM penetration into the lower respiratory tract than healthy,
25 normal weight adults. Children may also be expected to have a greater intake dose of PM per body mass
26 than adults. Route of breathing is instrumental in determining the amount of PM inhaled and also impacts
27 the size of particles that can reach the lower respiratory tract. In humans, the fraction of a breath entering
28 through the mouth increases the fraction of particles reaching the lower respiratory tract (Figure 4-3). In
29 contrast, rodents are obligatory nasal breathers and only a small percentage of larger particles
30 (i.e., >3 μm) reaches the lower respiratory tract (Figure 4-4).

31 Particle deposition in the respiratory tract occurs predominantly by diffusion, impaction, and
32 sedimentation (Section 4.2). Total respiratory tract particle deposition can reach nearly 100% in humans
33 for particles smaller than approximately 0.01 μm (via diffusion) and greater than 10 μm (via
34 sedimentation and impaction), but is minimal for particles between 0.3 to 0.7 μm . The nose and mouth
35 represent the first line of defense against particles depositing in the lower respiratory tract, with roughly
36 100% of particles 10 μm or greater depositing in the human nose. Inter-species differences in the
37 inhalability and nasal deposition of particles has also been shown to affect the size of particles that can
38 enter the respiratory tract and the percentage of particles deposited in various regions. While larger

particles tend to deposit in the nose in humans, in rodents almost 100% of particles $>5\ \mu\text{m}$ are deposited in the nose. Additionally, oronasal breathing in humans contributes to greater penetration of coarse particles into the lower respiratory tract, whereas rats breathe only nasally. There are also differences between children and adults in terms of breathing patterns and ventilation, indicating that children may receive a higher dose per lung surface area of ambient PM in the lower respiratory tract. Respiratory disease can lead to differences in both total deposition and deposition patterns relative to the disease-free lung. In general, the PM dose rate is increased by lung disease, but depends on the severity of and type of disease.

For any given particle size, the pattern of poorly soluble particle deposition influences clearance by partitioning deposited material between regions of the respiratory tract (Section 4.3). While particles depositing in the mouth are generally swallowed or removed by expectoration, particles deposited in the posterior nasal passages or tracheobronchial (TB) airways are moved by mucociliary transport towards the nasopharynx and swallowed. In the alveolar region clearance occurs mainly via macrophage phagocytosis. Clearance is more rapid in rodents than humans and has been shown to decrease with age beyond adulthood. Human studies have shown that ultrafine carbon particles do not rapidly or significantly translocate from the lungs into the circulation (Section 4.3.3.2). However, a new human study has demonstrated some translocation of nano-sized gold particles from the lungs into circulation. The finding of material in the blood in this new human study, but not prior human studies may, in part, be a matter of an increased signal to noise afforded in this new methodology and/or an indication that there is a difference in particle translocation from the lung depending on the inhaled particle type. Animal studies using poorly soluble nano-sized gold and iridium (Ir) particles have provided more extensive evidence of translocation into blood and secondary organs. The estimated urinary elimination by 24 hours post-inhalation of the gold nanoparticles is nearly identical between humans and rats. Soluble materials deposited in the respiratory tract can enter the blood more rapidly than insoluble materials. Recent evidence across species indicates that particles of varying composition, particle size (less than 200 nm diameter), and solubility can also translocate to the brain via the olfactory bulb. It remains unclear, though, whether translocation to the olfactory bulb and brain regions varies by species and whether certain species are more predisposed to this translocation route.

There is a dosimetric basis for several particle sampling conventions used to quantify airborne PM concentrations. The U.S. EPA has size-selective sampling conventions for fine particles indicated by $\text{PM}_{2.5}$ and PM_{10} as an indicator for the purposes of regulating the thoracic coarse particles (i.e., the inhalable particles that remain if $\text{PM}_{2.5}$ particles are removed from a sample of PM_{10} ; aka $\text{PM}_{10-2.5}$). $\text{PM}_{2.5}$ is not well representative [nor was it intended to be] of the occupational definition of respirable particles which has a 50% cut-point at $4\ \mu\text{m}$ versus $2.5\ \mu\text{m}$ for the $\text{PM}_{2.5}$ sampler (Figure 4-2). The selection of $\text{PM}_{2.5}$ for the NAAQS was mainly to delineate the atmospheric fine (combustion derived, aggregates, acid condensates, secondary aerosols) and coarse (crustal, soil-derived dusts) PM modes and for consistency with community epidemiologic health studies reporting various health effects associated with $\text{PM}_{2.5}$ but not on dosimetric considerations as was the case for the respirable particle sampler convention. Although

the respirable sampling convention has a dosimetric basis, it is reflective of the total PM mass concentration to which the alveolar region may be exposed not the PM mass deposition or dose. PM₁₀ is often referred to as the thoracic fraction of inhalable particles and there is an occupational sampling convention for thoracic particles both of which have a 50% cut-point at about 10 µm (Figure 4-2). However, it should be recognized that the fraction of inhaled 10 µm particles reaching the thorax is <20% for most activity levels and breathing habits. Breathing completely through the mouth, fraction of inhaled 10 µm particles reaching the thorax approaches 40%. Thus, using a 50% cut-point at 10 µm provides a conservative (protective) overestimate of thoracic particles.

1.4 Evaluation of the Health Effects of PM

This ISA evaluates relationships between an array of health effects and short-term and long-term exposures to PM (i.e., PM_{2.5}, PM_{10-2.5}, and UFPs) in epidemiologic, controlled human exposure, and animal toxicological studies. In assessing the overall evidence, strengths and limitations of individual studies were evaluated based on scientific considerations detailed in the Appendix. Short-term exposures are defined as those with durations of hours up to one month, with most studies examining effects related to exposures in the range of 24 hours to 1 week. Long-term exposures are defined as those with durations of more than 1 month to years. As detailed in the Preface, the evaluation of the health effects evidence focuses on exposures conducted at concentrations of PM that are relevant to the range of human exposures across ambient microenvironments (up to 2 mg/m³, which is one to two orders of magnitude above ambient concentrations), and (1) include a composite measure of PM³⁶ or (2) apply some approach to assess the direct effect of a specific PM size-fraction when the exposure of interest is a source-based mixture (e.g., diesel exhaust, gasoline exhaust, wood smoke). Drawing from evidence related to the biological plausibility of PM-related health effects and the broader health effects evidence described in detail in Chapters 5–11, information on dosimetry in CHAPTER 4 and Section 1.4, as well as issues regarding exposure assessment and potential confounding described in CHAPTER 3 and Section 1.3, the subsequent sections and accompanying table (Table 1-2) Table 1-2 summarize the key evidence that informed the causality determinations for relationships between PM exposure and health effects, specifically those relationships where a "causal" or "likely to be causal" relationship has been concluded (Table 1-1). Those relationships between PM and health effects where a "suggestive of, but not sufficient to infer" or "inadequate" causality determination has been concluded are noted in Table 1-5, but more fully discussed in the respective health effects chapters.

³⁶ Composite measures of PM may include mass, volume, surface area, or number concentration.

Table 1-1 "Causal" and "likely to be causal" causality determinations for short- and long-term PM exposure.

Size Fraction	Health Effects Category	Exposure Duration	Causality Determination	Section
PM _{2.5}	Respiratory	Short-term	Likely to be causal	1.4.1.1.1
		Long-term	Likely to be causal	1.4.1.1.2
	Cardiovascular	Short-term	Causal	1.4.1.2.1
		Long-term	Causal	1.4.1.2.2
	Nervous System	Long-term	Likely to be causal	1.4.1.3.1
	Cancer	Long-term	Likely to be causal	1.4.1.4.1
	Mortality	Short-term	Causal	1.4.1.5.1
		Long-term	Causal	1.4.1.5.2
UFP	Nervous System	Long-term	Likely to be causal	1.4.3.1

1.4.1 Health Effects of PM_{2.5}

Substantial scientific evidence exists across disciplines (i.e., animal toxicology, controlled human exposure, and epidemiology), with additional support from studies examining biological plausibility, showing that both short- and long-term PM_{2.5} exposure can result in a range of health effects, from changes in circulating biomarkers to mortality. However, the overall confidence in the PM_{2.5} exposure – health effects relationship varies depending on the exposure duration (i.e., short- or long-term) and broad health category (e.g., cardiovascular effects, respiratory effects) examined. Across the broad health effects categories examined, the evidence supporting biological plausibility varies, but generally includes modulation of the autonomic nervous system and inflammation as part of the pathways leading to overt health effects. Discussions of subsequent events that could occur due to deposition of inhaled PM_{2.5} in the respiratory tract are detailed in the biological plausibility sections of each health chapter and summarized in the following sections when detailing the health effects evidence.

1.4.1.1 Respiratory Effects

Recent scientific evidence continues to support a *"likely to be causal relationship"* between both short- and long-term PM_{2.5} exposure and respiratory effects, which is consistent with the conclusions of

the 2009 PM ISA. These causality determinations are based on the consistency of findings within disciplines, coherence among evidence from controlled human exposure, epidemiologic, and toxicological studies, and biological plausibility for respiratory effects, such as asthma exacerbation, development of asthma, COPD exacerbation, and respiratory mortality.

1.4.1.1.1 Respiratory Effects Associated with Short-Term PM_{2.5} Exposure

Epidemiologic studies provide strong evidence for overt respiratory effects, including respiratory-related emergency department visits and hospital admissions and respiratory mortality due to short-term PM_{2.5} exposure, but there is more limited evidence of respiratory effects from experimental studies to provide coherence. Collectively this evidence supports a "*likely to be causal relationship*" between short-term PM_{2.5} exposure and respiratory effects, which is consistent with the conclusions of the 2009 PM ISA (Table 1-2). This conclusion is based on multiple recent epidemiologic studies demonstrating generally consistent, positive associations with emergency department visits for asthma and combined respiratory-related diseases, as well as with respiratory mortality. Evidence from animal toxicological studies, although limited, is supportive of and provides biological plausibility for the associations observed in the epidemiologic studies.

Recent epidemiologic studies continue to provide strong evidence for a relationship between short-term PM_{2.5} exposure and several respiratory-related endpoints, including asthma exacerbation (Section 5.1.2.1), COPD exacerbation (Section 5.1.4.1), and combined respiratory-related diseases (Section 5.1.6), particularly from studies examining emergency department visits and hospital admissions. The consistent positive associations between short-term PM_{2.5} exposure and asthma and COPD emergency department visits and hospital admissions are supported by epidemiologic studies demonstrating associations with other respiratory-related effects such as symptoms and medication use that are indicative of asthma and COPD exacerbations (Section 5.1.2.2 and Section 5.1.4.2). The collective body of epidemiologic evidence for asthma exacerbation is more consistent in children than in adults. Epidemiologic studies examining the relationship between short-term PM_{2.5} exposure and respiratory mortality provide evidence of consistent positive associations, demonstrating a continuum of effects (Section 5.1.9).

Building off the studies evaluated in the 2009 PM ISA, recent epidemiologic studies expand the assessment of potential copollutant confounding. There is some evidence that PM_{2.5} associations with asthma exacerbation, combined respiratory-related diseases, and respiratory mortality remain relatively unchanged in copollutant models with gaseous pollutants (i.e., O₃, NO₂, SO₂, with more limited evidence for CO) and other particle sizes (i.e., PM_{10-2.5}) (Section 5.1.10.1). The uncertainty related to whether there is an independent effect of PM_{2.5} on respiratory health, is partially addressed by findings of animal toxicological studies. Specifically, short-term exposure to PM_{2.5} enhanced asthma-related responses in an animal model of allergic airways disease and enhanced lung injury and inflammation in an animal model of COPD (Section 5.1.2.4.3 and Section 5.1.4.4.2). Although there is a broad body of experimental

evidence demonstrating respiratory effects due to short-term PM_{2.5} exposure it is not entirely coherent with the results of epidemiologic studies. However, the experimental evidence does provide biological plausibility for some respiratory-related endpoints. This includes limited evidence of altered host defense and greater susceptibility to bacterial infection as well as consistent evidence of respiratory irritant effects. Animal toxicological evidence for other respiratory effects is inconsistent. Additionally, controlled human exposure studies conducted in people with asthma or COPD show minimal respiratory effects due to short-term PM_{2.5} exposure, such as decrements in lung function and pulmonary inflammation.

1.4.1.1.2 Respiratory Effects Associated with Long-Term PM_{2.5} Exposure

Epidemiologic studies provide strong evidence for effects on lung development, with additional evidence for the development of asthma in children due to long-term PM_{2.5} exposure. Evidence from animal toxicological studies, although limited in number, supports the findings of these epidemiologic studies. There is also epidemiologic evidence for a decline in lung function in adults. Collectively this evidence supports a "*likely to be causal relationship*" between long-term PM_{2.5} exposure and respiratory effects, which is consistent with the conclusions of the 2009 PM ISA (Table 1-2).

Recent epidemiologic studies continue to support an association between long-term PM_{2.5} exposure and several respiratory-related endpoints in children and adults. In children, studies in multiple cohorts provide strong evidence for decrements in lung function growth (Section 5.2.2.1.1). Robust and persistent effects were observed across study locations, exposure assessment methods, and time periods. An animal toxicological study demonstrating impaired lung development resulting from pre- and post-natal PM_{2.5} exposure provides biological plausibility for these findings (Section 5.2.2.1.2). Results of prospective cohort studies in children also provide some evidence for asthma development in children, and are supported by studies of asthma prevalence in children, childhood wheeze, and pulmonary inflammation (Section 5.2.3). Biological plausibility is provided by an animal toxicological study of long-term PM_{2.5} exposure demonstrating the development of an allergic phenotype and increase in airway responsiveness (Section 5.2.3.3.2). There is limited evidence of increased bronchitic symptoms and hospitalization in children with asthma in relation to long-term PM_{2.5} exposure (Section 5.2.7). In adults, long-term PM_{2.5} exposure was associated with an acceleration of lung function decline (Section 5.2.2.2.2). Consistent evidence was observed for respiratory mortality and cause-specific respiratory mortality for COPD and infection (Section 5.2.10), providing evidence of a continuum of effects in response to long-term PM_{2.5} exposure.

Although still limited in number, recent epidemiologic studies further examine potential copollutant confounding. There is some evidence that PM_{2.5} associations with respiratory mortality remained robust in models with some gaseous pollutants (Section 5.2.10); however, there is limited assessment of potential copollutant confounding when examining respiratory morbidity outcomes. The uncertainty related to the independence of PM_{2.5} effects is partially addressed by findings of animal

toxicological studies. Long-term exposure to PM_{2.5} resulted in oxidative stress, inflammation, and morphologic changes in both upper and lower airways (Section 5.2.8), in addition to the asthma-related and lung development-related effects mentioned above. Epidemiologic studies examining the effects of declining PM_{2.5} concentrations provide additional support for a relationship between long-term PM_{2.5} exposure and respiratory health by demonstrating improvements in lung function growth and bronchitic symptoms in children and improvement in lung function in adults in association with declining PM_{2.5} concentrations (Section 5.2.11). However, the limited examination of copollutant confounding in studies of declining PM_{2.5} concentrations is a notable uncertainty given the corresponding decline in other pollutants over the time-period of the evaluated studies.

1.4.1.2 Cardiovascular Effects

Consistent with the conclusions of the 2009 PM ISA, more recently published scientific evidence further strengthens that there is a "*causal relationship*" between both short- and long-term PM_{2.5} exposure and cardiovascular effects. These causality determinations are based on the consistency of findings within disciplines, coherence among evidence from controlled human exposure, epidemiologic, and toxicological studies, and biological plausibility for cardiovascular effects, such as reduced myocardial blood flow, altered vascular reactivity, myocardial infarctions, and cardiovascular mortality.

1.4.1.2.1 Cardiovascular Effects Associated with Short-Term PM_{2.5} Exposure

Strong evidence from epidemiologic studies demonstrating associations between cardiovascular emergency department visits and hospital admissions in combination with evidence for PM_{2.5}-induced cardiovascular effects from controlled human exposure and animal toxicological studies confirms and extends the conclusion of a "*causal relationship*" between short-term PM_{2.5} exposure and cardiovascular effects from the 2009 PM ISA (Table 1-2). This conclusion is based on multiple high-quality epidemiologic studies demonstrating associations with cardiovascular effects such as ischemic heart disease (IHD) and heart failure (HF) related emergency department visits and hospital admissions, as well as cardiovascular mortality. The epidemiologic evidence is primarily supported by experimental studies demonstrating endothelial dysfunction, changes in blood pressure, and alterations in heart function in response to short-term PM_{2.5} exposure. Additional evidence from epidemiologic, controlled human exposure, and animal toxicological studies also provides ample evidence of biologically plausible pathways by which short-term exposure to PM_{2.5} can result in overt cardiovascular effects.

Consistent with the 2009 PM ISA, the strongest evidence comes from epidemiologic studies that reported consistent positive associations between short-term PM_{2.5} exposure and cardiovascular-related emergency department visits and hospital admissions particularly for IHD and HF, as well as cardiovascular-related mortality. While the evidence is generally consistent across the copollutants

1 evaluated, the evidence was especially consistent for air pollutants that are not typically associated with
2 traffic (i.e., ozone, SO₂, PM_{10-2.5}). In some instances, associations in copollutant models were attenuated,
3 but this was only observed for the traffic-related pollutants (i.e., NO₂, CO), which generally had higher
4 correlations with PM_{2.5} than other copollutants. This recent evidence generally indicates that the
5 associations observed with PM_{2.5} and cardiovascular effects in single pollutant models remain relatively
6 unchanged in copollutant models, indicating that the observed associations with PM_{2.5} are not artefacts
7 due to confounding by another air pollutant (Section 6.1.14.1). These epidemiologic studies reduce a key
8 uncertainty identified in the 2009 PM ISA by providing evidence that gaseous pollutants are not likely to
9 confound the PM_{2.5}-cardiovascular relationship.

10 The independence of PM_{2.5} effects is further addressed by findings of recent controlled human
11 exposure and animal toxicological studies. The most consistent evidence from controlled human exposure
12 studies is for a PM_{2.5} effect on endothelial function. More specifically, in contrast to the previous review
13 where a single controlled human exposure study did not find changes in endothelial function following
14 short-term PM_{2.5} exposure, multiple recent controlled human exposure studies that examined endothelial
15 function reported that PM_{2.5} impaired at least some measure of vessel dilation following reactive
16 hyperemia or pharmacological challenge relative to filtered air exposure. Given the relationship between
17 endothelial function and blood pressure, these results are coherent with controlled human exposure
18 studies that reported changes in blood pressure following short-term PM_{2.5} exposure. The results of these
19 controlled human exposure studies are also coherent with evidence from animal toxicological studies
20 demonstrating endothelial dysfunction and changes in blood pressure or the renin angiotensin system
21 following short-term PM_{2.5} exposure. Moreover, changes in endothelial function and blood pressure
22 reported in experimental studies are consistent with time-series and case-crossover epidemiologic studies
23 reporting associations between short-term PM_{2.5} exposure and IHD, as well as with limited epidemiologic
24 panel study evidence of associations with blood pressure. In addition, animal toxicological studies
25 demonstrating that short-term PM_{2.5} exposure results in decreased cardiac contractility and left ventricular
26 pressure are coherent with epidemiologic studies reporting associations between short-term PM_{2.5}
27 exposure and HF.

28 Collectively, the evidence from controlled human exposure, animal toxicological and
29 epidemiologic panel studies provide a biologically plausible pathway by which short-term PM_{2.5} exposure
30 could result in cardiovascular effects such as an emergency department visits, hospital admission, or
31 mortality. This proposed pathway (Section 6.1.1) begins with pulmonary inflammation and/or activation
32 of sensory nerves in the respiratory track. It progresses to autonomic nervous system imbalance and/or
33 systemic inflammation that can potentially affect cardiovascular endpoints such as endothelial function,
34 HRV, hemostasis, and/or BP. Changes in the aforementioned cardiovascular endpoints may then lead to
35 the development of arrhythmia, thrombosis, and/or acute myocardial ischemia, potentially resulting in
36 outcomes such as myocardial infarction, IHD, HF, and possibly death.

Overall, across the scientific disciplines, recent studies extend and support the previous evidence for a continuum of cardiovascular-related health effects following short-term exposure to PM_{2.5}. These effects range from relatively modest increases in biomarkers related to inflammation, to subclinical cardiovascular endpoints such as endothelial dysfunction, the overt outcomes of emergency department visits and hospital admissions, specifically for IHD and HF, and ultimately cardiovascular-related mortality.

1.4.1.2.2 Cardiovascular Effects Associated with Long-Term PM_{2.5} Exposure

Multiple recent and previously available epidemiologic studies that extensively control for potential confounders provide strong evidence of positive associations with cardiovascular mortality, which in combination with supporting evidence from recent studies examining cardiovascular morbidity reaffirms the conclusion of a "*causal relationship*" between long-term PM_{2.5} exposure and cardiovascular effects in the 2009 PM ISA (Table 1-2). This conclusion is based on recent U.S. and Canadian cohort studies demonstrating consistent, positive associations between long-term PM_{2.5} exposure and cardiovascular mortality with more limited evidence from studies examining long-term PM_{2.5} exposure and cardiovascular morbidity.

Epidemiologic studies consisting of U.S.-based cohorts and subsequent analyses of these cohorts, provided the basis of the conclusions in the 2009 PM ISA. These studies in combination with recent cohort studies, continue to demonstrate consistent, positive associations and support a strong relationship between long-term PM_{2.5} exposure and cardiovascular mortality. The results of these recent cohort studies are consistent across various spatial extents, exposure assessment techniques, and statistical techniques in locations where mean annual average concentrations are near or below 12 µg/m³ (Section 6.2.10).

The body of literature examining the relationship between long-term PM_{2.5} exposure and cardiovascular morbidity has greatly expanded since the 2009 PM ISA. Recent epidemiologic studies examining cardiovascular morbidity endpoints consist of several large U.S. cohort studies each focusing on populations with distinct demographic characteristics (e.g., post-menopausal woman, male doctors, etc.) and extensive consideration of potential confounders. These studies have reported heterogeneous results, with several high-quality studies that adjusted for important covariates, including socioeconomic status (SES), reporting positive associations for cardiovascular morbidity endpoints. The strong associations reported between long-term PM_{2.5} exposure and coronary events (e.g., coronary heart disease [CHD] and stroke) among post-menopausal women in the Women's Health Initiative (WHI) cohort, highlighted in 2009 PM ISA, were strengthened in an extended analysis that considered individual and neighborhood level SES. Recent analyses of other cohorts of women (i.e., Nurses' Health Study, California Teachers Study) that were comparable to WHI in that they considered menopausal status or hormone replacement therapy did not show consistent positive associations with CHD, myocardial infarction or stroke. Longitudinal studies demonstrated that changes in the progression of atherosclerosis

in relation to long-term exposure to PM_{2.5} were variable across cohorts and found to depend, in part, on the vascular bed in which atherosclerosis was evaluated. However, within a study focusing on the progression of atherosclerosis in a healthy population, i.e., Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA-Air), an association was observed between long-term PM_{2.5} exposure and coronary artery calcification (CAC), which is a strong predictor of CHD (Section 6.3.4). A small number of studies report positive associations between long-term PM_{2.5} exposure and HF, blood pressure and hypertension. Longitudinal epidemiologic analyses also support the observation of positive associations with markers of systemic inflammation, coagulation and endothelial dysfunction. These HF studies are coherent with animal toxicological studies demonstrating decreased contractility and cardiac output, and increased coronary artery wall thickness following long-term PM_{2.5} exposure (6.2.4.2). Moreover, animal toxicological studies finding a relationship between long-term exposure to PM_{2.5} and changes in BP in rats and mice are coherent with epidemiologic studies reporting positive associations between long-term exposure to PM_{2.5} and hypertension. Similarly, evidence of atherosclerotic plaque progression in a genetically susceptible mouse model is consistent with epidemiologic studies reporting associations between atherosclerosis and long-term PM_{2.5} exposure.

The current body of evidence also reduces uncertainties identified in the 2009 PM ISA related to potential copollutant confounding and the shape of the concentration-response relationship for CVD effects following long-term PM_{2.5} exposure. Generally, most of the PM_{2.5} effect estimates relating long-term PM_{2.5} exposure and cardiovascular mortality remained relatively unchanged or increased in copollutant models adjusted for O₃, NO₂, SO₂, and PM_{10-2.5} (Section 6.2.15). In addition, most of the results from analyses examining the C-R function for cardiovascular mortality supported a log-linear, no-threshold relationship for cardiovascular mortality, especially at mean annual PM_{2.5} concentrations ≤12 µg/m³ (Section 6.2.10). Some studies reported that the slope of the concentration-response function tended to be steeper at lower concentrations, especially for IHD mortality, suggesting a supralinear concentration-response relationship. A limited number of cardiovascular morbidity studies examined the shape of the concentration-response relationship and generally reported steeper concentration-response functions at lower concentrations (starting at ~10 µg/m³) with the slope of the concentration-response function decreasing at higher PM_{2.5} concentrations (Section 6.2.16).

Evidence from animal toxicological and epidemiologic studies also provide biologically plausible pathways by which long-term PM_{2.5} exposure could lead to cardiovascular effect such as CHD, stroke, and CVD-related mortality (Section 6.2.1). These pathways initially involve autonomic nervous system changes and/or systemic inflammation that can potentially effect endpoints related to vascular function, altered hemostasis, hypertension, atherosclerotic plaque progression, and arrhythmia. Changes in cardiovascular endpoints such as these may then lead to IHD, HF, and possibly death.

Overall, there is consistent evidence from multiple, high-quality epidemiologic studies that long-term exposure to PM_{2.5} is associated with cardiovascular mortality. Associations with CHD, stroke and atherosclerosis progression were observed in several recent high-quality epidemiologic studies

providing coherence with the mortality findings. Results from copollutant models generally support the independence of the PM_{2.5} associations. Additional evidence of the direct effect of PM_{2.5} on the cardiovascular system is provided by experimental studies in animals demonstrating effects including atherosclerosis plaque progression, changes in cardiac contractility and BP.

1.4.1.3 Nervous System Effects

1.4.1.3.1 Nervous System Effects Associated with Long-Term PM_{2.5} Exposure

The 2009 PM ISA evaluated a small number of experimental animal studies pertaining to the effects of long-term exposures to PM_{2.5} on the nervous system. The literature base has greatly expanded with recent studies providing new information that strengthens the lines of evidence indicating that long-term PM_{2.5} exposure can lead to effects on the brain associated with neurodegeneration (i.e., neuroinflammation and reductions in brain volume), as well as cognitive effects in older adults (Table 1-2). Specifically, animal toxicological studies provide evidence for a range of nervous system effects including neuroinflammation and oxidative stress, neurodegeneration, cognitive effects, and effects on neurodevelopment. The epidemiologic evidence is more limited but multiple studies generally support associations between long-term PM_{2.5} exposure and changes in brain morphology, cognitive decrements and dementia. The consistency and coherence of the evidence across disciplines as it relates to region-specific brain inflammation, morphologic changes in the brain, cognitive effects and dementia in adult populations supports that there is a *"likely to be causal relationship"* between long-term PM_{2.5} exposure and nervous system effects, which is the first time a causality determination has been made for long-term PM_{2.5} exposure and nervous system effects.

There is strong evidence that long-term exposure to PM_{2.5} can modulate the autonomic nervous system leading to downstream consequences including cardiovascular effects (Section 6.2.1). In addition, the pathway involving neuroinflammation in specific regions of the brain (i.e., the hippocampus, cerebral cortex and hypothalamus) and morphologic changes in the brain indicative of neurodegeneration, is well substantiated and coherent across experimental animal and epidemiologic studies (Section 8.2.3, Section 8.2.4). Specifically, morphologic changes induced in the hippocampus of animals were accompanied by impaired learning and memory and there is consistent evidence from multiple, high quality, epidemiologic studies that long-term PM_{2.5} exposure is associated with reduced cognitive function (Section 8.2.5). Further, the presence of early markers of Alzheimer's disease pathology was demonstrated in animals following long-term exposure to PM_{2.5} CAPs and associations with neurodegenerative changes in the brain (i.e., decreased brain volume) and Alzheimer's disease or all-cause dementia were observed in a limited number of epidemiologic studies (Section 8.2.6). Although the loss of dopaminergic neurons in the substantia nigra, which is a hallmark of Parkinson disease, was demonstrated in animals (Section 8.2.4), high quality epidemiologic studies do not report associations

with Parkinson disease (Section 8.2.6). Overall, the lack of consideration of copollutant confounding introduces some uncertainty in the interpretation of the epidemiologic studies but this uncertainty is addressed, in part, by the direct evidence of effects provided by experimental animal studies.

In addition to the findings described above, which are most relevant to adults, several recent studies of neurodevelopmental effects in children have also been conducted. Positive associations between long-term exposure to PM_{2.5} during the prenatal period and autism spectrum disorder (ASD) were consistently observed across multiple epidemiologic studies (Section 8.2.7.2). However, several studies of performance on tests of cognitive function provided little support for an association. Overall, these epidemiologic studies of developmental effects are limited due to their lack of control for potential confounding by copollutants, the small number of studies, and uncertainty regarding critical exposure windows. Biological plausibility is provided for the ASD findings, by a study in animals that found inflammatory and morphologic changes in the corpus collosum and hippocampus, as well as ventriculomegaly in young animals following prenatal exposure to PM_{2.5} CAPs.

1.4.1.4 Cancer

1.4.1.4.1 Cancer Associated with Long-Term PM_{2.5} Exposure

Experimental and epidemiologic evidence indicating genotoxicity, epigenetic effects (i.e., hypo- and hyper-methylation of DNA), and increased carcinogenic potential due to PM_{2.5} exposure, along with strong epidemiologic evidence for increases in lung cancer incidence and mortality, supports a *"likely to be causal relationship"* between long-term PM_{2.5} exposure and cancer (Table 1-2). This causality determination represents a change from the *"suggestive of a causal relationship"*³⁷ determination reported in the 2009 PM ISA. The evidence base underlying this conclusion encompasses the decades of research on whole PM exposures and more recent research focusing specifically on PM_{2.5}.

PM_{2.5} exhibits various characteristics of carcinogens, as shown in studies demonstrating genotoxic effects (e.g., DNA damage), epigenetic alterations, oxidative stress, and electrophilicity. The examination of the role of PM_{2.5} in cancer development has often focused on whether whole PM, not specific size fractions, has mutagenic properties and whether exposure to whole PM results in genotoxicity or carcinogenicity. Additionally, it has been well characterized that some components of PM_{2.5}, specifically hexavalent chromium, nickel, arsenic, and PAHs are known human carcinogens. Extensive analyses of PM_{2.5} and PM_{2.5} extracts in the Ames *Salmonella*/mammalian-microsome mutagenicity assay demonstrate that PM contains mutagenic agents (Section 10.2.2.1). Additional in vitro and in vivo toxicological studies indicate the potential for PM_{2.5} exposure to result in DNA damage,

³⁷ Since the 2009 PM ISA, the causality determination language has been updated and this category is now stated as *"suggestive of, but not sufficient to infer, a causal relationship"*.

1 which is supported by limited human evidence (Section 10.2.2.2.). Some studies have also demonstrated
2 that PM_{2.5} exposure can result in cytogenetic effects, specifically micronuclei formation and chromosomal
3 aberrations (Section 10.2.2.3), as well as differential expression of genes potentially relevant to
4 genotoxicity or other aspects of cancer pathogenesis (Section 10.2.2.4). Although inconsistently examined
5 across studies, changes in cellular and molecular markers of genotoxicity and epigenetic alterations,
6 which may lead to genomic instability, are demonstrated in response to PM_{2.5} exposure. Further, the
7 carcinogenic potential of PM_{2.5} was demonstrated in an animal toxicological study in which chronic
8 inhalation enhanced tumor formation that was initiated by exposure to urethane. (Section 10.2.4).
9 Additionally, recent epidemiologic studies encompassing multiple cohorts that are diverse in terms of
10 both geographic coverage and population characteristics, provide evidence of primarily consistent
11 positive associations between long-term PM_{2.5} exposure and lung cancer incidence and mortality,
12 particularly in never smokers (Section 10.2.5.1). Experimental and epidemiologic evidence of
13 genotoxicity, epigenetic effects, and carcinogenic potential provides biological plausibility for
14 epidemiologic results of lung cancer incidence and mortality. Although limited in number, the assessment
15 of potential copollutant confounding, particularly with O₃, indicates that PM_{2.5} associations with lung
16 cancer incidence and mortality are relatively unchanged in copollutant models (Section 10.2.5.1.3). There
17 is limited evidence that long-term PM_{2.5} exposure is associated with cancers in other organ systems;
18 however, there is initial evidence that PM_{2.5} exposure may reduce survival in individuals with cancer.

1.4.1.5 Mortality

19 Consistent with the conclusions of the 2009 PM ISA, more recently published scientific evidence
20 reaffirms and further strengthens that there is a "*causal relationship*" between both short- and long-term
21 PM_{2.5} exposure and total mortality. These causality determinations are based on the consistency of
22 findings across a large body of epidemiologic studies and coherence among evidence from controlled
23 human exposure, epidemiologic, and toxicological studies, as well as biological plausibility for
24 respiratory and cardiovascular morbidity effects by which short- and long-term PM_{2.5} exposure could
25 result in mortality.

1.4.1.5.1 Mortality Associated with Short-Term PM_{2.5} Exposure

26 Strong recent and previously available epidemiologic evidence, in combination with evidence for
27 biological plausibility for cause-specific mortality from studies that examined the relationship between
28 short-term PM_{2.5} exposure and cardiovascular and respiratory morbidity, collectively indicates there is a
29 "*causal relationship*" between short-term PM_{2.5} exposure and total (nonaccidental) mortality, which is
30 consistent with the conclusions of the 2009 PM ISA (Table 1-2). This conclusion is based on multiple
31 recent multi-city studies conducted in the U.S., Canada, Europe, and Asia that continue to provide
32 evidence of consistent, positive associations between short-term PM_{2.5} and total mortality, as well as

1 epidemiologic studies that use study design and/or statistical analyses that further reduce chance,
2 confounding, and other biases.

3 Recent multi-city studies add to the body of evidence evaluated in the 2009 PM ISA and continue
4 to support a positive association between short-term PM_{2.5} exposure and total mortality with percentage
5 increases in mortality ranging from 0.19–2.80% at lags of 0 to 1 day in studies where mean 24-hour
6 average concentrations were primarily <20 µg/m³ (Figure 11-1; Table 11-1). The positive associations
7 observed across studies reflect traditional analyses using ambient monitors as well as analyses conducted
8 in both urban and rural locations that use new exposure assignment techniques and rely on multiple
9 sources of PM_{2.5} data (e.g., ambient monitors, statistical models, and satellite images). Whereas the
10 analysis of potential copollutant confounding was limited to single-city studies and studies of PM₁₀ in the
11 2009 PM ISA, recent multi-city studies conducted in Europe and Asia focusing on PM_{2.5} indicate that
12 PM_{2.5}-mortality associations are relatively unchanged in copollutant models with gaseous pollutants and
13 PM_{10-2.5} (Section 11.1.4). These results from copollutant models further support an independent effect of
14 PM_{2.5} on mortality. The associations reported for total mortality are also supported by analyses
15 demonstrating increases in cause-specific mortality, specifically for cardiovascular and respiratory
16 mortality which comprise ~33 and ~9%, respectively, of total mortality (NHLBI, 2017) (Figure 11-2).
17 The consistent and coherent evidence across scientific disciplines for cardiovascular morbidity,
18 particularly ischemic events and heart failure (CHAPTER 6), and to a lesser degree for respiratory
19 morbidity, with the strongest evidence for exacerbations of COPD and asthma (CHAPTER 5), provide
20 biological plausibility for cause-specific mortality and ultimately total mortality. The relationship between
21 short-term PM_{2.5} exposure and total mortality is additionally supported by analyses that examined the
22 concentration-response (C-R) relationship that continue to provide evidence of a log-linear, no-threshold
23 relationship, although studies have not conducted extensive systematic evaluations of alternatives to
24 linearity (Section 11.1.10).

1.4.1.5.2 Mortality Associated with Long-Term PM_{2.5} Exposure

25 Strong recent and previously available epidemiologic evidence from cohorts in the U.S., Canada,
26 and Europe demonstrates that there is a "*causal relationship*" between long-term PM_{2.5} exposure and total
27 mortality, which is consistent with the conclusions of the 2009 PM ISA (Table 1-2). This conclusion is
28 based on multiple cohorts that continue to provide evidence of consistent, positive associations, as well as
29 continued characterization of the relationship between long-term PM_{2.5} exposure and total (nonaccidental)
30 mortality through analyses that further reduce chance, confounding, and other biases. Additional evidence
31 indicating coherence of effects across scientific disciplines for cardiovascular and respiratory morbidity
32 and metabolic disease provides biological plausibility for cause-specific mortality, and supports the causal
33 relationship with total mortality.

34 Additional reanalyses and extensions of the American Cancer Society (ACS) and Harvard Six
35 Cities (HSC) cohorts as well as new cohorts consisting of Medicare participants, people that live in

1 Canada, or people employed in a specific job (e.g., teacher, nurse, etc.) further support a positive
2 association between long-term PM_{2.5} exposure and total mortality, particularly in areas with annual mean
3 concentrations <20 µg/m³, and in some cases below 12 µg/m³ (Figure 11-17 and Figure 11-18). Across
4 studies, positive associations were consistently observed regardless of the exposure assignment approach
5 employed, with some studies relying on ambient monitors while others used modeled or remote sensing
6 data or hybrid methods that combine two or more data sources. Recent studies have conducted analyses to
7 examine potential copollutant confounding and indicate that associations between long-term PM_{2.5}
8 exposure and total mortality are relatively unchanged in copollutant models particularly with O₃, with
9 more limited evidence for NO₂, and PM_{10-2.5} (Section 11.2.3; Figure 11-20, Figure 11-21). The evidence
10 for total mortality is further supported by analyses of cause-specific mortality, which report positive
11 associations with cardiovascular, respiratory, and lung cancer mortality. The coherence of effects across
12 scientific disciplines for cardiovascular morbidity, particularly for CHD, stroke and atherosclerosis, and
13 respiratory morbidity for the development of COPD, contribute to providing biological plausibility for
14 mortality due to long-term PM_{2.5} exposure. Recent studies extensively examined the C-R relationship
15 between long-term PM_{2.5} exposure and total mortality, specifically in several U.S. and Canadian cohorts,
16 and collectively continue to support a log-linear, no-threshold C-R relationship (Section 11.2.4; Table 11-
17 7).

18 A recent series of studies evaluates the relationship between long-term exposure to PM_{2.5} and
19 mortality by examining the temporal trends in PM_{2.5} concentrations and changes in life expectancy,
20 testing the hypothesis that decreases in PM_{2.5} concentrations would be associated with increases in life
21 expectancy (Section 11.2.2.6). These studies reported that decreases in long-term PM_{2.5} concentrations
22 were associated with an increase in life expectancy across the U.S. for multiple time periods examined.